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Abstract 
Pertussis, commonly known as ‘whooping cough’, is a respiratory infection caused by the 
bacterium Bordetella pertussis. Despite being a vaccine preventable disease, pertussis has 
remained largely endemic with recent epidemics causing significant morbidity and mortality. 
Worldwide, there is estimated to be 300 000 - 400 000 deaths due to pertussis each year 
(1).Whilst high global coverage of the primary childhood vaccine series has been achieved, 
infants too young to be vaccinated against pertussis remain susceptible. Subsequently, they 
bear the brunt of pertussis morbidity and mortality. A key pertussis control measure is the 
‘cocooning strategy’, whereby household contacts of an infant (<12months) are immunised to 
minimise the risk of transmission.  
This thesis aimed to explore whether cocooning can be implemented within the postnatal 
ward setting. The second aim was to determine whether a ‘message framing’ educational 
intervention increases uptake among postpartum women. The third aim was to determine 
enablers and barriers to vaccination among this target population. 
Message framing is a communication technique used to highlight what an individual may 
either gain from participating in a preventative behaviour or lose from not engaging in it. 
Theoretically, participants are more likely to engage in a preventative behaviour with 
temporal risk (e.g. side effects) when presented with the potential disease consequences of 
not engaging in it (loss frame) (2). However, a recent meta-analytic review of 38 studies 
found no significant difference between gain or loss-framed messages in promoting 
vaccination(3). The authors also reported that results might have potentially been modified by 
vaccine recipient (i.e. message recipient vs. vaccination of another, e.g. child). However, 
none of the included studies examined vaccination of the message recipient on behalf of 
another (e.g. cocooning). 
Our study involved a quasi-randomised control trial of message framing as information 
strategy to promote uptake, with baseline survey and follow up. The surveys contained both 
open and closed-ended questions, enabling both quantitative and qualitative analysis of 
baseline intentions as well as vaccine decision-making. To detect a 5% difference between 
the gain-frame, loss-frame, and control, with 80% confidence at the 0.05 level, the required 
sample size was 1080 subjects who were eligible for a pertussis booster (last dTpa>10years). 
Postpartum women who spoke English were recruited from the postnatal ward of a public 
tertiary referral hospital (Royal North Shore Hospital (RNSH)) and adjacently located private 
hospital (North Shore Private Hospital (NSPH)) in metropolitan Sydney, Australia. 
Recruitment was undertaken from November 2010- July 2012 at RNSH and March 2012-
December 2013 at NSPH.  
Following enrolment, each participant completed self-administered pertussis knowledge and 
attitude questionnaire based on the Health Belief Model constructs (perceived disease 
severity, susceptibility, vaccine benefits and barriers, cues to action). Demographic, perinatal 
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and routine perinatal vaccine data was also collected. We screened all participants for vaccine 
status, and, where possible, confirmed pertussis booster vaccine receipt with their provider 
(e.g. general practitioner). Women who had not received a pertussis booster vaccine within 
the last ten years were defined as ‘unvaccinated’ and enrolled into the Maternal Pertussis 
Controlled Trial. They were allocated an educational intervention using sequential block 
allocation by week (without allocation concealment), which included a ‘gain-framed’ 
brochure, a ‘loss-frame’ brochure or the state-health pertussis factsheet (control). This was 
revised for the private hospital sample, and block-randomisation combined with allocation 
concealment was implemented. At recruitment, the research nurse made participants aware 
that they were eligible for a free pertussis booster vaccination (which was also stipulated in 
the patient information sheet). This was administered at a later time on the postnatal ward by 
their midwife (if the participant accepted vaccination), and prior to completing a follow up 
questionnaire on vaccine decision-making. 
Screening of participant vaccine status indicated that the overall baseline pertussis booster 
coverage was 34%, ranging from 23.1% in the public hospital to 47.5% in the private 
hospital. Vaccination increased from 23%-70% in the public hospital (RNSH) and from 
44.8%-85.8% in the private hospital (NSPH). However, the message framing had no impact 
on vaccination uptake, in public or private hospital setting. This highlighted that routine 
pertussis information was as effective as gain and loss framed-messages in increasing 
maternal pertussis vaccination uptake in the postnatal ward, when provided by obstetric staff 
and accompanied by a free vaccine. Predictors of pertussis vaccination uptake in the public 
hospital setting included: pertussis booster vaccine recommendation by health care provider; 
perception of vaccination as beneficial; and baseline intention to be vaccinated. In the private 
hospital setting, predictors of uptake included: perception of vaccination as beneficial, in 
particular the belief that receiving the pertussis booster vaccination is a maternal 
responsibility for their baby’s protection; and identifying a ‘health professional’ as the 
influential pertussis information source. The common predictor of uptake on the postnatal 
ward was the perception of the pertussis booster vaccine as beneficial, which may indicate a 
knowledge gap that health professionals can address. 
This thesis provides high-level evidence that message framing does not significantly increase 
vaccine uptake among this target population; rather provision of any information does. We 
identified key enablers within this setting that mitigated access barriers and promoted 
vaccination. On the postnatal ward, women had unrestricted access to an immunisation 
provider with whom they could discuss concerns and who could administer the vaccine. 
Integration into postnatal care removed the need of appointment scheduling, transportation, 
provider and vaccine fees associated with immunisation in other settings. Furthermore, 
women who have just given birth are highly focused on protecting their baby and receptive to 
key information. With the recent policy switch to vaccination during pregnancy, rather than 
cocooning, this thesis highlights the importance of removing cost barriers, increasing access 
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to vaccine providers in the hospital setting and standardising patient-provider communication 
to both recommend the pertussis booster vaccine and address key vaccine safety concerns. 
An important finding of this thesis was that intention to be vaccinated did not always predict 
behaviour (i.e. vaccination uptake) among pregnant women or those in the immediate 
postpartum period. This is an important consideration for policy makers, as setting and timing 
of vaccination may have an impact on completion of vaccination. In addition, vaccine 
recommendation and mothers’ perception of vaccine benefits both independently predicted 
vaccine uptake in the postnatal hospital setting. Thus, the antenatal period is an opportune 
time for health professionals to: 1) discuss the benefits of vaccination for both mother and 
baby, 2) address any vaccine knowledge gaps or concerns and 3) provide a strong 
recommendation. It is likely that these actions will help shape maternal perceptions of 
vaccination and intentions to vaccinate. This vaccination discussion may be combined with 
discussions about other vaccinations, such as neonatal Hepatitis B vaccination and occur 
during third trimester consultations. 
Since 2013, Australian Immunization Guidelines have included pertussis vaccination during 
pregnancy, with a media release by the State Ministry of Health alerting providers and the 
general public to this change in pertussis control(4, 5). As a result, in July 2013 there has 
been a shift in the focus of NSW vaccine policy from indirect protection of neonates via 
cocooning (postpartum maternal vaccination) to direct protection via antenatal vaccination 
(this occurred mid-way though the project phase of this thesis). This thesis also presents the 
first published findings of provider-confirmed vaccine uptake during pregnancy among 
eligible women, since the recommendation for antenatal pertussis booster vaccination in 
Australian in March 2013. In this cross-sectional survey, we highlighted key attitudinal 
differences, particularly related to risk perception of the pertussis booster vaccine, between 
those who accepted third-trimester vaccination and those who declined it. With antenatal 
pertussis coverage of 9%, when delivered in the general practice setting, there is need for 
continued support of postpartum vaccination until high antenatal coverage can be achieved.   
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Definitions 
Cocooning or ‘cocooning strategy’- a pertussis control strategy. It involves vaccinating 
household contacts are against pertussis in order to prevent indirect transfer to an infant 
(<6months), who is too young to be fully vaccinated. 
Free vaccine- dTpa was funded under NSW Health, making it free to the recipient. Additional 
cost of vaccine administration was not funded, unless received the postpartum ward setting.  
General Practitioner (GP)- also known as ‘family doctor’. 
Midwife -Health professional who specialises in perinatal care (pregnancy, labour, birthing 
and the postpartum period).  
 Notifiable disease - a disease legally required by medical or lab personnel to be reported to 
government authorities (e.g. Public Health Unit) 
Postpartum - The time period after pregnancy and childbirth. Also referred to as ‘postnatal’. 
Primip/primiparous mother- A women who has given birth to one live baby. 
Reactogenicity – A common, predicted adverse reaction (e.g. swelling, erythema) due to an 
immunological response to any of the components of a vaccine.  
Resurgence - a disease burden which is larger than expected and occurring on a background 
of intermittent fluctuations of naturally occurring disease. 
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Introduction 
Pertussis, commonly termed ‘whooping cough’, is a bacterial infection caused by the 
organism Bordetella pertussis. It is transmitted by respiratory droplets and is highly 
contagious (R0 range 15-17)(6) . Symptomatology is characterised by a paroxysmal cough, 
inspiratory whoop and post-tussive vomiting(7). In the pre-vaccination era, the incidence of 
pertussis was estimated by the Centre for Disease Control (CDC) to be 150 cases per 100,000 
population (data from 1940-1945). Following the widespread implementation of vaccination 
in the 1940s, the incidence of pertussis cases declined significantly to 8 per 100 000 in the 
1960s and then down to 1 per 100 000 in the 1970s(8). However, despite continued high 
coverage of primary pertussis immunisation series among children globally, pertussis remains 
endemic and is a prominent cause of infant mortality worldwide. Globally, pertussis accounts 
for an estimated 300 000 deaths among children each year(9), making it one of the key 
vaccine-preventable diseases. The case fatality rate is estimated to be 0.8% in unvaccinated 
infants <6months(10, 11). In recent years an epidemiological shift has been observed in 
developed countries, with higher notifications among adolescents and adults. This has been 
attributed in part to waning vaccine-induced immunity and improved disease diagnosis and 
reporting(9). A key issue is that adult cases are frequently atypical, leading to late clinical 
presentation and low recognition rates. This makes them a prime reservoir from which 
pertussis can be spread, posing a serious threat to young infants.   
Selective vaccination of groups that are important in transmission is a strategy targeted at 
reducing the disease incidence among ‘at risk’ sub-populations in which disease 
consequences are severe. For pertussis, an epidemiological link between the increased 
incidence among adults and the serious threat this poses to young infants. Among susceptible 
household contacts a 90% transmission rate of pertussis has been reported(12). Among infant 
cases, the main source are mothers (39%) and fathers (16%), followed by other primary 
caregivers(13). Infants <3months, who suffer the highest morbidity and mortality, are the 
most vulnerable as they are too young to be fully vaccinated against pertussis. Therefore, 
pertussis control strategies have targeted vaccination of adult household members and 
caregivers in an attempt to make a ‘cocoon of protection’ around the infant, thus breaking the 
transmission link. Referred to as ‘cocooning’, this strategy was first introduced in 2006 
following the first Roundtable Pertussis Initiative meeting(9). In order to be effective on a 
population level, this strategy has been estimated to require a high coverage rate of 85%(14).   
Difficulties implementing the cocooning strategy have been reported, with delayed 
postpartum vaccination (<6weeks) leaving a gap during the critical newborn period. To 
address this, new immunisation platforms within the hospital setting have been explored (e.g. 
neonatal unit and the postnatal ward). Offering pertussis booster vaccination within this 
setting has resulted in uptake among new parents of 54%-86%(15-17). Whilst 
implementation in this setting is feasible, this has not been established in the Australian 
context. Furthermore, educational strategies have not been rigorously evaluated in this 
context. Being a recent strategy, first introduced internationally in 2006, there is a need for 
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further research to explore the impact of attitudes and knowledge barriers in addition to those 
posed by vaccine delivery within the health system. These include a lack of access to a 
provider and/or setting where vaccination is available, restricted clinic hours, cost of the 
vaccine and its administration, obtaining a vaccine prescription or order, as well as available 
infrastructure for vaccine providers. Research has highlighted the importance of pertussis 
education, yet delivery and content yield varying outcomes. Thus, there is a need for 
randomised control trials to evaluate pertussis education within this context. 
 Since 2013, Australian immunization guidelines have included pertussis vaccination during 
pregnancy, with a media release by the State Ministry of Health alerting providers and the 
general public to this change in pertussis control(4, 5). As a result, in July 2013 there has 
been a shift in the focus of NSW vaccine policy from indirect protection of neonates via 
cocooning (postpartum maternal vaccination) to direct protection via antenatal vaccination 
(this occurred mid-way though the project phase of this thesis).  
 Aim of thesis 
The overall aim of the thesis was: a) to assess implementation of routine pertussis (dTpa) 
vaccination in the maternity ward to new mothers in both public and private hospital settings 
and b) to determine the impact of gain-loss message framing on vaccine uptake. We 
hypothesised that the implementation of routine pertussis vaccination on the postnatal ward 
would be highly feasible and would achieve vaccine coverage of 75-80% in the study 
population.  
The secondary objective was: a) to determine what factors (including knowledge, attitudes, 
intentions, and perceived susceptibility and severity of pertussis) influence the uptake of the 
pertussis booster vaccine. 
Exploratory objectives were: a) to identify the reasons postpartum women gave for choosing 
whether or not to receive the pertussis booster vaccine prior to discharge and b) to determine 
if and why mothers who consented to receiving the vaccine were not vaccinated before 
discharge. 
Baseline survey aims: 
Our study reports pertussis vaccine coverage among new mothers and their partners receiving 
maternity care in both public and private hospital settings. We also identified correlates of 
pertussis vaccination status among a large sample of new mothers who gave birth in two 
metropolitan hospitals. An outline is presented on the next page.  
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The Introduction introduces the field of research, maternal vaccination, and highlights the 
Chapter five
Conclusion
Chapter four
Discussion
Chapter three
Results
Chapter two
Methodology
Chapter one
Literature Review
Introduction
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current practice in response to Pertussis. In addition, it identifies a gap in current knowledge 
and gives a brief overview of how this study aims to bridge this.  
 
Chapter 1 begins with a literature review outlines the bacteria pertussis, its symptomology 
and management. Next, it addresses the use of vaccines to control this disease. Next, it 
provides background of the recent pertussis epidemics, and strategies of pertussis control. 
This is discussed within the context of vaccine implementation and evaluation.  
Chapter 2 presents the methodology of the study. It discusses the approach and its strength, 
as well as the modification of the methodology for the RCT in the private hospital site. The 
overall study design is a quasi-randomised controlled trial with a pre and post survey, 
utilising both quantitative and qualitative approaches.  
 
 
Chapter 3 presents the results of the study. Firstly, it presents the results from the baseline 
survey of both public and private maternity patients, examining factors that differed between 
those who had been previously vaccinated and those who had not. It also presents the 
findings of the Maternal pertussis controlled trial (RNSH, public hospital site) and 
randomised controlled trial (NSPH, private hospital site) It also includes a mediation analysis 
of vaccine intentions, due to their impact on vaccine uptake in the controlled trial. In addition, 
it includes results of a cross-sectional survey of postpartum women eligible for vaccination 
during pregnancy. Here, we report on uptake during pregnancy.  
Chapter 4 presents the discussion of the study findings.  
 
 
 
Chapter 5 concludes with the major findings of the study and how they can be used to inform 
vaccine policy.  
The value of our research 
This study assists to determine how mothers make decisions about vaccination for themselves 
and what factors influence these decisions. It is the largest cross-sectional study of attitudes 
of newly delivered mothers on pertussis vaccination to date. Additionally, it is the first 
randomised-controlled trial of message framing as an educational intervention among 
postpartum women in the hospital setting. Message framing has not been studied in this 
population, so this trial will determine if "gain or loss" style of pamphlet is more effective in 
the promotion of vaccination than routine information. This study also evaluated whether the 
pertussis booster vaccine could be implemented in the postnatal hospital setting (cocooning), 
   
 
 
19 
and whether it yielded a sufficient uptake needed for vaccination effectiveness on a 
population level. From the data presented in this thesis we have provided recommendations 
about the best possible timing and methods to provide booster vaccination in order to protect 
newborns against pertussis. In particular, we consider the benefits (and barriers if applicable) 
in providing free dTpa during the immediate post-partum period (<7days following 
childbirth).  In a post-hoc analysis, we examined uptake of vaccine during pregnancy, among 
eligible participants. From this, we provided the first data in Australia on key attitudes and 
knowledge as well as vaccine benefits and barriers among women vaccinated against 
pertussis during pregnancy versus those who were not. This is of particular importance as 
there are individual, setting and provider factors which impact upon vaccine completion 
during pregnancy and the immediate postpartum period.     
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Chapter 1 Literature Review 
Overview 
Bordetella pertussis is a gram-negative bacillus which express the following virulence 
factors: pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PER)(6). B. 
Pertussis has exclusive affinity for the mucosal layers of the human respiratory tract, with 
attachment to host cells facilitate by its virulence factors (FHA, PRN, FIM). The bacteria is 
then enabled by other virulence factors (PT, TCT, ACT) to destroy the epithelial lining 
resulting in a breakdown in the host's defence(18). This bacterium causes pertussis, a 
respiratory infection commonly known as ‘whooping cough’. The incubation period can 
range from 4-21days, although averages 7-10days (10). Transmission occurs via droplets 
from an infected individual to a susceptible contact. Pertussis is highly contagious 
demonstrated by up to 17 secondary cases attributed to a primary case (R0 range 15-17, 
indicating the expected number of people to be infected by one diseased person)(6). During 
the early catarrhal stage, this highly communicable infection has a secondary attack rate as 
high as 90% among unimmunised contacts(18). 
Clinical Manifestations  
Pertussis initially affects the upper respiratory tract before progressing to a dry, non-
productive cough over the following 2-7 days. Often, the cough is paroxysmal in nature and 
characterised by an inspiratory whoop. In children, vomiting frequently follows these 
symptoms. If pertussis is left untreated, symptoms usually last between 6-10 weeks.  
Adult symptoms tend to be atypical in presentation, often manifesting with a paroxysmal 
cough (70-93% cases) that persists for more than three weeks (mean 36-48 days), and 
predominantly occurs at night (65-87% of cases) (19). The most common accompanying 
symptoms are whooping (8-82% of cases) and vomiting (17-65% of cases), although 
sweating attacks, syncope and encephalopathy can also occur(19). Pertussis is more than a 
chronic, non-distinctive cough, and those with classic symptomatology tend to have 
prolonged illness requiring frequent use of healthcare(20).  The typical and atypical clinical 
features of pertussis are outlined in Table 1.1.  
 
Table 1.1: Typical and atypical clinical features of Pertussis 
Typical Clinical features (3 stages) Atypical clinical features 
1. Catarrhal (2 weeks) 
Non-specific symptoms: 
 Rhinorrhoea 
 Sore throat 
 Conjunctivitis 
 Non-productive cough 
Adults: 
 Prolonged cough 
 Paroxysmal cough 
 Whoop 
 Phlegm 
 Post-tussive vomiting 
2. Spasmodic (2 weeks) Infants: 
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   Paroxysmal cough (+/- 
cyanosis/facial discolouration)  
 Followed by deep inspiration (whoop) 
5. And / or vomiting. 
6. Occurrence: >30times per 24hours; 
mainly at night 
7. Onset: spontaneous or precipitated by 
stimuli. 
 Apnoea 
 Cough (no whoop) 
 Cyanotic episodes 
 Vomiting 
 Poor feeding 
 Fever 
 Seizure 
 Sudden infant death syndrome 
3. Convalescent (2 weeks -several 
months) 
 Cough subsides gradually 
 Relapse if other respiratory infection 
acquired 
Partially immunised: 
 Reduced duration of catarrhal 
phase  
 Whoop may not occur 
                                                                           Source: Galiza & Heath, 2009(7) 
 
 
Diagnosis 
The diagnosis of pertussis usually takes the form of a clinical diagnosis, with a history of 
close contact with a case and laboratory investigations providing confirmation. However, 
among adults in particular a clinical diagnosis can be problematic. This is due to a reduction 
in clinical suspicion which often results from the misperception that pertussis is a disease of 
childhood(20). In addition, patient presentation to a health care facilities may be delayed 
among adults with atypical symptomatology(20), perhaps due to a diminished disease risk 
perception.  
Once the provisional clinical diagnosis of pertussis has been established, barriers to 
laboratory investigations can further hinder diagnosis. The most common is that the 
sensitivity of diagnostic tests can be decreased due to problems with specimen timing, 
transportation and culture(20). The gold standard for laboratory investigations is pertussis 
culture, which although is highly specific, it only has a sensitivity of 80%(7). This is 
potentially problematic as it can result in a false negative result in one in five pertussis cases. 
A more sensitive test is polymerase chain reaction (PCR) analysis which remains a reliable 
diagnostic tool even if antibiotics have been commenced or three weeks after disease 
onset(21). Accurate and timely diagnosis of pertussis is vital, especially in adults who pose a 
transmission risk to vulnerable infants. 
 
 
Diagnosis of adult pertussis  
The three methods of detecting the bacteria, Bordetella pertussis, are by culture, polymerase 
chain reaction (PCR) or serology. Culture has a high specificity relative to PCR (100% vs. 
93%, respective)(22). However due to the limited sensitivity of culture, PCR detection of 
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Bordetella DNA has become more commonly utilised as it is highly sensitive (58% vs. 97% 
respectively)(23). Over time, the sensitivity of PCR decreases and therefore serology is also 
recommended if the adult patient presents during the initial 2-3week period of coughing.   
 
Serology done by enzyme-linked immunosorbent assays (ELISA) generally uses pertussis 
toxin (PT), which is the only purified antigen of B pertussis with high specificity. A specific 
marker of recent exposure to Bordetella pertussis is an IgG anti-PT antibody concentration of 
>100-125EU/ml(19). There are some limitations with pertussis serology. Firstly, there is poor 
standardisation of testing and immunisation status is not always considered when interpreting 
results. This can be problematic as testing cannot distinguish between antibodies induced by 
vaccination and those elicited by a wild-type bacterial infection(6). Table 1.2 taken from 
Leber (2014) summarises the advantages and disadvantages of the various methods of 
pertussis detection. 
 
Table 1.2: Laboratory testing for diagnosis of pertussis(22) 
 
 
The pathogenicity of Bordetella pertussis has recently come to the forefront of research due 
to changes in the genomic sequence of bacterial PRN and PT. This has given rise to concern 
over increased virulence, which has caused some strain-resistance to macrolides, and 
potential reduction in vaccine efficacy due to antigenic drift(24). The variance between 
circulating isolates and vaccine strains has been attributed to the resurgence of pertussis, 
triggered by changes in vaccine programs. Due to the atypical presentation of pertussis, the 
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following clinical management algorithm has been generated by Wood & McIntyre 
(2008)(25): 
Table 1.3: Clinical management algorithm(25) 
Clinical suspicion of pertussis     
Coughing illness more than 2 weeks  
(or cough of any duration with contact with a confirmed case) 
 
Paroxysms          
Inspiratory whoop         
Post-tussive 
vomiting 
        
Epidemiological links     
One person in chain of contact likely to be infectious  
(from catarrhal stage to 3 weeks after onset of cough) 
Laboratory evidence of pertussis in one of the cases   
Second person has onset of illness within 20 days after contact   
Laboratory investigation (onset of symptoms i.e. cough)    
<3 weeks: nasopharyngeal swab for culture and PCR;  
consider pertussis IgG serology 
>3 weeks: Consider pertussis toxin IgG if available    
  
 
Management 
Antibiotics are the mainstay for preventing further pertussis transmission, and are required by 
both the case and those at risk due to close contact. Macrolides, which exert a bacterial static 
effect by inhibiting protein synthesis, are selected as they eliminate the infective period 
within 7days of use(19). This causes eradication of bordetella pertussis from the respiratory 
tract, provided the treatment course is commenced within 21 days of symptom onset (7). For 
adults, Erythromycin 250mg 6th hourly for 7 days is the prescribed treatment (6). For 
children, a 10mg/kg single dose of Azithromycin on day 1, followed by 5mg/kg dose on days 
2-5 is the recommended treatment (if <6months, 10mg/kg dose for 5 days)(6).Whilst correct 
antibiotic usage is effective in preventing transmission, it has negligible effect on the clinical 
course (26). However, there is some evidence to suggest it may also alleviate symptoms when 
given during the catarrhal stage,(6).Supportive management includes oxygen therapy, 
suctioning and fluid management for infants unable to manage fluids orally(26). Among 
close contacts, the duration of the course of Erythromycin is five days, accompanied by 
vaccination against pertussis where not ‘up to date’ with current immunisation guidelines(4). 
In patients with lung failure aggressive treatment involves the use of extracorporeal 
membrane oxygenation (ECMO)(27).  
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Complications  
Complications arising from pertussis most commonly occur in childhood, particularly among 
infants less than six months old. They include pneumonia, failure to thrive secondary to post-
tussive vomiting, secondary bacterial infections, pulmonary hypertension, conjunctival 
haemorrhage, rectal prolapse, encephalopathy, seizures, brain damage resulting from cerebral 
hypoxia, and death(26). Complications among adults tend to be less severe. They include 
hearing loss, urinary incontinence, weight loss, sinusitis, otitis media, inguinal hernia, 
cracked rib, pneumothorax, aspiration, carotid artery dissection, pneumonia and, rarely, death 
(20, 26, 28).  These can be classified as either infectious (e.g. sinusitis, otitis media and 
pneumonia) or mechanical, due to persistent coughing (e.g. hernia, back pain, rib fractures, 
pneumonia and, rarely, carotid artery dissection)(19).   
 
Post exposure prophylaxis 
 
Australian guidelines recommend the use of antibiotic prophylaxis following exposure to 
pertussis from either a suspected or confirmed case. Macrolides used for treatment are the 
drug of choice for post-exposure prophylaxis, although the course is 5 days for an exposed 
adult(4).  
 
Historical context  
Globally, pertussis was a common childhood illness (200 000 annual reported cases) prior to 
the introduction of the whole cell pertussis vaccine in the 1950s (8). Wide-scale role out of 
pertussis immunisation over the following two decades lead to a drop in the incidence of 
pertussis by over 80%(8).In 1974, the WHO’s expanded Programme on Immunisation was 
established and included three doses of whole cell pertussis vaccine. There has been a steep 
increase over the past three decades in the global coverage of the primary diphtheria-tetanus-
pertussis (DTP) immunisation series, increasing from 20% in 1980 to 82% in 2009 (indicator: 
dose three of DTP)(29). High coverage of pertussis vaccination among infants continues to 
prevent morbidity and has averted around 687 000 deaths worldwide(18). Nevertheless, in 
recent times pertussis has re-emerged despite sustained high coverage of primary pertussis 
immunisation (19). The main factor implicated is waning immunity, especially among 
adolescents and adults as reflected by an increased incidence. Contrary to the misnomer of 
lifelong immunity, the protection induced by an acellular pertussis booster vaccine lasts 5-6 
years. Immunity may extend up to 15 years following natural infection with pertussis(19).. 
Epidemiology 
 
Pertussis occurs worldwide, with epidemics taking place every 3-4 years generally in spring 
and summer. Compared to the pre-vaccine era, there has been a 50-fold drop in incidence(30) 
which has been attributed to large scale vaccination during the 1950s-1960s. In 2008, global 
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vaccination against pertussis was estimated to have averted about 687 000 deaths(18). 
Worldwide, around 82% of all infants receive 3 doses of the pertussis vaccine(18). However, 
delays in the onset of this primary immunisation series leaves infants <6months with little or 
no protection. Although both incidence and mortality reduced by over 90% in the developed 
world, the past decade has seen a gradual increase in pertussis cases reported in industrialised 
countries(18).  There has been a changing epidemiological pattern whereby disease incidence 
has increased in adolescents and adults. A large proportion of this shift has been attributed to 
waning immunity to pertussis, with additional factors including increased disease awareness 
and changes in disease susceptibility, active surveillance, improved diagnostic techniques and 
vaccine characteristics(28). Currently, clinical notifications and laboratory reports form the 
basis of pertussis surveillance in most countries(25).  
 
Burden of disease 
Pertussis remains one of the main causes of vaccine-preventable deaths, accounting for an 
estimated 200 000-400 000 deaths each year, worldwide(7). Theoretically, disease 
elimination by vaccination should be possible as pertussis is an exclusively human 
pathogen(25). However, in reality, it still remains one of the top ten vaccine-preventable 
childhood illnesses. It is also a significant cause of death in infants, among whom pertussis 
incidence remains the highest(18). Furthermore, there is an estimated 20-40 million cases of 
pertussis worldwide(7), with developed countries carrying less than 10% of this burden(18). 
It has been postulated that the true burden of pertussis is underestimated, which is, in part, 
attributed to insensitive diagnostic tests as well as low levels of recognition and 
reporting(25). 
Incidence 
The overall incidence of pertussis has not only increased over the last decade, but there has 
also been some variation according to age groups. The United States of America (USA) CDC 
reports that since 2004, there has been a yearly average of 3055 pertussis cases. In addition, 
there have been over 19 cases resulting in the death of an infant (<12 months), with the 
burden mainly seen in infants <2 months who are too young to be vaccinated(31).  
 
Between 1998-2002, pooled data across 16 European countries showed the highest pertussis 
incidence among infants <12 months old (with a 70% hospitalisation rate)(28). It also 
highlighted a 115% increase in pertussis rates among those >14 years over this period of 5 
years(32).  
 
A shift has been seen in the Australian context, with higher notifications in adolescents (10-
19 years) compared to children (1-9 years) and adults aged 20-59 years comprising 63% of 
notifications(33). The trends that continues is among infants <6 months who have the highest 
notification rates each year, which is proposed as the current focus for protection strategies in 
Australia(33).  
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We should not just consider the incidence of disease within a population, but also the severity 
of it. One way of doing so is by looking at the hospitalisation rates of cases with the 
confirmed disease. As this thesis is focused on protecting infants from Pertussis, we report 
aggregated data of pertussis hospitalisation rates among infants in developed countries (Table 
3). From 2001-2002, Australia faced one of the highest hospitalisation rates of 154 per 100 
000 infants under 12 months.  
 
Table 1.4: Pertussis hospitalisation rates for children <1 year in industrialised countries 
Country Year Hospitalisation rate 
<12 months 
 (per 100 000) 
Source 
USA 2000 
 
58.2 
 
Auger et al.,(34) 
Spain 1997–2001 
131.4 (<12months) 
625.3 (<1month) 
Sizaire et al., (35) 
Denmark 1998-2001 
 
278.6 (0-5 months) 
12.6 (6-23 months) 
Hviid et al.,(36) 
Canada 2012 125 Smith et al.,(37) 
 
Australia  2005 108 Wood et al.,(38) 
England 2012 578 (number of hospital 
admissions) 
Amirthalingam, et al.(39) 
France 1996-2007 257 (<3months) Bonmarin et al. (40) 
Switzerland 2006-2011 38.8 Heininger et al(41) 
                                            Adapted and updated from Wood & McIntyre, 2008(25) 
Pertussis transmission to infants 
When devising control measures, the impact of increased incidence in a specific age group 
(e.g. adults) on other age groups (e.g. infants) needs to be considered.  An example is the 
epidemiological shift observed in developed countries, whereby there are increasing pertussis 
notification rates amidst adults and adolescents. Atypical pertussis, late clinical presentation 
and low recognition rates make adult cases a prime reservoir, and create epidemiological 
challenges in estimating the true disease burden(28). This is problematic, as pertussis is a 
highly communicable disease and has a secondary attack rate of up to 90% amongst non-
immune household contacts(42).  As infants primarily contract pertussis from household 
contacts(13), ‘cocooning’ aims to help protect them indirectly via caregiver vaccination.    
 
A national study identified parents as the presumptive source of pertussis for 68% of the 110 
infants hospitalised due to pertussis in 2001(43). Other adults in close contact with infants 
   
 
 
27 
can also transmit the disease to the infant, with studies reporting grandparents and health care 
works as examples(44). Siblings are an additional source of pertussis transmission to infants, 
with a recent study published by Skoff et al. in Paediatrics in October 2015 indicating 
siblings have replaced mothers as the most common source of infection (43, 45).  It could be 
hypothesised that this is a reflection of recent pertussis control measures, such as the 
introduction of maternal pertussis booster vaccination in United States in 2011. However, this 
study was conducted in the United States between 2006-2013, and may vary to the Australian 
setting. A case control study conducted in the USA with subjects aged 6-59 months found 
that features of household structure were a significant risk factor for pertussis. It found that 
the risk of contracting pertussis was 6.8 times higher if the mother was <25years of age, 2.5 
times higher if they lived with someone other than a parent or sibling, and 2.2 times higher if 
they lived with a sibling 6-11years old(46). Additionally, cases were significantly more likely 
to live with any household member who had reported a coughing illness over 13 days 
duration(46). They also noted that any combination of three or more pertussis vaccinations 
were highly protective against pertussis(46). As this study focuses on infants who are eligible 
for the completed primary vaccine series (>6 months), one could hypothesis that transmission 
risk would be higher among young infants (<6 months) who cannot be fully vaccinated. 
 
Australia 
In Australia, pertussis still remains a prominent public health problem despite a well-
established immunisation program. Under public health legislation, it is a notifiable disease 
that has remained the most common vaccine preventable disease in Australia. Over the 
decade of 1995-2005, notifications numbered 75 458 (33).  This increased dramatically 
between 2000 and 2010, with multiple pertussis epidemics contributing to more than 139 000 
reported cases(4). During this 11-year period, the highest annual incidence of pertussis was in 
2010 where 156 cases per 100 000 population were reported(47).   
 
In the state of NSW, a similar distribution is likely due to recurrent epidemics every 3-4 years 
against the backdrop of endemic circulations of pertussis(33). Pertussis notifications in 2008-
2009 were 2.7 times higher than in the previous five years, reflecting a peak in outbreaks 
(48). The hospitalisation rate was 3.1 times higher than in the previous 5 years, with the 
burden largely born by infants(48). However, when interpreting data surrounding this 
epidemic, there is a need to consider other factors that may have contributed to increased 
numbers of cases. The most notable is the recent introduction of a highly sensitive PCR 
diagnostic test for identifying pertussis early on compared to the previously used methods of 
serology, which usually comes back positive following 2-3weeks from symptom onset(33).   
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When we look at the severity of pertussis using the proxy of hospitalisations, we can see that 
the burden of disease continues among infants. Among this age group, the data is shifted to the 
left in graph 1.5, indicating the most frequent hospitalisations due to pertussis sequelae occurs 
between 3-15 weeks of age. When we look at the cumulative hospitalisations resulting from 
pertussis, we see a trending off around 24 weeks that coincides with third dose of the pertussis 
vaccine (and completion of the primary immunisation series).  
 
Graph 1.5: Australian pertussis hospitalisations <12 months of age 1994-2004 (n=4114)^ 
 
^Graph 1.5 taken from Wood et al., 2008 (38) 
 
Prevention 
Prevention of pertussis is paramount, because it is a serious disease that is very difficult to 
treat. To control disease burden, there are two types of pertussis vaccines available. 
Whole cell pertussis vaccine 
The whole cell pertussis vaccine, which was developed in the 1940s, has been the cornerstone 
of pertussis control for decades. The whole cell vaccine (wP) is a suspension of the 
inactivated B. pertussis organism, usually in formalin, with an aluminium salt adjuvant and 
thiomerals preservative (also known as thiomersal). It is widely available in combination with 
diphtheria (D) and tetanus (T), forming the DTP vaccine. Whilst highly effective, the whole 
cell pertussis vaccine has increased reactogenicity, which manifests as redness and swelling 
at the injection site, and systemic reactions such as fever and agitation. This is backed by 
strong evidence, with a Cochrane review showing a significant reduction in the risk of 
hypotonic hyporesponsive episodes if the acellular pertussis vaccine was used for the primary 
series immunisation compared to the wP vaccine (six trials with a total of 121,573 
participants, RR 0.26, 95% CI 0.08 to 0.81, P value = 0.02)(49). Due to a dose-response trend 
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in local reactions, whole cell (wP) vaccines are not recommended for use in adolescents and 
adults.  
Acellular pertussis vaccine  
The acellular pertussis vaccine (aP) was developed to address this issue of increased 
reactogenicity. It contain purified components of the B.pertussis organism such as inactivated 
pertussis toxin, but some formulas also include filamentous haemagglutinin, fimbrial antigens 
and pertactin(18). Efficacy variation exists not just due to variation in the components 
included, but variances in purification, inactivation and formulation. In similarity to the 
whole cell vaccines, the acellular pertussis vaccination is also frequently combined with 
diphtheria and tetanus to form the DTPa or dTpa vaccine. When used for the primary series 
of immunisation, aP carries no increased risk of an adverse response. However, as an 
increased frequency of swelling has been observed with subsequent doses, a reduced antigen 
content of acellular pertussis is used in the booster vaccine (dTpa) for adolescents and adults. 
Vaccine efficacy 
Immunity 
There is much debate surrounding whether naturally acquired or vaccine-induced immunity 
against pertussis declines faster. This is difficult to determine, as reduced levels of circulating 
Bordetella pertussis may have contributed due to a decreased opportunity for immunity to be 
boosted(50). A recent review on immunity against pertussis concluded that immunity from 
vaccination lasted 4-12 years compared to the 4-20 years range following infection with 
pertussis(50). Vaccine efficacy is difficult to objectively measure due to the interplay 
between factors such as case definition, setting of the exposure, vaccine schedule, time since 
vaccination, age at vaccination, exposure level. Differences between the two types of 
pertussis vaccines is also noteworthy, with the whole cell vaccine has a higher long and short 
term potency but more side effects than the one or two component acellular vaccine(26). 
However, for efficacy the whole cell vaccine is comparable to both the three and five 
component acellular vaccines. The best level of protection has been observed in those that 
receive a whole cell pertussis vaccine initially in childhood then an acellular pertussis booster 
vaccine later on(46).  
The National Prospective Randomized Acellular Pertussis Vaccine Trial (APERT), 
conducted across 8 sites in the United States, demonstrated that the pertussis booster vaccine 
had an efficacy of 92% among healthy adults over a two and a half year period (N=2781; 15-
65 years) (51).  As protection is reported to last between 4-12 years, further research is 
needed to determine how long this effect lasts before waning occurs. There is emerging 
evidence to suggest that antibody levels following vaccination with the pertussis booster 
vaccine (dTpa) wane after five years. In light of this evidence, The 2013 Australian 
Immunisation Handbook modified its recommended interval for pertussis vaccination from 
10 years to 5 years for pregnant women(4). However, recent data shows that antibody levels 
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following vaccination within the last five years may not be high enough to facilitate IgG 
pertussis antibody to the foetus at a level which is protective(52). In light of this research, 
some developed countries, like the US, now recommend a pertussis booster vaccine during 
each pregnancy(31). 
Case definition 
The case definition, in terms of disease severity, is also a factor dictating vaccine efficacy. 
For instance, a completed primary course of vaccination in an infant may have a high efficacy 
in preventing fatal or severe disease, yet have lowered efficacy in averting mild disease(26, 
53). Paradoxically, high vaccine coverage leads to a reduction of the circulating Bordetella 
pertussis pathogen, which mitigates natural boosting of immunity through exposure, and may 
eventually result in an increase in disease (26). Case definition also needs to be tailored 
according to the surveillance system to which it is being applied(26). During periods where 
pertussis is prevalent, a clinical case definition of a cough lasting over 13 days has high 
sensitivity (84-92%) and specificity (63-90%)(26, 54). Here we see the importance of a case 
definition when devising public health strategies to manage an outbreak or endemic pertussis. 
At the population level, careful consideration must be given to case definition when devising 
strategies to address pertussis control. 
Historical context of global pertussis immunisation 
Globally, pertussis was a common childhood illness prior to the introduction of the whole cell 
pertussis vaccine in the 1950s. Wide-scale role out of pertussis immunisation over the 
following two decades lead to a drop in the incidence of pertussis by over 80%(42). In 1974, 
the WHO’s expanded Programme on Immunisation was established and included three doses 
of whole cell pertussis vaccine. There has been a steep increase over the past three decades in 
the global coverage of the primary diphtheria-tetanus-pertussis (DTP) immunisation series, 
increasing from 20% in 1980 to 82% in 2009 (indicator: dose three of DTP)(29). To this day, 
pertussis vaccination of young children continues to prevent morbidity and mortality 
worldwide. In fact, it is estimated that high pertussis vaccine coverage among infants has 
averted around 687 000 deaths worldwide(18). However, with pertussis still accounting for 
195 000 childhood deaths each year, continued efforts particularly in developing countries 
are required to improve coverage.  
The Australian Vaccination Schedule 
In Australia high coverage of the primary immunisation series against pertussis has been 
achieved. This is largely due to mass immunisation programs against pertussis, which have 
been in place since 1942.  However, it was not until 1975 that the first national vaccine 
schedule for pertussis was established (Table 5). Since its commencement, there have been 
several changes to the timing of the three dose primary series. Most notably is the earlier 
commencement time from 3 months to 2 months, which was implemented in 1982. Since 
2008, vaccination at 6 weeks of age has also been recommended due to the high rates of 
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morbidity and mortality among infants under 5 months of age(38). Another notable change to 
the Australian vaccination schedule is the switch in 1999 from the whole cell pertussis 
vaccine (DTPw) to the less-reactogenic acellular version (DTPa). At this time, the 18month 
pertussis booster was removed from the schedule due to extensive limb swelling occurring 
within 48 hours of vaccination (4). The pathogenesis of this remained unclear. Extensive limb 
swelling was defined by swelling/erythema that affected both joints above and below the 
injection site and involved at least half of the circumference of the limb (4). The licencing of 
a lower dose acellular version for adults (dTpa), and the recognition that immunity waned 
following ten years saw the introduction of an adolescent booster vaccine in September 2003. 
This replaced the diphtheria-tetanus booster vaccine (dT), and by January 2004 it was funded 
for students aged 15-17 years via the existing school immunisation platform. The pertussis 
booster vaccine was later extended to adults in 2009, although only funded under certain 
conditions for selective groups. In table 1.6, we see an outline of the modifications to the 
Australian pertussis vaccination schedule since 1975(55): 
Table 1.6: Australia Vaccination Schedules: Age of pertussis vaccination (1995-2009)  
Year Months    
 2 3 4 5 6 18 4yrs 15-17yrs Adults 
1975  X X X  X    
1978  X X X      
1982 X  X  X     
1985 X  X  X X    
1994 X  X  X X X   
1997 X  X  X X * X *   
1999 X *  X *  X * X * X *   
2003 X *  X *  X *  X * X ^  
2009 X *#  X *  X *  X * X ^ X^ 
DTPw unless specified: *DTPa, #at 6weeks), ^dTpa; shading- primary series  
 
Vaccination strategies 
Despite a well-established primary immunisation program, pertussis has again become a 
concern in both developed and developing countries. To address the increasing burden of 
pertussis worldwide, a scientific forum called the Global Pertussis Initiative (GPI) was 
established in 2005(56). This forum enabled international experts to collaborate on strategies 
to combat pertussis. Recommendations to improve disease control through expanded 
immunisation strategies were based on an analysis of epidemiological trends of pertussis. 
These recommendations focused on seven key immunisation strategies, which are based upon 
both universal and selective immunisation of target groups (Table 6). These strategies each 
address a primary objective, which focuses on the either reduction of disease transmission or 
morbidity among a specific group. These groups were selected based on increasing 
epidemiological data of pertussis cases and hospitalisations, in conjunction with vaccine 
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efficacy data. As strategies to protect one target group may involve immunisation of another, 
secondary objectives were also derived.     
Table 1.7: Immunization strategies assessed by the Global Pertussis Initiative 
 
 SOURCE: Forsyth et al 2004.(9) 
 
Universal versus selective immunisation 
The two primary ways of addressing adult vaccination are universal vaccination, to build up 
herd immunity, and selective vaccination, to prevent adults passing pertussis to vulnerable 
groups. An example of selective vaccination is the ‘cocooning strategy’ or ‘cocooning’, 
where household contacts of a young infant are vaccinated to prevent transmission. These 
were both considered at the Global Pertussis Initiative (GPI), with cocooning recommended 
in countries where economically feasible(56). Whilst universal adult vaccination has been 
postulated by the GPI as a logical goal to eliminate pertussis, in practice there are numerous 
barriers to implementation(56). 
When applying any strategy, it is important to consider the elements of a vaccination 
program, which will aid uptake. Key components include vaccine efficacy, access/service 
delivery, sustainability and impact of the strategy on other age groups(9). Additional 
components which have been reported as important in adult vaccination programs are 
education and public awareness(56). Without generating awareness, the reach of the program 
will be limited. However when awareness is coupled with education, it will encourage 
intention or willingness to vaccinate. When considering a vaccine strategy, community 
   
 
 
33 
demand, enhanced access to immunisation services and interventions to increase provider 
promotion are needed to increase the effectiveness of the vaccination program. Below is a 
review of the evidence surrounding strategies to improve vaccine coverage (Table 1.8).  
Table 1.8: Review of Evidence regarding interventions to improve vaccine coverage(57) 
Interventions Examples 
 
Increasing 
community 
demand for 
vaccinations 
 
 
 
 Increase knowledge of vaccine services 
 Increase demand for vaccine services: 
o Client reminder/recall- by mail, telephone, text (7-13% impact on 
uptake) 
o Education- provide knowledge to target population +/- providers 
o Vaccination requirements for childcare, school, college attendance 
o Community-wide education-improves availability of information, and 
increases knowledge, thereby change behaviour (e.g. radio, TV, mail, 
posters.) 
o Client or family incentives (either rewards or penalties) 
o Client held medical/vaccination records 
 
Enhanced access 
to vaccination 
services* 
 
 
 
 Expanded hours or access in clinical settings (hospital, clinic, rooms, ED) 
 Reducing administrative barriers (develop drop in clinic or express lane 
vaccination service). 
 Reducing out-of-pocket costs-> improves vaccine availability or vaccine 
demand 
 
Provider-based 
interventions 
 
 Provider reminders 
 Barriers: administrative burden placed on providers/system. 
 
A recent systematic review(58), which was conducted by The New Vaccine Introduction 
Impact Published Literature Working Group in 2012, looked at the integration of a new 
vaccine into existing vaccine programs and the impact of the country’s broader health 
systems. It stemmed from a request from the Strategic Advisory Group of Experts (SAGE) on 
Immunization, which informs the World Health Organization on global immunisation policy. 
A search spanning almost one hundred years was conducted, yielding 15, 795 articles from 
which 654 (4%) potentially relevant articles underwent full review. A total of 130 articles 
covering ten diseases were included in analysis. The main components of a successful new 
immunisation strategy that were identified included: information, health workforce education, 
service delivery, new technologies, financing and sustainability as well as leadership and 
governance. In addition, vaccine introduction lead to a reduction in disease incidence that led 
to a drop in the usage of related curative health services. 
Health system integration  
When introducing a vaccine strategy, it is important to consider the impact it will have on 
both existing vaccination programs as well as the health system. In the aforementioned 
systematic review of new vaccine strategies, the most efficient means of introduction was 
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integration into an existing delivery platform (58). However, this may require modification of 
existing delivery strategies to ensure they have the infrastructure to manage additional 
vaccination. In addition, existing services must have adequate staffing and consultation time 
for vaccine education and consent, administration and documentation. This review also found 
that new vaccines added to existing programs did not appear to impact coverage of the 
existing immunisation program, however a need for increased cold-chain capacity was often 
reported.  
Platform 
Utilising existing vaccination platforms can help overcome some of the implementation 
challenges and reduce cost. The Australian National Human Papillomavirus (HPV) 
vaccination Program is an example of a successful new universal vaccination initiative, 
including its introduction among childbearing women. Here, the program included an on-
going universal strategy for young adolescents in the first year of secondary school (11-14 
years), with a 2-year a catch-up to age 26 in females. The setting was adjusted depending on 
the age (and life stage) of the target population. Delivery was school-based for teenage girls 
aged 12-18 and via general practitioners (GPs) for young women aged 18-26 years. To 
improve reporting of vaccination by GPs to the National HPV Vaccine Register (NHVR), 
developed to assess coverage, an incentive payment of $6 per vaccine notification was 
introduced for general practitioners(59). Coverage of the HPV vaccine has been moderately 
high compared with most other countries, with little evidence of impact on other vaccines 
offered at this age (59). 
Infrastructure 
Vaccine storage is an important consideration when introducing a vaccine strategy, 
particularly when using a new immunisation platform. For example, the introduction of the 
pertussis booster vaccination into the postpartum setting could be accommodated by the 
existing infrastructure as the rubella vaccine is routinely given in this setting. However, with 
the shift towards pregnancy, implementation may pose more of a challenge as vaccine fridges 
are not a mainstay of obstetric rooms(60). Even where vaccine fridges are part of routine 
infrastructure, limitations on space may be problematic when additional vaccines are 
introduced. One solution to reduce vaccine storage requirements is the introduction of 
combination vaccines. These have additional benefits, such as fewer injections for the patient, 
and cost saving due to the reduction in needles, syringes, storage requirements as well as 
administration. Whilst this is currently not feasible for recommended antenatal vaccines 
(pertussis and influenza), inclusion of pertussis into the existing diphtheria/tetanus vaccine 
provides opportunity to increase pertussis coverage among the general adult population.  
Stakeholders 
Vaccine campaigns now include multi-disciplinary government departments (health, 
education, and defence), local government as well as academic institutions(58). In the UK, 
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establishment of an HPV vaccine implementation group was used as a vehicle to engage 
multiple stakeholders(61).  As school-based delivery was a new vaccination platform in the 
UK, more may be needed to be done to ensure its success.  Engagement of stakeholders has 
also been identified as a key component of the success of a postpartum pertussis vaccination 
within the postnatal ward setting. In the US, supporting healthcare professionals with targeted 
education and an understanding of the rationale of vaccination has been suggested to promote 
their role as an advocate for vaccination(15).  
Evaluation 
Program evaluation is an important step that should occur with the introduction of any 
vaccine strategy. To enable vaccine coverage to be assessed, legislation was used in Australia 
to mandate data collection for the national HPV registry(62). In Australia, we also have the 
Australian Childhood Immunisation Register, which collects data on all vaccines delivered to 
pre-school age children. We also have systems for monitoring vaccine safety, through passive 
and active methods (e.g. AusVaxSafety). Other countries have developed systems to monitor 
vaccine safety and efficacy. Integrating vaccine monitoring with disease surveillance is 
needed to comprehensively assess immunisation strategies. 
Current pertussis immunisation strategies 
Childhood immunisation has been the mainstay of pertussis control in Australia, and is still 
implemented nation-wide. Additional vaccine strategies targeting adults have been employed. 
In 2003, a pertussis booster vaccine was introduced for adolescents aged 15-17 years.  In 
2003, health worker immunisation was recommended to staff working in areas with ‘at risk’ 
patients (e.g. paediatrics, maternity, ICU, NICU)(63). Ten years later, dTpa booster vaccine 
recommendations were extended to all health workers who had not had one within the last ten 
years(4). Whilst these are government recommendations, it is the responsibility of each health 
service to enforce staff compliance with mandatory pertussis booster vaccination. The extent 
to which it can be enforced varies according to the classification of the employee’s role, with 
the highest level of jurisdiction over clinical staff.  
Pertussis booster vaccination coverage among Australian adolescents and adults 
The pertussis booster vaccine (dTpa) has been licenced and available in Australia for adults 
since 2003(55). However, it was not until 2008 that the pertussis booster vaccine was 
nationally recommended for select groups of adults(64): 
a) Couples planning a pregnancy or parents with a newborn,  
b) Grandparents, carers and household contact of young children 
c) Healthcare workers  
d) Adults working with young children (<4years) 
 
Whilst the dTpa vaccine was recommended for selected groups of adults, the commonwealth 
government of Australia did not fund it. This required costs to be covered by the individual.  
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There has been little data evaluating vaccination coverage among adults in Australia. A 
population survey spanning 2003-2009 estimated 11.3% coverage among adult Australians 
(65).  Of all the states, coverage was highest (17.3%) in the state of NSW 17.3%.  Among 
participants from NSW, self-reported pertussis vaccine uptake increased from 13% in 2008 to 
48.4% in 2009. This time period coincided with the NSW state wide cocooning campaign, 
which included free vaccination of new parents and grandparents of an infant (<12months). 
Data supporting this was that the highest pertussis vaccine uptake of 44.2% (95% CI: 37.2-
51.5%) was among participants who were parents of an infant (<12months) (n=277) (65).  
Since 2013, the recommended interval between administration of this vaccine has been 
modified from ten years to five years due to concerns over waning immunity(4). Self-
reported pertussis vaccine status among postpartum mothers indicates that 5-year coverage 
may be low (6%-17%) (15, 17, 65), making it important to study reasons why some mothers 
are vaccinated either prior to or, during pregnancy, or just after, and others are not. 
The cocooning strategy 
The focus of this dissertation is on the best practice for communicating perinatal pertussis 
booster recommendations as part of selective immunisation of caregiver contacts of a 
newborn. This is congruent with the primary objective of reducing disease transmission to 
young infants. Therefore, we will now focus on ‘selective immunization of new mothers, 
family and close contacts of newborns’, which is often referred to as ‘cocooning’. 
The term ‘cocooning’ within the field of immunisation refers to a strategy whereby infants 
are protected from infectious diseases, namely pertussis, through the vaccination of adults in 
close contact with them. A ‘circle of protection’ is formed by vaccinated adults around the 
infant, who is unable to be fully immunised, and therefore attempts to interrupt the spread of 
pertussis to him/her. The term ‘cocooning’ is used interchangeably with the ‘cocooning 
strategy’.  
Cocooning’ is a strategy of vaccinating pregnant woman immediately postpartum and all 
other close contacts of infants aged <12months with a pertussis booster to reduce the risk of 
transmission to infants via indirect protection(31). The strategy was first recommended in 
2005 by the Advisory Committee on Immunisation Practices and has since been widely 
implemented in developed countries(31). However, not all governing agencies support the 
strategy. The WHO concluded that there was insufficient evidence to recommend this 
strategy due to ‘unproven effectiveness’ and ‘significant programmatic difficulties’(18).  
Although cocooning is not universally recommended, it should not be discounted as a 
measure to control pertussis within specific country contexts. The cocooning strategy was 
devised in response to the following dilemma surrounding pertussis control. Pertussis is 
problematic in infants under 6 months of age as they cannot be fully protected by current 
vaccination schedules(25). This is due to the delay in the onset of vaccination until six-eight 
weeks of age due to the immaturity of the newborn’s immune system. However, this delay 
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leaves newborns without any protection against pertussis, and young infants partially 
protected until they have received all three doses of the pertussis vaccine by six month of age. 
It is unsurprising, then, that the incidence of pertussis is around 20-fold higher among these 
infants(66). Furthermore, complications and deaths attributed to pertussis occur almost 
exclusively in this age group(15). Recommendations from the Global Pertussis Initiative 
stemmed from the idea of reducing the ‘reservoir’ of pertussis by immunising adult contacts, 
in an attempt to protect young infants. An infected adult has the potential to transmit pertussis 
for weeks, as both atypical symptoms and decreased physician awareness hinder pertussis 
diagnosis in adults(25). As parents act as the primary vector in 30-57% of infant cases of 
Pertussis, the first step is immunising household members of newborns(56). 
The cocooning strategy aims to indirectly protect an infant by vaccinating the adults in their 
household. It relies heavily on increasing herd immunity, which is a crucial factor in 
providing indirect protection to infants who have not completed the primary vaccination 
series. However, there has been much debate as to whether this strategy is more effective in 
protecting the individual from severe outcomes of infection rather than preventing infection 
per se?(26). The following outlines the benefits and drawbacks of the cocooning strategy(67): 
Advantages: 
 Possible greater acceptability among women than vaccination during pregnancy 
 Improved accessibility to other household members along with enhanced teaching 
opportunities 
 Potential to combine postpartum immunization with a neonatal immunization 
program 
 
Disadvantages:  
 Serum antibody response in postpartum women may not be sufficiently rapid to 
protect infants in the first weeks of life. 
 Provides indirect protection (rather than direct protection) to the infant.  
Implementation: International settings 
Cocooning strategies have been implemented internationally in various settings. In Texas, 
one study achieved 75-86% postpartum uptake by offering a free vaccine in a maternity 
hospital of medically underserved women (where baseline coverage was 6%) (15, 68)(15, 
65). Another study achieved a 53% postpartum pertussis vaccine uptake in a maternity 
hospital in Taiwan(17). A third study, in France, provided a pertussis vaccine prescription on 
hospital discharge, to be filled and administered by the woman’s general practitioner. 
Reported uptake at 3-months was 69%(69). Whilst implementation of the cocooning strategy 
appears feasible in the postpartum period, understanding what factors promote higher uptake 
and the role of socio-demographics and attitudes is crucial to informing educational 
interventions aimed at increasing uptake.  
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Implementation: The Australian Setting 
The ‘cocooning’ strategy has been recommended internationally since 2006, starting with the 
USA(70). However, the national approach to pertussis control in Australia has been 
disjointed. In 2004, the Global Pertussis Initiative (GPI) was established as an expert 
scientific forum to address the issue of pertussis. One of the recommendations was for 
Australia to implement selective vaccination of healthcare workers in addition to new 
mothers, family and close contacts of newborns(9). Four years later, in 2008, the Northern 
Territory was the first state/territory in Australia to partially implement this recommendation. 
From 2009 to 2011, there was a staggered introduction of the cocooning strategy with the 
funded dTpa vaccine across the remaining states and territories (except Tasmania)(figure 1). 
Variation was noted in the selection of ‘adult’ (grandparent, mother, father, caregiver), their 
SES (healthcare and pensioner card holders only in SA) and the age of the infant (newborn, 
<6months, <7months, <12months)(55).  
In March 2009, NSW Health announced that the pertussis booster vaccination would be 
funded for new parents of an infant (<12months). The rationale presented to the public was:  
Due to the ongoing pertussis outbreaks in NSW (>3000 new cases in the first 10 
weeks of 2009), a time limited program of free dTpa vaccine is been offered to all new 
parents, grandparents and any other adults who regularly care for infants under 12 
months of age. The free vaccine is available only from GPs.(71) 
 
Initially, the funded pertussis vaccination for parents and grandparents of an infant 
(<12months old) was available through general practice, prior to its deployment in maternity 
hospitals in 2011. It was then restricted in June 2012 to new mothers during the first 
postpartum fortnight, with vaccination provided in both the postnatal ward and general 
practice settings. In July 2013, the funding of this vaccine was limited to postpartum women 
in public hospitals as an adjunct to the new national guideline of vaccination during the third 
trimester of pregnancy. The introduction of antenatal vaccination was congruent with a new 
international recommendation that had been implemented widely in the USA during 
2011(31), and then the UK during 2012(72, 73).  
 
Figure 1.9: Implementation of the cocooning strategy in Australia from 2008-2014 
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# mothers of newborn infants. 
* parents, grandparents (and carers-NSW only) of infants <12months. 
^ parents of infants <6months. 
% parents, grandparents (and carers-WA only) of infants <7months 
& parents and grandparents of infants <6months with a concession card. 
~ maternity in patients and mothers <2weeks postpartum via GP. 
+ postpartum women in public maternity hospital only. 
Month and year of 
programmatic changes,  
by state/ territory 
Mar 2009 
NSW* 
Apr 2009 
ACT* 
Oct 2008 
NT# 
June 2009 
VIC* 
Aug 2009  
QLD^ 
 
May 2009 
NT% 
Jan 2011 
WA% 
OCT 2010 
SA& 
 
Jul 2012 
NSW~ 
Dec 2011 
ACT 
June2012 
VIC 
Dec 2012 
WA 
June2012 
QLD 
July 2013 
NSW+ 
 
DEC 2010 
SA 
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Evaluation of the cocooning strategy 
The impact of the cocooning strategy was predicted through mathematical modelling due to 
lack of available empirical evidence with which to assess its effectiveness(25). When 
epidemiological data on pertussis in the USA was modelled, it was predicted that the disease 
could be controlled if 65% of close contacts of newborns were vaccinated(74). In modelling, 
cocooning leads to a reduction of 70% in clinical cases of pertussis among 0-3 months old 
and 65% among 4-23month old(75). Among adults, cocooning leads to a 9-17% reduction in 
typical pertussis cases and an 11-25% in mild adult cases of pertussis(75). A 2013 modelling 
study based its estimate on the 72% coverage achieved with postpartum maternal 
vaccination(68), and reported a 20% reduction in annual infant pertussis cases based on an 
incidence of 63.6 cases per 100 000 (infants <12months)(14). Furthermore, the cocooning 
strategy provides more indirect protection when all contacts around a newborn are 
immunized against pertussis(74). Thus, pertussis booster vaccine coverage is a key factor to 
this strategy’s success. 
It has been argued by the CDC that the cocooning strategy has achieved only a moderate 
vaccine coverage among postpartum mothers and limited success for other household 
members (27). They is reflected by data from the US where only 58% of families had one or 
more household contacts vaccinated(15, 31), which is 14% lower than required by modelling 
predictions.  
In certain at-risk populations, a higher level of coverage may be required to protect infants. 
Observational data indicated that pertussis illness was not reduced in infants <6months of age 
by the vaccination of postpartum mothers with dTpa and that efforts need to focus on all 
household and key contacts of the infant(76). This study was implemented in a predominately 
Hispanic, medically underserved population. Whilst cultural and socio-economic factors 
(particularly impact of household structure) may hinder its generalizability, it suggests a 
higher coverage may be required among at-risk groups.  
In a more recent modelling of strategies, universal adult vaccination yielding 40% coverage 
was shown to be more effective in reducing the overall incidence of pertussis than the 
cocooning strategy (74). This would require 40% coverage of routine adult vaccination every 
ten years in order to have the largest reduction in pertussis incidence, and prevent 
resurgence(74). However, for an equivalent number of vaccinations, a stronger impact would 
be seen combining a single adult booster and the cocooning strategy (incidence of 33 vs. 161 
per 100 000 population)(74). The authors note that economic evaluation needs to be more 
detailed than merely numbers of vaccine doses required. A USA evaluation of routine and 
target vaccination strategies using modelling demonstrated that pertussis incidence can be 
reduced (from 37 per 100 000 to 10 per 100 00) when a single, routine adult booster 
(optimally given at 40 years of age) is added to the cocoon strategy(74).With any 
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immunisation strategy, whether universal or targeted, implementation is a key consideration 
to achieving high coverage.    
Key stakeholders in cocooning implementation 
Part of any program to ensure high uptake in a target group involves the strong support from 
health professionals required to deliver the vaccine(77). To this extent, midwives and nurses 
who are administering the vaccine are important stakeholders in smooth implementation of a 
hospital, ward-based pertussis booster vaccination program. The key factors for postnatal 
administration of pertussis booster by a midwife has been reported to be the midwife’s 
perceived susceptibility of newborns to pertussis and their own self-efficacy in vaccination 
provision(78). Pertussis booster vaccination before leaving hospital was perceived as very 
important by midwives from the private hospital, but was not ranked as highly by midwives 
working in a large public hospital(78). This highlights the need for further education to 
highlight to midwives the importance of timely vaccination, as delay in conferral of 
protection may leave the newborn vulnerable to pertussis. 
Education strategies 
To implement the cocooning strategy in the hospital setting requires education of both the 
healthcare workers and patients. In a study in Texas, healthcare worker education focused on 
the severity of pertussis and cocooning rationale. Education was delivered in the format of 
obstetrical grand rounds and in-services provided at regular intervals and convenient times, 
with information reinforced and updates given throughout the study period(15). For study 
participants, posters were placed in clinical areas and an education program was incorporated 
into antenatal classes. In addition, mothers were given a pertussis information pack 
containing bilingual educational materials about the pertussis infection; vaccine 
recommendations and a vaccine information statement were provided. The study yielded with 
86% vaccination uptake (N.B. only 91% of total cohort of 3455, was eligible, making vaccine 
uptake 94% among eligible subjects). Reported barriers to uptake included restricted visiting 
hours due to H1N1 pandemic, limited clinic hours and inaccurate recall of vaccine history. 
A handful of international studies have implemented educational strategies to increase 
pertussis booster vaccine uptake of postpartum mothers within the hospital setting. One study 
conducted brief education sessions and distributed a factsheet amongst parents in the neonatal 
unit. Whilst this increased pertussis knowledge and willingness to be vaccinated, reported 
uptake was only 8% at the six-week follow up(79). Yet in another study, distributing 
factsheets via the infant’s bedside and offering caregivers free vaccination 20 hours a day 
increased coverage from 2% to 87%(16). Within the postnatal ward setting, a study yielded a 
53% uptake by providing pertussis education brochures, a video and a ‘briefing’ by a nurse 
during a third trimester appointment(17). Another study, resulting in a 75% uptake 
postpartum, coupled nurse-lead discussion with postpartum education (bilingual brochure; 
posters)(68). Whilst education delivered by trusted stakeholders appears to influence uptake, 
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evidence is limited. Ensuring uptake of the pertussis booster is challenging as new parents 
have many competing demands for their time: while intention is high, vaccination completion 
may still be low(79). Identification of reasons for inadequate vaccination is vital to increase 
uptake levels and improve coverage. Furthermore, providing vaccination in the immediate 
postpartum period to both parents via the hospital system is predicted to increase pertussis 
booster uptake among this target population.   
Challenges of the cocooning strategy 
The cocooning strategy is targeted at both mothers and other household contacts. The 
following section discusses the challenges of maternal immunisation with in the postpartum 
a) hospital and b) community settings. Following this, the challenges of immunising 
household contacts will be addressed.  
Hospital setting 
Implementation of the cocooning strategy in the USA has been reported as problematic. This 
is due to barriers faced within the hospital setting(68). For example, in studies where 
vaccination was provided by healthcare personnel external to the routine hospital setting of 
delivery, the hours of availability were reduced. This often meant that vaccination was 
provided during clinic hours (Monday-Friday), with no availability over the weekend. 
However, in studies that integrated vaccination into the routine hospital setting, such as the 
NICU or postpartum ward, unrestricted access to a vaccinator was available. Access was 
further increased when a standing order for pertussis booster vaccination was available, as 
nursing staff can administer but not prescribe a vaccine.  
A midwife’s own perceived self-efficacy of providing vaccination was the key factor in 
providing postpartum pertussis immunisation in one study(78), highlighting the importance 
of staff training. This is paramount, as nurse-midwives are ‘pivotal’ to high postpartum 
uptake(15). A postpartum dTpa standing order and ward stock can further allay hospital 
vaccination barriers, with implementation yielding uptake over 80% (15). A printed 
postpartum vaccine order has been used to flag a patient’s susceptibility to the provider, and 
has reportedly increased the odds of rubella vaccination odds by 6.8 (95% CI 3.3-13.7) 
following its introduction(80, 81). To mitigate implementation challenges of the cocooning 
strategy, elements of successful adult vaccination programs, such as free vaccination(15), 
staff training(15), standing orders or prescription(15, 69, 82) and accessible stock(15) need to 
be incorporated in the hospital setting. 
Maternal response to vaccination 
One weakness of the cocooning strategy is the 14-day delay in antibody response following 
pertussis booster immunisation, which leaves neonates vulnerable to exposure. In postpartum 
women, antibody responses achieved 90% of their maximum titre by two weeks following 
immunisation whilst protection in breast milk was detected in one week and peaked at day 10 
then decreased slowly until day 28(67). Although mothers’ response to pertussis 
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immunisation is relatively rapid, it was concluded that this provides insufficient protection of 
the neonate for the weeks following birth(67). This response is similar to a study among adult 
health care workers, which showed that 88-94% had a response to the pertussis booster 
vaccination by two weeks(83). To overcome this shortfall, vaccination during pregnancy is 
currently recommended in the USA (with cocooning as an alternative) as it provides direct 
protection(31).  Furthermore, modelling comparing antenatal versus postnatal vaccination 
suggests that vaccination in pregnancy would avert more cases of pertussis at a lower cost 
among infants <2months of age(84). 
Household Contacts 
‘Cocooning completion’, whereby all adult household members are vaccinated ensuring 
maximal indirect protection to the infant, is logistically challenging. International studies 
have utilised novel settings, as the delivery platform for adult pertussis vaccination. These 
include the neonatal unit, postpartum ward and paediatric office, with uptake among fathers 
ranging from 8-71% (15, 82, 83). In the paediatric office setting, vaccination offered 2-4 
weeks after the baby’s birth resulted in a 45-69% uptake(85, 86). However, if vaccination 
occurred within days of birth, the number of fathers needing to be vaccinated to prevent one 
infant pertussis hospitalisation would decrease from 1608 to1406(87). This is feasible in the 
hospital setting, with vaccine uptake ranging from 6.5% on the postnatal ward to 87% in the 
NICU(15). A study in Texas interviewed postpartum women regarding their household 
contacts’ vaccination status to determine eligibility for the Tdap booster (aged 11-64 years, 
no prior Tdap vaccine or medical contraindications). There was a range of 1-15 eligible 
household contacts, yet only 58% of families had one or more household members 
vaccinated(68). In one study, household contact immunisation on the postnatal ward was 
impeded by restricted visiting due to an influenza outbreak(15). In Australia, a cross-sectional 
survey conducted in Victoria reported vaccine coverage among new fathers was 50%, with 
5% uptake prior to their baby’s birth(82). However, this yielded a small sample (n=105) with 
only a 43% response rate and was limited to one state in Australia. Pertussis vaccine uptake 
among partners in the Australian setting has not been sufficiently evaluated. To increase the 
efficacy of the cocooning strategy, increased vaccine coverage among household members is 
warranted.  
 
Prenatal Vaccination 
A key public health intervention is maternal vaccination during pregnancy, which is 
recommended when a mother or infant are at significant risk of disease for which a safe and 
effective vaccine is available(88). This is applicable to pertussis, where young infants are 
vulnerable to infection despite sustained high coverage of the primary vaccination series(18). 
This is due to immunization being delayed until after the newborn period, which leaves those 
under 6 months with little or no protection. Maternal vaccination during pregnancy addresses 
this gap by providing direct protection to the foetus, thus affording some protection during 
the neonatal period. However, it is unknown to what extent maternal antipertussis antibodies 
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are effective in preventing pertussis in the infant offspring.  During early infancy, prior to the 
commencement of the primary Dtpa series, it has been hypothesised that maternal antibodies, 
which have been transferred across the placenta, may protect the offspring from pertussis(31). 
However, evidence is limited. Theoretically, maternal vaccination at 30-32weeks gestation is 
optimal in that it avoid any first trimester concerns regarding vaccine-related pregnancy loss 
whilst still ensuring a maternal immune response is induced prior to maximal placental 
transfer(89). 
Figure 1.10: IgG transfer from the mother to the foetus during pregnancy across the syncytiotrophoblasts of the 
placenta. 
 
 
1. Syncytiotrophoblasts are bathed in maternal blood 
and internalize maternal IgG in endosomes (FcRn is 
expressed on the internal surfaces of the endosome).  
 
2. Upon acidification in the endosome, maternal IgG 
bound to FcRn is protected from degradation by 
lysosomal enzymes and then is transcytosed.  
 
3. The endosomes fuse with the membrane on the 
foetal side of the syncytiotrophoblast, where the 
physiological pH promotes the dissociation of IgG 
from FcRn to the foetal circulation. 
 
NB: High levels of IgG antibodies cause IgG 
degradation due to the saturation of FcRn receptors.  
 
 
         Figure & explanatory text taken from: Palmiera et al., 
2012. Clin Dev Imm(90) 
 
 
 
There has been higher concentrations of the pertussis antibodies in the cord blood of a 
newborn whose mother has either received a pertussis booster vaccination during or just prior 
to pregnancy(91, 92). These pertussis specific antibodies have been suggested to supply some 
protection resulting in reduced disease severity but may not be effective in preventing 
pertussis in the offspring (see figure below). Concerns have been raised about the possibility 
of the offspring having a blunted immune response to the primary DTPa series(93, 94). 
However, this may not be such a concern as transferred maternal pertussis antibodies have a 
half-life of around 6 weeks(95), which is the earliest time the Australian primary DTPa series 
can be commenced in an infant in the clinical setting. Another secondary benefit of maternal 
immunisation is the protection it affords the mother during pregnancy. With limitations on 
treatment options during pregnancy, and the propensity for severe illness due to lowered 
immunity, the benefits of this vaccine strategy are magnified.  
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Unlike the indirect protection afforded by cocooning, vaccination during pregnancy at 30-32 
weeks gestation optimises placental transfer of maternal pertussis antibodies to the 
foetus(31). This results in direct protection during the neonatal period, when newborns are 
most vulnerable prior to the commencement of the primary pertussis vaccination series. The 
question still remains as to the extent of protection afforded by this technique. A recent study 
involving 105 participants concluded that maternal vaccination either in early pregnancy or 
prior to conception provided insufficient pertussis antibodies to protect the newborn against 
pertussis(52). Thus, vaccination during the third trimester was recommended for each 
pregnancy. However, this was based on 19 women vaccinated during pregnancy, which is 
why further research investigating neonatal pertussis antibody levels is required. 
 
Figure 1.11: effect of maternal neutralising antibody on foetal IgG and transfer of IgA via 
breast milk the protection afforded in the first year of life versus no protection(96). 
 
The most prominent example of maternal vaccination during pregnancy, which was rolled out 
globally in the 1990s, is the World Health Organisation’s (WHO) Maternal and Neonatal 
Tetanus Elimination Program(97). There has been 93% reduction in deaths from neonatal 
tetanus, with over 80% coverage achieved among women of childbearing age (1999-2012). 
Key programmatic strategies include 1) ‘strengthening routine immunization of pregnant 
women with tetanus toxoid vaccine’ and 2) supplementary immunization activities in areas of 
high risk (i.e. targeting women of child bearing age with 3 properly-spaced doses of tetanus 
toxoid) and 3) reliable surveillance(97). When considering targeted maternal vaccine 
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strategies to protect against infant pertussis, elements of successful programs should inform 
implementation. 
Maternal vaccination during pregnancy (27-36 weeks gestation) has been recommended since 
2011 by the Advisory Committee on Immunization Practices (ACIP) of the Centre for 
Disease Control and Prevention (CDC)(31). Implementation in the USA (2011) and UK 
(2012) has yielded a 49%-79% uptake(72, 98). An observational study in the UK showed 
vaccine efficacy was 90% in preventing pertussis in infants <2months(39). Additional trials 
have also demonstrated the safety of pertussis booster vaccination during pregnancy(99, 100). 
Since 2013, Australian Immunization Guidelines have included pertussis vaccination during 
pregnancy, with a media release by the State Ministry of Health alerting providers and the 
general public to this change in pertussis control(4, 5). As a result, in July 2013 there has 
been a shift in the focus of NSW vaccine policy from indirect protection of neonates via 
cocooning (postpartum maternal vaccination) to direct protection via antenatal vaccination 
(this occurred mid-way though the project phase of this thesis). This change in policy results 
from a lack of research into the efficacy and cost-effectiveness of postpartum immunisation 
as well as a recent USA study highlighting the implementation difficulties of this 
strategy(67). A recent study conducted in three antenatal clinics in NSW hospitals reported 
that 80% of participants were willing to receive the pertussis booster vaccine during 
pregnancy(101).  However, the primary purpose of this study was to assess antenatal 
influenza vaccination that could have influenced participant’s receptiveness to antenatal 
pertussis vaccination. Furthermore, this study only assessed vaccine willingness rather than 
vaccine intentions and uptake. Currently, research determining the acceptability of antenatal 
vaccination and utilisation of the antenatal clinic as an immunisation platform for pertussis 
vaccination in Australia is lacking. 
Acceptability among target groups is vital to achieve high coverage of vaccine strategies. When 
considering new mothers, it is not known whether acceptability differs depending on vaccine 
timing (e.g. during pregnancy versus postpartum). Additionally, the setting of vaccine 
provision may also impact coverage, due to both barriers and acceptability of the immunisation 
platform. A study looking at immunisation against Influenza during pregnancy found uptake 
varied depending on whether the vaccine was received via general practice or at the hospital 
where an immunisation nurse specialist was present in the antenatal clinic (102, 103). However, 
access to vaccination in the antenatal setting is not the only factor at play.  
Obstetricians and midwives are key stakeholders when it comes to antenatal vaccination. 
However, for them to ‘run with the baton’, they need to adopt immunisation as an integral part 
of their roles. One logistical issue is that obstetricians do not always stock vaccinations in their 
rooms which, unlike the case for paediatric vaccination, creates an additional access 
barrier(104). A private obstetrician has been found to be associated with higher acceptance of 
influenza vaccination during pregnancy, in comparison to midwife-led or resident clinic 
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care(105). However, this research was conducted during an influenza pandemic, when 
awareness of the need for vaccination may have been heightened among providers.  
Knowledge and attitudes that relate to vaccination  
Two key factors which determine vaccine uptake are public acceptance of and public 
confidence in immunisation(106). This is due to the fact that behaviour is driven by an 
individual’s perception, irrespective of whether they are based on the facts or stem from a 
misconception(107).  For health promoting behaviours that carry a small amount of risk, such 
as vaccination, this can be problematic as these concerns have the potential to outweigh 
disease concerns. This can lead to ‘immunisation hesitancy’, which negatively impacts on 
population uptake of routine vaccines(106).  
Historical influence of vaccine perception 
In the 1960s, following two decades of widespread early childhood immunisation, adverse 
public perceptions of the whole-cell pertussis vaccine started to take effect. With the 
incidence of pertussis having decreased, it is believed that this disease was now being 
perceived as ‘mild’ and ‘scarce’ due to social and medical development(108). With pertussis 
‘under control’, disease severity was soon overshadowed by potential adverse vaccine 
reactions, such as seizures, infantile spasms, SIDS and encephalopathy. These ‘reactions’ 
were later demonstrated as unrelated to the whole cell pertussis vaccine (with the exception 
of encephalopathy that carries a <1:100, 000 attributable risk). However, vaccine uptake had 
already declined by as much as 50% in countries such as England and Wales. Pertussis 
vaccine coverage was only 30%, giving room for the disease resurgence(107). This illustrates 
how ‘immunisation hesitancy’ is associated with poor vaccine uptake, which leads to low 
vaccine coverage and subsequent disease resurgence.  
Origins of vaccine perception 
Whilst vaccination is often perceived as a personal choice, it is to some extent inextricably 
linked to social norms. A recent review by Cairns et al., (2012)(106) listed the following 
contributors to general vaccine perceptions: 
 Active anti-vaccination movement. 
 Rapid dissemination of both information and misinformation using technological 
mediums (e.g. internet). 
 Perception of the consequence of either delaying or declining a vaccine may be 
minimised, as vaccine preventable diseases (VPD) are seldom seen first-hand. 
 Decreased public trust in expert opinion. 
In this review, the authors concluded that addressing vaccine misperceptions with scientific 
evidence derived from passively disseminated population studies is inadequate. It has been 
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suggested that active preparedness rather than a passive response to vaccine safety events is 
required by public health systems(109).  
Risk perception 
The central factor which impacts vaccine misperceptions is the way ‘risk’ is perceived. In a 
national survey in the USA, the majority of parents had an understanding on the benefits of 
vaccination but also held misconceptions which negatively impacted their vaccine 
confidence(110). In today’s society, the public’s confidence in vaccines continues to be 
undermined by the propagation of perceived vaccine risks via social media. With the decrease 
in disease presentation on a societal level coupled with the ‘unnoticed’ risk of atypical 
pertussis presentations, vaccine safety has become the primary concern.  
Access to information 
Another key determinant of vaccine uptake is access to information on vaccination. However, 
‘information’ does not necessarily mean a brochure but rather information from a trusted 
healthcare provider. When considering childhood vaccination, one study found that one in 
three parents reported that they did not have access to enough information to make a decision 
about vaccinating their child. Yet another study, which provided parents with vaccine 
information in the waiting room, found that only 5% of parents read the information prior to 
the consult with the paediatrician(111). Whilst access to information on vaccination is an 
important factor, both the type of information and the institution it is derived from are also of 
significance.  
Trust- a central component in vaccine education 
‘Trust in the medical establishment’ is a central concept that has emerged in qualitative 
research on infant vaccination.  A mother’s trust in the competence of a healthcare provider 
was aided by certain qualities that made them ‘trustworthy’. These included: a large amount 
of scientific information, a passionate manner when discussing vaccination, ‘spent a long 
time’ and took a ‘whole person’ approach by treating the patient as an individual rather than 
being condescending(112). Another qualitative study found that promoters of vaccination, 
key sources of information and inhibitors of vaccination were three key domains of vaccine 
decision-making for mothers (Table 7) (112). The following were ‘promoters of vaccine 
acceptance’: a) trust in the doctor, b) satisfaction with provider’s vaccine discussion, c) 
compliance with cultural norms, and d) adherence to social contact. The key information 
source for the parents, who vaccinated their children (vaccinators), was the paediatrician, as 
they were also the preferred trusted source. Whilst they may be identified as such, demands 
on their time may hinder their ability to provide the necessary information on vaccination for 
parents. Another study found that paediatricians spent 1.9 minutes on average discussing 
vaccination(111). This translate to less than 10 minutes of cumulative vaccine discussion by 
the time a child reached the completion of the primary immunisation series(111). 
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For parents, who declined vaccination for their child (non-vaccinators), the trusted vaccine 
information source was the homeopath/naturopath, followed by the internet, books and 
parenting magazines. The parents who delayed the vaccination of their child (late 
vaccinators) expressed conflict about how to get their questions answered and who to trust, 
and often resorted to a range of sources. The key inhibitors of vaccination that were identified 
included a) fear of vaccine error b) belief the child would contract the disease anyway c) 
belief that vaccine preventable diseases (VPD) is ‘not so bad’ and d) fear about permanent 
adverse events.  
Table 1.12: Promoters and Inhibitors of Accepting Vaccination 
Promoters of accepting vaccination 
Vaccinators 
Trusting the doctor 
Feeling satisfied by the paediatrician’s discussion 
Feeling that vaccinating is the cultural norm 
Believing in the social contract 
Having positive past experiences with vaccines 
Wanting to prevent disease 
Inhibitors of accepting vaccination 
        Vaccinators 
Fearing mistakes being made 
        Both vaccinators and non-vaccinators 
Believing children get the disease anyway (especially chicken pox and influenza) 
Believing that vaccine-preventable diseases are not so bad (e.g., chickenpox) 
       Non-vaccinators 
Feeling alienated by and distrusting the paediatrician 
Having a previous negative experience with the medical establishment resulting in distrust 
Having a trusting relationship with an influential naturopath/homeopath or other who supported not 
vaccinating 
Distrusting the doctor’s information: doctor does not know and does not have the time 
Distrusting motives: vaccination is just a money-maker for paediatricians and vaccine industry 
Believing that diseases are not around, are not serious, or are easily treatable 
Worrying about permanent adverse effects (e.g., autism) 
Feeling that since other children are vaccinated their child is not at risk (“reverse social contract”) 
Table 1.12 taken from: Benin et al., 2006. Pediatrics 117(5). 1532-1540(112). 
 
Timing of vaccination discussion 
Whilst this study focused on the decision mothers made for their infants, vaccine decision-
making actually starts during pregnancy and therefore discussions surrounding vaccination 
need to commence then(112). In Australia, where midwives are the primary care provider for 
the majority of pregnant women(113), vaccine discussions are an integral part of their health 
promotion role. This is of particular importance for a number of reasons: firstly, midwives 
instigate the first discussion about infant vaccination with pregnant women during their third 
trimester appointment. Secondly, midwives provide the first infant vaccination shortly after 
birth. Thirdly, the majority of Australian women birth in a public hospital and will not have a 
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paediatrician for their infant. Lastly, the first scheduled contact with their general practitioner 
at the six-week postpartum check-up when infant vaccinations are due. Our previous research 
into midwives’ attitudes towards pertussis vaccination found that it was determined by the 
perception that it was part of the midwifery role along with a midwife’s perceived confidence 
and skill in providing pertussis booster vaccination(78). Additional education may be needed 
to strengthen vaccine discussions in around not just infant vaccination, but for pregnant 
women also. 
 
Parental attitudes towards pertussis booster vaccination  
Ascertaining the level of parental knowledge and attitudes specifically towards pertussis is 
important when implementing vaccine strategies such as ‘cocooning’. A study conducted 
within the nursery of a tertiary hospital examined the impact of an educational intervention 
among 150 parents and grandparents(79). The intervention was comprised of a 5-10 minute 
oral education session and a one-page information sheet in English & Spanish. To assess its 
affect, participants completed a pre and a post questionnaire that explored their knowledge of 
pertussis. Baseline responses indicated that 67% of subjects were aware of pertussis 
transmission occurring via airborne droplets, 36% were aware that waning immunity 
impinged on pertussis protection and only 15% were aware of the Advisory Committee on 
Immunization Practices’ recommendations around pertussis vaccination(79). Initial vaccine 
concerns were ‘whether the vaccine was necessary’ followed by safety, efficacy and potential 
adverse effects. Following the educational intervention, the perception of the infant being at 
high risk of pertussis increased from 32% to 76%. Despite the intervention leading to a 
13.3% increase among parents willingness to be vaccinated, vaccine uptake was a low 8%. 
This highlights that although education may shift the attitude towards pertussis severity for 
the infant, there were additional factors impinging on behavioural change. Following the 
educational intervention, the primary concern surrounding vaccination necessity still 
remained. Additionally, lack of time and forgetting the recommendations were the primary 
reasons for not getting vaccinated within the six weeks following the intervention. 
The cocooning strategy, which focuses on indirect infant protection, is unlike other 
mainstream vaccination strategies focusing on primary prevention in the recipient. However, 
it is not evident in the literature whether parents understand the concept of ‘indirect 
protection’. Tam et al., reported that their educational intervention was more successful at 
increasing the subject’s awareness of their own risk to pertussis rather than awareness about 
their baby’s risk(79). Another cocooning study, which was conducted in a neonatal intensive 
care unit, reported that the 11.1% refusal rate was due to either disbelief in vaccination or 
pertussis being viewed as an insignificant health event(16). The latter is an important factor 
to consider when educating parents about pertussis booster recommendations.  
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Mothers’ attitudes towards acceptance or decline of the pertussis booster vaccination were 
studied in Taiwan(17). In a large public teaching hospital (5000 births per year), 1207 
postpartum women completed a three-page questionnaire (comprised of 25 multiple-choice 
questions). Pertussis vaccine uptake was 53%, with key reasons being 1) belief that the 
woman would be the most likely source of pertussis infection for her baby (49.5%) 2) belief 
that pertussis was a severe disease for newborns (20.3%) and 3) belief that the risk was high 
for her baby to contract pertussis (9.1%). Reasons for declining the vaccine (47%) were 
vaccine side effects (24.3%), believing the neonate is not highly susceptible to pertussis 
(20.8%) and the fear of vaccine effect on breastfeeding (16.2%).   
 
Provider attitudes towards pertussis booster vaccination 
Trust in the medical establishment is a key factor in vaccine-decision making by new 
mothers. However, the recent shift towards maternal vaccination during the antenatal and 
immediate postpartum period has put the onus on obstetric providers. We have previously 
shown that their attitudes and beliefs directly impact vaccine administration (78).However the 
extent of our research may be limited to health systems where a midwife is the main provider 
of low risk pregnancy care.  
In the obstetric-led context, one study reported that 68% of obstetricians and 48% of obstetric 
nurses thought it was ‘beneficial’ to vaccinate postpartum women against pertussis(60). 
However, in practice, the majority of obstetricians (96%) reported providing the vaccine to 
<10% of postpartum women. The perceived provider barriers to pertussis vaccination 
reported by obstetricians include patient refusal (94%), reimbursement (83%), vaccine cost 
(77%), a lack of vaccine stock (77%) and ‘discomfort’ providing pertussis vaccine education 
(53%). Additional barriers related to vaccines in general included time constraints (71%), 
storage difficulty (68%), frequent changes in immunisation recommendations (61%), lack of 
personnel (55%) and liability concerns (52%). Time constraints during consultations have 
been previously reported, with 1.9 minutes being the average reported time paediatricians 
spent discussing vaccination with their patients(111). Currently, there is no data on the time 
obstetric providers spend discussing vaccination with women during the perinatal period(69).  
Provider acceptability within the antenatal setting 
Pertussis booster vaccination provision by midwives is both acceptable and easily integrated 
within the postnatal ward setting(78). Obstetric ward nurses have been identified as vital to 
increasing postpartum uptake within the ward setting(15). Within the clinic setting, antenatal 
vaccination has been successfully delivered by non-obstetric providers. Provision of 
Influenza vaccination by dedicated nurse immunisers in the antenatal outpatient clinic was 
aided by direct patient referrals by obstetric providers, patient understanding of vaccine risks 
and benefits, visibility of within the clinic, interpreter assistance and inclusion of nurse 
immunisers as part of healthcare team(102). This indicates there is general support by 
obstetric providers for vaccination during pregnancy.  
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The structure of care provision is an important factor to consider when reorientating vaccine 
delivery from the postpartum to antenatal setting.  The main difference is that postpartum 
women are inpatients, making them a ‘captive audience’. Furthermore, obstetric staff are 
present around the clock to answer vaccination queries whilst providing routine care. The 
shift to vaccine provision to the antenatal clinic setting dramatically reduces contact time and 
intensity. Barriers highlighted with the provision of other routine antenatal vaccinations need 
to be considered when implementing pertussis booster vaccination within the clinic setting.  
Nevertheless, with the correct structural supports obstetric provider acceptability may be 
translated into vaccine provision within the antenatal clinic setting.  
Health education 
Overview of health promotion: 
Attitudes, beliefs and intentions are psychological factors which influence a person's decision 
whether or not to engage in a particular health protective behaviour. An attitude is an 
evaluation of a behavioural outcome which is formed by a belief that dictates whether 
performing that behaviour will lead to a positive or negative outcome (114). Health decision-
making may also be influenced by ‘subjective norms’. A subjective norm is an individual’s 
perception of whether influential figures (e.g. doctor) think they should perform a certain 
behavior and their compliance with this recommendation. Whilst the factors involved in 
decision-making are interactive, they are not always commensal. For example, a patient may 
believe that vaccines are protective (belief), yet perceive the side effects as severe (attitude) 
and therefore have no intention to be vaccinated (intentions). Understanding how these 
factors interact is important when formulating vaccine communication. As these factors are 
represented in theories of health behaviour, they are a useful framework for understanding 
and predicting health behaviour.  
Theoretical underpinnings of health communication  
When evaluating health communication, it is important to have a framework which assists in 
unpacking the way a person interprets and applies information required for making a health-
based decision. The two main health theories, the Health Belief Model and Theory of planned 
behaviour (TPB), use an expectancy-value framework to predicate health behaviour of an 
individual(114). Both assume that this decision-making is a rational and well thought-through 
process by the individual. A recent comparison study showed that whilst the TPB 
outperformed the HBM in predicting vaccine uptake, particularly for intentions, subjective 
norms and self-efficacy, the HBM constructs of perceived susceptibility and barriers were 
stronger predictors of uptake(114).  
Health Belief Model 
The Health Belief Model was developed in 1950s to help forecast whether individuals would 
participate in disease prediction and prevention programs. It measures attitude and knowledge 
constructs of health behaviour: disease susceptibility and severity, barriers to vaccination, 
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effectiveness of vaccination, and cues to action(115). The following Figure 1.13 is a 
diagrammatic representation of the levels of health decision-making represented by the 
Health Belief Model constructs:  
 
 
 
Figure 1.13: Diagramatic representation of HBM addressing areas of decision making 
 
Theory of planned behaviour  
Theory of planned behaviour (TPB) stemmed from the Theory of Reasoned Action, which 
postulated that behavioural intentions serve as a proximal cause of behaviour, and are formed 
by attitudes and subjective norms(114). Both theories support the notion that intentions are 
the vehicle through which attitudes and beliefs indirectly influence behaviour. In addition to 
this, the TBP includes the construct ‘perceived behavioural control’ that refers to perceived 
control, perceived difficulties and self-efficacy of performing specific health behaviour. This 
is predicted to have both an indirect and direct effect on behaviours via intentions.  
Figure 1.14: A comparison of the HBM and TPB(114). 
Health Belief Model Theory of Planned Behaviour 
Perceived barriers Perceived behavioural control: self-efficacy 
Cues to action 
Attitudes and subjective norms 
(Indirectly related due to social influence) 
-  Behavioural intentions 
Self-efficacy 
(later added) 
Self-efficacy 
 
Prospect Theory 
Prospect theory, a behavioural economic theory developed in 1979 by Kahneman & 
Tversky(116), is useful when evaluating the risk inherent with certain health behaviours. It 
purports that a person is more willing to accept a risk when they evaluate the health 
behaviour in terms of associated costs rather than when it is described in terms of associated 
benefits(117). This explains why a message framed in terms of loss would make a reader 
more likely to engage in risk-seeking behaviour, while the opposite is true of gain-framed 
messages(118). This theory was been tested for risk associated with preventive behaviour of 
Intentions
Attitudes
Beliefs
• Setting specific
• Provider specific
• Time specific
• Percieved benefits
• Perceived barriers
• Parental responsibility
• Disease severity and susceptibility
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sunscreen usage (risk of skin rash) and hepatitis vaccination (pain).  Sunscreen usage is a 
health behaviour that does not carry a risk (such as infection site pain), so the ‘loss’ of skin 
cancer motivates its use. When this theory was applied to vaccination, the results did not 
support it. Here, participants who read loss-messages were more averse to temporary risk, 
thus indicating the importance of temporary discomfort (117). This is highly relevant to 
vaccination behaviour, because there is temporary risk involved in enduring a vaccination. 
However, there are some conflicting results as this theory has been applied to health 
behaviours as a whole. Therefore, further research is needed to fully understand which types 
of messages are beneficial for vaccine decision-making in particular.   
 
Determinants of vaccine intention 
In the planning phase of this study, it was noted that testing of ‘message-framing’ was based 
on whether the individual intended to receive the vaccine(119, 120). However, vaccine 
intentions do not always translate into vaccine completion. This is due to the complexity of 
vaccine-decision making, whereby attitudes, perceived norms and self-efficacy all determine 
intention. Underpinning these are behavioural, normative and control beliefs as represented in 
the schema below: 
 
Figure 1.15: Schema of Beliefs related to factors determining vaccine intention.  
 
With this in mind, theorists surmised a way of addressing individual’s beliefs in order to 
encourage vaccine completion. Interventions need to be targeted either at the ‘non-intenders’ 
or with those who are not acting on their intentions(121). This involves identifying critical 
beliefs underlying a person’s intention to perform (or not perform) any given behaviour and 
use them as a target for persuasive communication. For example, among those intending to be 
vaccinated the intervention should be designed to help the individual act on their intention 
through skill-promotion and reducing environmental barriers (see table below). Among those 
Behavioural
Attitudes
E.g. The vaccine for 
whooping cough is 
effective for 
preventing whooping 
cough among adults.
Normative
Percieved norms
E.g. It is my 
responsibility to be 
vaccinated to protect 
my baby.
Control
Self-efficacy
E.g. I don't have the 
time to get a 
vaccination
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who do not have any intention to be vaccinated, both normative and self-efficacy beliefs need 
to be addressed.  
Attitudes can be changed by strengthening the association between the existing belief and the 
attitude. For example, attitudes towards vaccine efficacy for adults could be linked to the 
normative belief of parental responsibility to promote vaccine uptake. For those with 
intention not to be vaccinated due to a negative experience, a different approach may be 
needed by health professionals. This is due to the fact that it is more difficult to change 
beliefs based on direct experience, rather than inference or information provided by an 
outside source(122). 
 
Table 1.16: The Intention-behaviour Matrix: Implications for Interventions(122): 
  Performance of the Recommend Behaviour 
  NO YES 
Intention to 
perform the 
recommended 
behaviour 
NO Change outcome and normative and 
self-efficacy beliefs 
Change outcomes and normative 
and self-efficacy beliefs 
YES Improve skills 
Reduce/help overcome 
environmental barriers 
No intervention or maintain 
positive intention 
Fuzzy Trace Theory 
Fuzzy trace theory is useful in unpacking the cognitive connections made when vaccine 
information is received and interpreted by an individual. It highlights the interaction between 
background knowledge, dual mental representation as well as the process by which values are 
retrieved and applied to vaccine decision-making. Dual mental representation incorporates 
gist and verbatim. Communication of gist and verbatim representations are not based solely 
on verbal information, but extend to numbers, images and events. This is crucial as decision 
making is guided by gist rather than verbatim facts(123). This is linked to the way a person 
stores a stimulus concept as both visual and verbal codes, which are later utilised when 
recalling information(124). This ‘dual-coding’ is advantageous as it increases the chance of 
an individual remembering the stimulus. However, it can be disadvantageous in situations 
such as rare adverse vaccine reaction, where knowledge gaps frequently ‘filled’ by 
information from anti-vaccination sources prevent the individual from extracting the essential 
meaning (‘gist’) of vaccine messages (123). 
In light of falling vaccine confidence, vaccine perception rather than disease perception may 
be more effective in encouraging vaccine uptake. That being said, one may perceive the risk 
of contracting a disease as high, but this may not automatically translate into a preference for 
vaccination. To shift an individual’s preference towards vaccination, you first need to change 
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their perception so that the ‘cost’ of being vaccinated is nil. This may be of particular 
importance among new mothers who have an innate tendency to mitigate all risk.   
Maternal Attachment Theory 
The cocooning strategy differs from other strategies as it focuses on primary prevention for 
the baby and secondary prevention for the vaccine recipient. Therefore, it is useful to explore 
theoretical underpinnings of maternal attachment. Maternal attachment is a biologically 
driven construct, inherent within humans and other primates, designed to pre-serve the 
species through nurturing and protective behaviours. The maternal-offspring bond forms in 
early pregnancy, with the development of feelings such as love and protection that provide a 
strong emotional tie. The driving force is the parental caregiving system, which functions to 
provide protection, comfort and care for the offspring. A key dimension of antenatal 
attachment that has emerged in qualitative literature is ‘an innate desire to protect’(125). This 
fits in the schema of ‘parental caregiving system’, which desires to provide protection to 
prevent threat to the offspring rather than seeking protection when the offspring is under 
attack.  
A desire to protect the unborn baby and meet his/her needs, even at the expense of the 
mother’s own, is one of three indicators of maternal-foetal attachment(126). During the 
immediate postpartum period the maternal-offspring bond predominates. This is relevant 
when targeting health promotion strategies to new mothers on the postnatal ward. Knowledge 
of their innate desire to protect their offspring assists in the way recommendations are 
communicated. As vaccination carries a ‘cost’ for the recipient (e.g. injection site pain), one 
could postulate that highlighting the benefits to the baby may cause the mother to overlook 
her own discomfort. 
Attachment and antenatal care 
There is limited knowledge of how antenatal attachment is associated with antenatal care, 
with the majority of studies limited to testing the impact of ultrasound has on attachment. 
Survey data indicates that there is a correlation with increased levels of antenatal attachment 
and the strength of desire to protect the foetus. In addition, it supports a review by Muller 
(1992), which reports an increase in maternal antenatal attachment over the course of the 
pregnancy. To engage women in health related behaviours during pregnancy, parental 
responsibility to the foetus needs to be increased by strengthening prenatal attachment. 
However, shaping maternal representations of these health related behaviour may also need 
to be targeted(127). This may be particularly relevant to vaccination, where the inherent 
‘risk’ of this health promoting behaviour may dissuade pregnant women from engaging in it. 
It is important to consider this when devising educational interventions and communication 
strategies aimed at increasing vaccine uptake during pregnancy.    
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Review of health education 
A systematic literature review of evidence for effective promotion of national immunisation 
schedule promotional communications in Europe was carried out. Interventions targeted both 
personal and structural barriers whilst also communicating the benefits of immunisation. The 
evidence indicated that improved service delivery on its own is insufficient, but is associated 
with a positive intervention effect when coupled with education(106). Interventions targeted 
at improving knowledge were overall successful at achieving this goal, however 
demonstrated no positive effect on vaccine intentions or vaccine uptake. The review 
classified the interventions as ‘mass communications’, personalised communications and 
education/training. However, isolating the most effective communication method proved 
difficult due to the heterogeneity of interventions, the inclusion of structural changes, and 
varying evaluative methods(106). This was further hindered by the overall lack of clarity 
around the theoretical basis for the interventions. 
Health education for vaccination needs to factor in the components of decision-making. This 
includes knowledge of the vaccine and attitudes towards the vaccine as well as preferences 
around vaccine provider and setting. In order to evaluate the efficacy of health education, it is 
important for interventions to be grounded in theory. We undertook a literature review of 
message framing, and evaluated studies accordingly.  
 
Extrinsic influences on attitudes & beliefs  
The relationship between beliefs and attitudes are influenced by extrinsic sources, such as 
family, friends and practitioners. For example, if a mother perceives that an influential figure 
holds a certain opinion about a health behaviour, this will shape her decision-making about 
that behaviour. When considering vaccination, particularly where vaccination is being 
received ‘on behalf of the child’, subjective norms may be of particular influence. Provision 
of vaccination in the maternity ward where the mother is an impatient may contribute to the 
influence of subjective norms on vaccine decision-making. This could, in part, account for 
why such high uptake has been achieved within the hospital setting in other countries(15, 17). 
Effect of attitudes and beliefs on intentions 
Whilst vaccine intentions are an important precursor to vaccine uptake, they do not always 
predict behaviour. There are several extrinsic factors, such as access barriers, which need to 
be considered when implementing any adult vaccination program.  
Message Framing 
Health promotion encompasses the use of both prevention and screening as a means by which 
an individual can increase control over their health. Encouraging engagement in these 
activities can be challenging, particularly on a population level. Different health messages 
that highlight factually equivalent information are considered generally persuasive(17). An 
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example is message framing, which is applicable for both prevention and screening. It 
involves presenting the information in the gain frame (benefits from engaging with the 
activity) or loss frame (costs from not engaging in the activity).    
Several framing studies have sought to determine what type of message is most effective 
when promoting health behaviours. A large review of framing studies found that gain-framed 
appeals were more persuasive; however it yielded only a small effect size and dental hygiene 
was the predominant health behaviour examined(3). While vaccination may be comparable as 
its relative easy to perform, it differs due to its perceived risk. There is limited evidence to 
suggest this may be overridden, depending on the way a disease is perceived. One study 
reported gain-framing as most effective in promoting health behaviour if symptoms were 
difficult to imagine, yet if symptoms were easily imagined then loss-framing was 
favoured(118). However, emerging research suggests that the focus should be shifted from 
disease perception to health behaviour perception. 
A useful framework to evaluate message framing appraises the context in which a health 
decision is made. This includes a) internalisation of the advocated frame and b) risk 
perception of performing the health behaviour(117). For example, when thinking about 
receiving a vaccine, the patient may perceive the pain associated with the injection as a risk 
(risk perception). Frame efficacy takes into consideration the ‘illness-detecting’ (I.e. I will get 
very sick without the vaccine) or ‘health-affirming’ (The vaccine will protect my health) 
function of the behaviour. Lastly cognitive and affective processes, which moderate both 
judgment of the message frame and resulting behaviour, are considered.   
Public perception has been shown to impact upon the way individuals respond to message 
framing of a particular vaccine. This was noted in a study evaluating the effect of message-
framing on the measles-mumps-rubella (MMR) vaccine (120). Due to media coverage of 
potential side effects of the MMR vaccine, there was a general public perception of this 
vaccine as more dangerous. The study found that a loss-framed message increased intentions 
for parents to have their children vaccinated with MMR vaccine. This highlights the 
important of understanding how risky the public perceives a specific prevention behaviour to 
be (120). 
Further support for the postulation that different types of messages work better with different 
types of prevention behaviours was offered by Bartels et al., 2009(128).  Their experiment 
focused on hypothetical vaccination.  Two different vaccine scenarios were presented: one 
that was effective 9/10 times and one that was effective 6/10 times.  The more effective 
vaccine was designed to seem less risky than the less effective vaccine.  After reading one of 
the effectiveness reports, participants were given either a gain- or loss-framed message 
encouraging them to receive the vaccination.  Message-framing alone did not predict 
intention to vaccinate.  However, gain-framed messages were more persuasive among 
participants who had read about the more effective (9/10) vaccine.  And, similarly, loss-
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framed messages were more persuasive for participants who had read about the less effective 
vaccine(128). 
Message framing also can have varying impacts depending on the ‘risk taking’ behaviour of 
the individual. In the case of Human Papilloma Virus (HPV) vaccination, differing types of 
messages were more effective depending on the characteristics of individuals who read about 
HPV vaccination.  For example, if an individual had multiple sex partners or used condoms 
less often, a loss-framed message was more effective in those intending to be vaccinated.  
However, this was not true in other participants studied(119). 
 
 
Framing Vaccination in Real-Life 
Prior to the study’s commencement, there was only one real-life version of the vaccination 
framing study, where the outcome factor was vaccine uptake. This looked at increases 
influenza immunisation among older adults in several counties by providing individuals with 
information presented in a gain- or loss-style format.  The information was sent to individual 
homes and then immunisation rates for the counties were totalled.  There was no difference in 
level of immunisation rate achieved between counties that received different types of 
messages.  There was, however, a significant improvement over counties that got no message 
(129). During the candidature, there has been a growing body of evidence of framing studies 
involving vaccine uptake as the outcome factor (rather than only vaccine acceptance). This is 
summarised in the discussion of a meta-analytic review in the paragraph below.  
 
 
Summary of Framing Studies 
Generally, gain-framed messages have tested as more persuasive when promoting preventive 
behaviours.  However, the results regarding vaccination are more uncertain as it carries an 
element of risk. Theoretically, participants are more likely to engage in a preventative 
behaviour with temporal risk (e.g. side effects) when presented with the potential disease 
consequences of not engaging in it (loss frame)(2). However, a recent meta-analytic review 
of 32 studies found no significant difference between gain or loss-framed messages in 
promoting vaccination(3). The authors reported underpowered studies as a key weakness 
(median N=130.5), highlighting the need for additional data to explore the possibility of 
vaccine recipient as a modifier (i.e. message recipient vs. vaccination of another, e.g. child). 
Furthermore, none of the included studies examined vaccination of the message recipient on 
behalf of another (e.g. cocooning) or the pertussis vaccine. 
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It is unknown how risky vaccination is perceived to be.  From the few studies on the topic, it 
seems that various factors may determine whether gain- or loss-framed messages are more 
effective in the field of vaccination.  No studies have been performed with pertussis booster 
vaccination, and where vaccination is received by an individual to protect another belong to a 
‘at-risk’ population.  The present research will significantly contribute to the knowledge of 
message framing about vaccination by comparing a gain-frame pamphlet with a loss-frame 
pamphlet (both developed for the study) and with a usual care information sheet.  
 
This will be the first controlled trial of vaccine education delivered to new mothers within the 
postnatal ward setting. In the context of epidemic pertussis, where young infants are unable to 
be fully vaccinated against the disease, an effective control strategy is paramount. This 
literature review has highlighted the challenges of pertussis diagnosis and the limitations of 
treatment, as well as control strategies in Australia and abroad. In addition to testing gain and 
loss message framing, this trial aims to report on patient, provider and setting factors that 
enable vaccine uptake among this target group.      
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Chapter 2 Methodology 
This chapter (2) will illustrate the methodology of the study: a cross-sectional baseline survey 
within a controlled intervention trial. The purpose of the baseline survey was to examine 
which attitudes; knowledge and beliefs about pertussis and vaccination were associated with 
vaccine status in a cross-sectional or retrospective analysis. This enabled us to compare those 
who were ‘up to date’ with current pertussis booster vaccine recommendations versus not. 
The study used the controlled design trial to test the impact of the framing of a health 
message (in terms of gain or loss) on vaccine uptake within the postpartum hospital setting. 
During the study, there was a change in national immunisation guidelines to include a 
recommendation about pertussis booster vaccination during the third trimester of pregnancy. 
This created a group of postpartum women who had been vaccinated during pregnancy. 
Therefore, the baseline questionnaire was also used to determine attitudinal and knowledge 
differences between participants vaccinated during pregnancy versus not.   
In this chapter, details will be outlined regarding the background and health system context of 
the study. In addition, it will set out in detail the study setting, participants, questionnaires 
and measurements, study procedures and statistical analysis. It also includes a justification to 
the modification of the study design for the private hospital study site. This includes a pilot 
study on maternal vaccination against pertussis in response to the change in national 
guidelines that occurred during the candidature (May, 2013).   
Background to this study 
The background of the development of the message framing intervention, and the pilot testing 
is included in Appendix 8. These were carried out by the candidate’s associate supervisor, Dr 
Spring Cooper, prior to the candidate’s commencement on the study. The questionnaires used 
in this study were developed in this manner, as well, with modifications by the candidate to 
the amended follow up (pertussis vaccination in pregnancy (Appendix 9). Whilst the 
candidate, Elizabeth Hayles, carried out the recruitment in its entirety, this was initially in her 
capacity as a research assistant (November 2010-July 2011).  There were 630 subjects 
enrolled in the Maternal Pertussis Study in her role as a Research Assistant (secondary data 
analysis).  
Public Health Care Structure in the state of New South Wales, Australia 
In Australia, public healthcare is government-funded, enabling all women to access free 
obstetric care at a hospital within their local council area. In NSW, there are 15 Local Health 
Districts and statewide specialist networks that include paediatric and forensic mental health 
services. The Sydney Metropolitan Region is serviced by eight Local Health Districts (Figure 
2.1 pictured: blue). A further seven Local Health Districts cater for rural and regional areas 
(Figure 2.1pictured: grey). Our study was conducted at Royal North Shore Hospital, located 
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within the Northern Sydney local health district, and the adjacent North Shore Private 
Hospital.  
 
 
Figure 2.1Northern Sydney Local Health District (125) 
(One of the eight metropolitan health districts of Sydney, Australia) 
 
Study setting 
Participants were recruited from two sites located on adjacent campuses in Northern Sydney. 
The first site was a hospital, which delivers both midwifery-lead and tertiary obstetric care 
for the general public (RNSH), whilst the other site is a hospital providing private obstetric 
care (NSPH). Each hospital caters for approximately 2500 births per year.  
The public hospital is located in the Northern Sydney Local Health District (pictured above) 
and routinely services four local government areas - Mosman, Willoughby, Lane Cove and 
North Sydney. In addition, it is a neonatal referral centre for NSW, including in-utero and ex-
utero transfers. The public hospital is a tertiary referral centre catering for level 6 acuity of 
care. Level 6 is the highest acuity of hospital care, which can cater for normal, moderate and 
high-risk deliveries. There is an obstetric registrar as well as an anaesthetic registrar on site 
24 hours. There is 24 hours access to ultrasound and access to maternal-foetal specialist. It is 
the only intensive care unit for babies in the Northern Sydney metropolitan region and cares 
for babies who are born prematurely or who are unexpectedly sick following birth. It is a 
level 6 Tertiary Neonatal Unit with 25 cots, of which 14 are Intensive Care cots(123). 
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The private hospital caters for level 2 acuity of care. In Australia, a Level 2 hospital caters for 
‘normal risk delivery’ only. However, this setting is also able to cope with sudden unexpected 
complications until transfer. There is 24-hour access to a medical officer, either on-site or 
available within 10 minutes from the hospital. This hospital also has a Level 2 Neonatal 
Service, with the special care nursery able to cater for the sick neonate (not requiring 
mechanical ventilation) or premature neonate from 32 weeks gestation. There is also 24-hour 
on-call access to a paediatrician.  
Participants 
We prospectively recruited postpartum women from the postnatal wards of two metropolitan 
hospitals in Australia from November, 2010 to December, 2013. A systematic random 
sample was obtained by going from room to room around the postnatal ward. Each woman on 
the ward was approached, if available, in a consecutive room-by-room fashion. The 
researcher would return to the room at a later time if the woman was busy or asleep. 
Recruitment occurred on weekdays, particularly Monday, Wednesday and Friday to fit in 
with the average two-three day hospital stay. However, due to a single recruiter and variation 
in maternal length of stay on the postnatal ward as well as a small proportion of women 
discharged directly from the delivery suite, not every postpartum woman was approached and 
informed of the study.  
From June 2013 to December 2013, we surveyed postpartum women (<day 7 of childbirth) 
who were eligible for the pertussis booster vaccine during their pregnancy (no dTpa<5years). 
This was in response to the introduction in the Australian Immunisation Handbook of 
vaccination during the third trimester of pregnancy as an alternative to postpartum 
vaccination (4). Exclusion criteria were those who had been up to date prior to pregnancy 
(dTpa<5years). For this sub-group, we approached postpartum mothers receiving private 
obstetric care on the postnatal ward of a metropolitan hospital in Sydney (NSPH), Australia. 
Inclusion Criteria 
Eligible women were postpartum, aged 18 years or older, could communicate in English and 
give written informed consent. Women who had given birth at another hospital and 
transferred to the study hospital, or were booked in elsewhere but had given birth here were 
eligible if within 7 days postpartum.  
Exclusion Criteria 
Exclusion criteria include women <18years, those who required an interpreter or were 
clinically unwell, those unable to given informed consent, those who were pregnant and those 
who had a stillborn or neonate in a critical condition.  
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Eligibility for the Controlled Intervention Trial 
Participants were considered to be ‘up to date’ when they reported receiving pertussis booster 
vaccination (dTpa) within the last ten years. GP verification was undertaken for participants 
unable to recall the month and year. The sample size was formulated for an interventional 
study in which this descriptive study was nested(107). The Australian Immunisation 
Handbook (2008) suggests a pertussis booster vaccination for adults every 10 years; however 
it notes that further data is required to make a definite recommendation(64). This interval was 
revised in 2013, with the current recommendation of 5 years between pertussis booster 
vaccines. However, as the study was in progress the ten-year interval continued as the criteria 
for ‘up to date’, with confirmed vaccination showing the proportion of women still within the 
5 year interval of the current recommendation. 
Sample size 
We conducted an initial sample pilot and determined the coverage was very low, with the 
anticipated proportion of vaccinated women around 20%, and determined an increase by 60 
percentage points to 80% coverage. To detect a 5% difference between the gain-frame, loss-
frame, and control, with 80% confidence at the 0.05 level, the required sample size was 1080 
subjects who were eligible for a pertussis booster (last dTpa>10years). However, it was also 
of interest to determine differences between participants who were up to date with their 
pertussis booster vaccine compared to those who were not. Therefore, the purported 1080 
subjects to recruit was increased as N=1080 was subjects who were not ‘up to date’ with their 
pertussis booster vaccine status (last received >10 years ago). With a background rate of 23% 
of subjects ‘up to date’, an additional 334 subjects were recruited (N=1413) to the baseline 
study only. However, only subjects not up to date were enrolled into the control intervention 
trial. 
Procedures 
Baseline questionnaire  
We administered a knowledge and attitudes questionnaire based on the Health Belief Model 
(HBM) constructs(115, 122) , which measured perceived susceptibility to contracting 
pertussis, perceived severity of pertussis, perceived barriers to vaccination, perceived 
effectiveness of vaccination and cues to action. This main health theory was selected as it 
uses an expectancy-value framework to predicate health behaviour of an individual. In 
addition, women were asked questions about pertussis information sources, intention to 
receive the pertussis booster vaccine, demographic details and self-reported vaccination 
status. The baseline questionnaire was based on previous research(130) and pilot tested on 
pregnant women (n=16) for face validity. Coverage was estimated from confirmed pertussis 
booster vaccine receipt (dTpa<10 years). Both the content and format of the questions in 
relation to each Health Belief Model construct are outlined in Table 2.2 below:  
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Table 2.2: Theoretical framework of the Maternal Pertussis Questionnaire 
 Questionnaire Item Type/ 
measurement 
Pertussis 
information 
sources 
Where have you heard of pertussis? 
Where have you heard of whooping cough? 
Which source is most influential to vaccine decision 
making? 
Multi-selection; 7 
items +other (open-
response). 
HBM constructs  
Disease 
severity 
How severe or mild are the consequences of pertussis for an 
adult, for a newborn baby? 
5 point Likert scale: 
mild-severe 
Disease 
susceptibility 
How likely are you or your baby to catch whooping cough? 
How common or rare is whooping cough in your 
community? 
How easy or difficult is it to transmit whooping cough? 
 
5 point Likert scale 
Vaccine 
benefits 
It will help prevent my child from getting whooping cough 
The benefits outweigh the risks 
It’s my responsibility to get vaccinated to protect my child. 
The vaccine is effective in preventing whooping cough in 
the person vaccinated. 
 
5 point Likert scale 
Vaccine 
barriers 
I have access to the information needed to make a decision 
about vaccination. 
I’m concerned about the safety of the vaccine for adults. 
It’s not easy for me to find time to get vaccinated. 
 
5 point Likert scale 
Cues to action Pertussis booster recommendation. 
Provider of recommendation 
Close-ended. 
Open-ended 
Other variables  
Intentions How do you feel about getting a pertussis booster vaccine 
once your child is born? Why? 
Intention to receive pertussis vaccine 
Strongly agree-
strongly disagree 
Open-ended 
question 
Close-ended 
Vaccines 
during 
pregnancy 
Influenza vaccine uptake 
Antenatal influenza recommendation. 
Provider of recommendation 
Close-ended. 
 
Open-ended 
Neonatal 
vaccine 
If available and recommended, would you have you baby 
vaccinated against pertussis at birth? 
Yes. No. Unsure 
Open-ended- why? 
Demographics Age bracket, marital status, country of birth, primary 
language, education level, and employment status. 
Close-ended 
questions. 
Open-ended 
questions to specify 
country and 
language, only.  
 
Questionnaire Mode 
All participants in the private hospital completed a self-administered, electronic-based 
knowledge and attitudes questionnaire on an Apple iPad®. The questionnaire was powered by 
web-based survey software (Peoplepulse®), which was managed by the IT Department at the 
University of Sydney. Due to a lack of infrastructure, participants in the public hospital 
completed a paper-based version of this questionnaire. A literature review was conducted to 
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determine modal differences between paper and electronically administered questionnaires. 
Medline yielded 165 studies, which showed mixed results (search terms ‘computers, 
Handheld/ or iPad AND survey or questionnaire’; Appendix 15). However, there was no 
rigorous evidence to suggest it would have a strong impact on the way a participant 
responded. The benefits of an electronic questionnaire would be a reduction in non-responses 
and therefore increase data completeness. As the participant directly entered data, it would 
have increased accuracy over data entered by a researcher from a paper questionnaire. In 
terms of feasibility, it would minimise data entry time and cost as well as enable data 
collation in real time.  
 
Data collection & Outcome measurement 
Data collection utilised both paper-based (public hospital) and electronic modes (Apple 
iPad®). Reliability and internal consistency has been demonstrated in one study to be 
comparable between these two data collection model(131)1].  
The main outcome, pertussis vaccination uptake, was collected using the inpatient medication 
chart at discharge from hospital. Baseline data was collected using a paper-based or iPad 
electronic questionnaire at recruitment. A short paper-based questionnaire on reasons for 
accepting or declining vaccination was also collected at discharge. Questionnaire and 
outcome data were entered onto a database (Microsoft Excel, 2010).  
Randomised / Controlled Intervention Trial 
We conducted a quasi-randomised control trial with three arms (two interventions and a 
control), with a pre and post questionnaire.  
Allocation of the Intervention 
Individual randomised allocation of the intervention was not possible within this setting. As 
participants were inpatients in a maternity ward that had shared-facilities, sample 
contamination was likely. To minimise this risk, block allocation was chosen. The interval of 
one week was selected, partly as the average length of stay was 2-3days, which would give 
sufficient clearance of participants allocated the various intervention or control brochure. A 
longer time frame may have been problematic where excessive media coverage might 
override the impact of the intervention.  It was for this reason, also, that sequential allocation 
was chosen. This would prevent repeated use of the same intervention or control over a 
course of weeks, which can occur when using a random sampling frame. Sequential block 
allocation by week was implemented for the Maternal Pertussis Trial, which was commenced 
at the public hospital in November 2010 (RNSH).    
Commencement of the Maternal Pertussis Study at the second site, North Shore Private 
Hospital (NSPH), was delayed until March 2012 due to external factors. At this time, the 
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pertussis epidemic within NSW had been continuing for quite some time so the concerns 
regarding media coverage outweighed those of methodological rigour. Hence, randomised 
block allocation was implemented as this was seen to be more rigorous than sequential block 
allocation. This was implemented in consultation with the PhD supervisory team, associate 
investigator Dr Nicholas Wood and an expert advisor, Professor Val Gebski (NHMRC 
biostatistician).  
Random block allocation by week was generated using a computerised random number table. 
It was located at an external site and each Monday the brochures (gain-framed, loss-framed 
or control) were changed accordingly. In addition, allocation concealment of the education 
intervention was feasible within the private hospital setting as subjects could be approached 
in individual rooms on the postnatal ward. This was carried out with the assistance of a 
research midwife, who was blinded to the intervention. The intervention or control brochure 
was placed in an opaque 100gsm white envelope and put on the postnatal ward each Monday 
for the research nurse. She was told the number allocated that week (e.g. 1, 2 or 3) and used 
the corresponding subject numbers for recruitment (e.g. If 1, the study number started in 210, 
if 2 then 220, if 3 then 230). This enabled the researches to keep track of which participant 
received which intervention, which were decoded at the conclusion of the study. Once the 
research nurse had allocated the patient the intervention, she no longer entered that room. 
However, it is possible that the research nurse may have seen the allocation if the patient 
brought the brochure outside their room. As the research nurse did not enter the patient 
lounge, this would have been very unlikely.    
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Figure 2.3: Flowchart of the Maternal Pertussis Trial 
 
  
GAIN 
(n=346) 
LOSS 
(n=348)  
CONTROL  
(n=386)  
Education Intervention (sequential block allocation by week)  
 The research nurse collected baseline questionnaire, distributed education and 
informed participants that a free vaccine was available and to speak to hospital staff.  
 
Mothers enrolled and completed the 
baseline questionnaire  
Mothers approached on the 
postnatal ward within 8 hours-
3days postpartum 
(n=1486) 
 Excluded: (n=53) 
 Declined participation  
 Not eligible 
 
Missing data (n=29) 
 Technical error  
 questionnaire missing or not 
returned  
Mothers screened for pertussis booster 
vaccine status (dTpa<10years) (n=1404) 
 
Vaccine uptake on the 
postnatal ward* 
 Excluded from intervention phase: 
Mothers ‘up to date’ with pertussis 
booster at baseline (dTpa<10years) 
(n=324; 23%) 
Follow up questionnaire: 
Completed by all participants on the ward following vaccination or vaccine decline  
 
i  t   t  
postnatal ward 
69.1% (n=239) 
 
 
 
Vaccine uptake on the 
postnatal ward 
71.8% (n=250) 
 
 
 
Vaccine uptake on the 
postnatal ward  
68.8% (n=265) 
 
 
 
Phase 2 
2 
Phase 1 
   
 
 
69 
Phase 2: Education intervention 
We presented health messages in three ways: gain frame, loss frame and a control. The gain-
loss message framing intervention was specifically developed for the trial by Associate 
Professor Spring Cooper (Appendix 8). It was reviewed by an expert immunisation panel 
before being pilot tested on expectant mothers. Flesch-Kincaud measurements were used to 
check reading levels and both SMOG index and Gunning-Fog score to identify polysyllable 
words that needed to be simplified for the readership. Next, both gain and loss pamphlets 
were pilot-tested on pregnant mothers in the antenatal clinic. The gain-loss message framing 
intervention indicated either what mothers may gain from the cocooning strategy or what 
they may lose by not engaging in the cocooning strategy. Table 2.4 below outlines the 
differences in message framing: 
Table 2.4: Framing Differences within the Whooping Cough Brochures 
 GAIN (appendix 9) LOSS (appendix 10) 
Title 
(front page) 
Whooping Cough Booster 
vaccination keeps you and 
your baby protected. 
Whooping Cough: Without a 
booster vaccination, you and 
your baby are at risk of 
infection. 
‘How can I 
prevent 
whooping 
cough? 
(Middle; inside) 
‘Vaccinating yourself can 
protect your baby’s health’  
‘If a newborn baby’s parent 
and main carers have not 
received a booster vaccination, 
the baby will have a higher risk 
of catching the infection.’ 
Who should get 
a booster? 
(Right; inside) 
‘The best way to protect your 
baby from whooping cough is 
by vaccinating yourself’ 
‘If adults caring for the baby 
are not vaccinated, they miss 
out on the best way to prevent 
whooping cough in the baby. 
 To increase immunity and 
prevent adults passing 
whooping cough to babies, 
the following groups should 
have a whooping cough 
booster vaccination.’ 
‘Unless the following groups 
receive a whooping cough 
booster vaccination, adults 
passing whooping cough to 
babies in more likely to occur’ 
 
We used the standard NSW Health pertussis fact sheet (double sided) as the control. It was 
accessed from http://www.health.nsw.gov.au/factsheets/infectious/pertussis.html (Date: 
14/SEPT/2009) and was the only available pertussis resource at the commencement of the 
study (Appendix 11). The facts sheet was developed by the Ministry of Health Surveillance 
Unit based on best available evidence to inform practice, according to the Communicable 
Disease Network of Australia guidelines(132). 
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Vaccination Administration 
In both hospital sites, vaccine administration was by the clinical midwife as we aimed to 
replicate what would happen in normal clinical practice. Owing to the need for the vaccine to 
be dispensed from pharmacy, the research nurse at the public hospital study site would assist 
by getting the vaccine charted by the resident medical officer on the postnatal ward, and carry 
out the process of gaining this vaccine from pharmacy. This was done as routine postnatal 
vaccinations are usually obtained from the vaccine fridge on the postnatal ward, and thus this 
would imitate the routine practice in the hospital setting. This differed to the private hospital 
setting, whereby the vaccine was given as part of ward stock. Furthermore, the average length 
of stay differed between the public and private hospitals, which may have accounted for 
increased opportunity to be vaccinated for women at the private hospital site. In the public 
hospital, the average length of stay is 48-72 hours, which differs from the 4-6 day stay in the 
private hospital.  
Study limitations may also have impacted upon vaccine uptake, as subjects requesting 
vaccination in the public hospital had it individually dispensed by the hospital pharmacist 
whilst the private hospital had a ward stock. However, the research nurse was responsible for 
placing the allocated vaccine in the public hospital ward fridge prior to the subject being 
discharged, so it was unlikely this would have impacted significantly on vaccine availability 
between the study sites. 
Follow up Questionnaire 
All participants completed a one-page paper-based follow up questionnaire that looked at 
vaccine decision-making. It contained both open and closed ended questions, and was 
completed by participants prior to discharge from the postnatal ward. Where follow up was 
missing or not returned, vaccine uptake was confirmed by medical record. The follow up was 
paper based to enable it to be handed in once the vaccine had been administered by the 
postnatal ward midwife. It also meant that the research nurse did not have to re-enter the 
room once she had given out the brochure.  
Data management 
Data was collected using either a paper-based questionnaire (public hospital) or an electronic 
questionnaire via an Apple iPad® (private hospital). Clinical variables were verified using the 
hospital obstetric information system (ObstetriX database), a mandatory data source for NSW 
Perinatal Data Collection(108). Study/outcome factors were recorded on a database designed 
specifically for the study (Microsoft Excel, 2010). The sample size was formulated for the 
interventional study (Appendix 1). Self-reported pertussis booster vaccination was used as the 
indicator of ‘up to date’ status. GP verification occurred for participants unable to recall both 
month and year of pertussis vaccination. Vaccine uptake was confirmed after discharge by 
accessing each participant’s medication chart, which also enabled identification of system 
errors (where the vaccine had been prescribed but not administered). 
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Data Analysis 
Frequency distribution was determined for each questionnaire item. For pertussis and 
vaccination attitudinal questions, the Likert Scale was used to allocate a score for each 
question, with ‘strongly agree’ receiving a 5 and ‘strongly disagree’ receiving a 1. The 
increments between responses on a Likert Scale are assumed to be equal. Here, numerical 
scores on an ordinal scale were used to create ordinal data that enabled ranking of the 
participant’s level of agreement to a question. The total scores ranged from 5-25, with those 
who perceived vaccine benefits were high achieving a high score. Individuals who missed 
one or more questions were excluded from this analysis. Responses to these questionnaire 
items were then condensed into three categories: agree, neither agree nor disagree and 
disagree. For attitudinal questions, the Likert Scale was used to allocate a score for each 
question (i.e. ‘strongly agree’= 5). Subscales were created by adding items for each HBM 
construct, with total scores ranged from 5-25 (i.e. those who perceived multiple vaccine 
benefits achieving a higher score).  
A chi-square analysis was undertaken to test for predictors of pertussis booster vaccination 
uptake and demographic, attitudinal, awareness and behavioural variables. Significant 
variables in the univariate analysis were used in the multivariate analysis.  Multiple logistical 
regression (backwards stepwise) was performed using significant variables (p<0.05) to 
determine independent predictors of vaccine uptake. Statistical analysis was conducted using 
SPSS (PASW version18). Missing observations were excluded from analysis. Two sided 
statistical tests were performed and significance was set at p<0.05. Logistic regression was 
used to explore the role of vaccination intention as a mediator between predictors and vaccine 
uptake.  
The thematic analysis of qualitative follow-up responses involved data familiarisation, 
coding, theme identification and review by two experienced qualitative researchers (SC, 
S.RS) as well as the candidate (EH). The data was then organised into themes, which enabled 
quantification of the frequency of a particular theme. Each theme was double checked, with 
responses difficult to classify undergoing review by three individual coders to check for 
additional themes.   
Mediation Analysis 
We conducted a mediation analysis as an ad-hoc analysis to explore whether vaccine 
intentions mediated vaccine uptake (Figure 5). This is a form of process analysis which not 
only examines treatment effect, but develop and test a theory about general causal 
mechanisms leading to an outcome behaviour (133). To quantify the extent of the mediation, 
we calculated the percentage change in the effect between the unmediated odds ratio (ORum) 
and the mediated odds ratio (ORm) using the following equation: (ORum-1)-(ORm-1)/ 
(ORum-1) [110]. These were also examined for influence for vaccine uptake and included in 
the multiple logistical regression analysis. For attitudinal questions, the Likert scale was used 
to allocate a score for each question (i.e. ‘strongly agree’= 5). Subscales were created by 
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adding items for each HBM construct, with total scores ranged from 5-25 (i.e. those who 
perceived multiple vaccine benefits achieving a higher score). Statistical analysis was 
conducted using SPSS (PASWversion18). Missing observations were excluded. Two sided 
statistical tests were performed, with significance set at p<0.05. 
 
Figure 2.5: Pictorial depiction of a mediational analysis 
      
 
 
 
 
 
 
 
 
 
Example: 
Independent variable (Vaccine benefits; Vaccine recommendation);Mediator Variable (Vaccine 
intentions); Dependent Variable (Vaccine uptake). 
 
 
Qualitative Analysis 
Prior to discharge, participants completed a self-administered follow-up questionnaire that 
explored their vaccine decision-making. It included both closed and open-ended questions. A 
key question was ‘What factors were most influential to your vaccine decision-making?’ Our 
thematic analysis of these responses involved data familiarisation, coding, theme 
identification and review by two experienced qualitative researchers (S.RS, SC). We 
organised the data into themes, and quantified the number of times a particular theme was 
reported. Each theme was double checked, with responses difficult to classify undergoing 
review by three individual coders to check for additional themes (EH, S.RS, SC). 
 
Ethical considerations 
The study was approved by the Northern Sydney Local Health District Human Research 
Ethics Commission and North Shore Private Hospital Ethics Committee, and registered with 
the Australia New Zealand Clinical Trials Registry(134). The Executive of the Human 
Research Ethics Committee (HREC) at the University of Sydney reviewed the Maternal 
Pertussis study (Protocol No 14570). The Committee acknowledged the right to proceed 
under the authority of Northern Sydney Health Human Research Ethics Committee on the 
16th February 2012. This study involved human data collection and was carried out in 
accordance with the ethical guidelines of the Australian National Health and Medical 
Research Council (135). In addition, the study abided by the medical principles of 
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beneficence, non-maleficence, respect for persons and justice. This is reflected in the use of 
the patient information sheet, respect of a participant’s decision to withdraw at any time, and 
avoiding patients which staff highlighted as physically unwell or emotionally distress. As the 
pertussis booster vaccination was funded by a NSW Health initiative, not participating in the 
Maternal Pertussis Study did not preclude an individual from being offered the vaccination 
on the postnatal ward by midwifery staff. It also includes maintaining confidentiality of 
information.   
 
Chapter 3 Results:  
Baseline Results  
Demographics 
A total of 2520 postpartum women from two maternity wards in metropolitan Sydney 
participated in this study. This comprised 96.4% (2520/2614) of those screened between 
November, 2010 and June, 2013 (figure 1), which is a subsample of the patient population 
(combined ~5000 births per year).  Data from 37 participants were lost. Among participants, 
33.7% reported receiving a pertussis booster vaccine within the previous ten years 
(837/2483), including twelve women vaccinated during pregnancy. Vaccination rates were 
higher among multiparous women (OR: 4.43, p<0.001, 95% CI: 3.7-5.3), older women 
(p<0.001), those born in Australia (OR: 2.0, p<0.001, 95% CI: 1.69-2.38), those who spoke 
English (OR: 3.5, p<0.001, 95% CI: 2.67-4.55) and those at the private hospital (OR: 3.02; 
p<0.001, 95% CI: 2.54-3.59)(Table 1). There were 13 mothers who reported a history of 
pertussis disease (open-ended volunteered response).  
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Figure 1: Maternal Pertussis Study Flow Chart 
 
 
 
 
  
Mothers not ‘up to date’ at 
baseline (n=1646; 66.3%) 
 
(n=207) 
Mothers ‘up to date’ at 
baseline (n=837; 33.7 %) 
 
Mothers enrolled in the Maternal Pertussis Study (N=2520) 
Public hospital (November 2010-June 2012) 
Private hospital (March 2012-June 2013) 
 
(n=207) 
Mothers approached on the 
postnatal wards (n=2614) 
(n=207) 
Excluded (n=94) 
 Declined participation (n=88)~ 
 Not eligible (n=6) 
Loss to follow up (n=37) ^ 
 missing questionnaires (n=29) 
 blank questionnaire due to 
technical error (n=8) 
 
Baseline questionnaire (N=2483; 98.2%) 
Public hospital (n=1404) 
Private hospital (n=1079) 
Phase I 
~Recruitment rate 96.4% (96.4% electronic mode vs. 96.4% paper mode) 
^ Data completeness- 98.5% (missing data: 0.7% electronic mode vs. 2% paper mode) 
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*Confirmed with family doctor/date of receipt known (49.8%; 417/837); dTpa vaccine available in Australia; the 
‘cocooning’ strategy involved state-funded pertussis booster vaccine (dTpa) for parents and grandparents of an infant under 
12 months. 
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Table 1: Demographics of postpartum mothers and pertussis booster vaccination  
Variable  Total Not up to 
date 
Up to date  Univariate 
N=2483 n=1646 
(66.3%) 
n=837 
(33.7%) 
OR (95% CI) 
Maternal age (yrs.)    p<0.001 ^ 
 <25  96 (3.9) 80 (4.9) 16 (1.9)  
 25-34  1470 (59.2) 1004 (61.0) 466 (55.7)  
 35-44 901 (36.6) 554 (33.7) 347 (41.5)  
 45 or over 15 (0.6) 8 (0.5) 7 (0.8)  
Parity    p<0.001  
 Primiparous 1357 (54.7) 1097 (66.6) 260 (31.1) 1 (ref) 
 Multiparous 1125 (45.3) 549 (33.4) 576 (68.9) 4.43 
(3.70-5.29) 
Living with partner    p<0.05 
 Yes 2408 (97.8) 1587 (97.3) 821 (98.8) 1 (ref) 
 No 54 (2.2) 44 (2.7) 10 (1.2) 0.44* 
(0.22-0.88) 
Country of birth    p<0.001  
   Other (overseas) 1222 (49.2) 905 (55.0) 317 (37.9) 1 (ref) 
  Australia 1261 (50.8) 741 (45.0) 520 (62.1) 2.0 (1.69-2.38) 
Indigenous status    - 
  Yes 14 (0.6) 11 (0.7) 3 (0.4)  
  No 2468 (99.4) 1635 (99.3) 833 (99.6)  
Language    p<0.001  
  English 2002 (80.7) 1238 (75.3) 764 (91.4) 3.5(2.67-4.55) 
  Other 479 (19.3) 407 (24.7) 72 (8.6) 1 (ref) 
Employment status    - 
 Working (FT/PT) 1538 (62.6) 1011 (62.1) 527 (63.6)  
Unemployed/ 
homemaker/ 
Studying 
920 (37.4) 618 (37.9) 302 (36.4)  
Education level    0.024^ 
  < High school 236 (9.6) 175 (10.7) 61 (7.3)  
Certificate/ 
Diploma / 
partial degree  
470 (19.1) 303 (18.6) 167 (20.1)  
  Degree or higher 1756 (71.3) 1154(34.0) 602 (72.5)  
Hospital     p<0.001 
  Private  1079 (43.5) 566 (34.4)  513 (61.3) 3.02  
(2.54-3.59) 
  Public 1404 (56.5) 1080 (65.6) 324 (38.7) 1 (ref) 
Variable heading in italics ^multiple variables (no odds ratio) 
 
   
 
 
77 
Multiple Logistic Regression 
We undertook a multiple logistical regression of questionnaire variables that were potential 
modifiers of vaccination status using significant variables (p<0.05) for the univariate analysis 
(Table 1 & 2). These included flu vaccine recommendation; whooping cough & pertussis 
sources; pertussis vaccine recommendation; beliefs of pertussis vaccine benefits and barriers; 
pertussis susceptibility & severity, maternal age.  
In the multiple logistical regression analysis, factors associated with vaccine uptake prior to 
giving birth were hearing of ‘whooping cough’ from a health professional (OR: 2.38, 
p<0.001, 95% CI:1.73-3.27) or the workplace (OR: 2.22, p=0.02, 95% CI:1.13-4.37), 
perceiving the consequences of whooping cough as severe for adults (OR:1.23, p<0.001, 95% 
CI: 1.10-1.38) and that whooping cough is ‘common’ in one’s community (OR:1.29, 
p<0.001, 95% CI:1.13-1.46). They also agreed that the whooping cough booster vaccine 
would help prevent their child from getting whooping cough (OR: 1.21, p=0.046, 95% CI: 
1.003-1.47) and that it was their parental responsibility to have the vaccine (OR: 1.32, 
p=0.029, 95% CI: 1.028-1.686) (Table 5). Women ‘up to date’ with their pertussis vaccine 
perceived themselves as being less likely to contract pertussis (OR: 0.63, p<0.001, 95% CI: 
0.55-0.73), less likely to report a lack of time to get a vaccination (OR: 0.73, p<0.001, 95% 
CI: 0.66-0.81) and less concern over vaccine safety (OR: 0.79, p<0.001, 95% CI: 0.70-0.88). 
These participants who were vaccinated also had twice the odds of reporting that a family 
member had been recommended the pertussis booster vaccine (OR: 2.08, p<0.001, 95% CI: 
1.58-2.74).  
The cocooning strategy was introduced in NSW in 2009, and it was possible that multiparous 
woman may have been offered the vaccine under this strategy during their previous 
pregnancy. Therefore, a sub-group analysis by parity was conducted to control for the effect 
of the existing strategy (which had been implemented in the general practice setting). 
Amongst first-time mothers, those who were up to date with their pertussis booster vaccine 
were more likely to be private patients, have received whooping cough information from a 
health professional and/or their workplace, perceived whooping cough as ‘common’ in their 
community, report little or no concern over pertussis vaccine safety and report that a family 
member had also been recommended the pertussis booster vaccine (Table 2). Vaccinated 
first-time mothers perceived that they were less likely to catch whooping cough than 
unvaccinated mothers.  
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Table 2: The beliefs and attitudes of postnatal mothers and pertussis booster 
vaccination status.  
Study factor# Vaccinate
d 
n=837(%) 
Unadjusted 
Odds ratio 
(95% CI) 
p Adjusted odds 
ratio (95% CI)* 
p 
Where have you heard of whooping cough?     
Health professional 727 (86.9) 2.38 (1.73-3.27) <0.001 2.45 (1.58- 3.80) <0.001 
Work^                                    37 (4.4) 2.23 (1.13-4.37) 0.02 2.5 (1.0- 6.23) 0.05 
How likely are you to catch whooping cough? 
Likely 
Neither likely /unlikely 
Unlikely 
191 (22.8) 
158 (18.8) 
482 (57.5) 
 
0.63 (0.55-0.74) 
 
<0.001 
 
0.78 (0.65-0.92) 
 
0.004 
How severe or mild are the consequences of a whooping cough infection for an adult?  
Severe 
Neither severe /mild 
Mild 
459 (54.8) 
148 (17.7) 
226 (27.0) 
 
1.23 (1.1-1.39) 
 
<0.001 
 
- 
 
- 
How common or rare is whooping cough in your community? 
Common 
Neither common /rare 
Rare 
428 (51.1) 
196 (23.4) 
209 (24.9) 
 
1.29 (1.13-1.46) 
 
<0.001 
 
1.33 (1.11-1.6) 
 
0.002 
By getting a booster vaccine for whooping cough, I will help prevent my child from getting whooping 
cough. 
Agree 
Neither agree /disagree 
Disagree 
807 (96.3) 
16 (1.9) 
13 (1.5)  
 
1.22 (1.0-1.47) 
 
0.046 
- - 
It is not easy for me to find time to get a vaccination. 
Agree 
Neither agree nor 
disagree 
Disagree 
114 (13.7) 
81 (9.7) 
640 (76.4) 
 
0.73 (0.66-0.81) 
 
<0.001 
 
- 
 
- 
It is my responsibility to get vaccinated to protect my child’s health. 
Agree 
Neither agree / disagree 
Disagree 
813(97.0) 
13 (1.6) 
9 (1.1) 
 
1.32 (1.03-1.69) 
 
0.029 
 
- 
 
- 
I’m concerned about the safety of whooping cough vaccine for adults 
Agree 
Neither agree / disagree 
Disagree 
73 (8.7) 
107 (12.8) 
656 (78.3) 
 
0.79 (0.70-0.88) 
 
<0.001 
 
0.82 (0.69-0.97) 
 
0.020 
Family member/s recommended pertussis booster vaccine. 
Yes 
No/unsure 
628 (75.5) 
204 (24.5) 
2.08 (1.58-2.74) <0.001 1.57 (1.04-2.37) 0.032 
Where have you heard of pertussis?    
I have not heard of it. - - - 0.63 (0.41-0.96) 0.03 
Significant (p<0.05) variables included in multiple logistic regression: flu vaccine recommendation; whooping cough & 
pertussis sources; pertussis vaccine recommendation; pertussis vaccine benefits and barriers; pertussis susceptibility & 
severity, maternal age. ^Obtained from free-text from ‘other’ category #significant demographics in multivariate analysis: 
private hospital (OR: 2.34; p<0.001, 95% CI: 1.75-3.14); English speaking (OR:1.65; p=0.024; 95% CI: 1.07-2.6); Parity 
(multiparous: OR: 6.11; p<0.001, 95% CI: 4.72-7.92) *Analysis adjusted for parity (excluding multiparous participants 
eligible for funded vaccine following prior pregnancy under NSW Health ‘Cocoon’ campaign’) 
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Univariate analysis of baseline attitudes 
Pertussis vaccine and disease beliefs 
 A higher perceived severity of pertussis for an adult (p<0.001), reduced perceived 
susceptibility to contracting pertussis (p<0.001) higher perceived vaccine benefits (p<0.001) 
and lower vaccine barriers (p<0.001) were associated with prior vaccination (Table 2).  
Source of vaccine information  
There were 41.7% of up to date mothers who had not heard the term ‘pertussis’ compared to 
57.3% of ‘not up to date’ mothers (OR 0.29; p<0.001, 95% CI: 0.24-0.36). Nearly all the 
participants in our sample had heard of ‘whooping cough’. Among the few who had not 
previously heard of ‘whooping cough’, most were unvaccinated (101/103) (Table 4). 
Vaccinated women were significantly more likely to have heard of the disease ‘whooping 
cough’ from numerous sources than unvaccinated women, including the following: health 
professional (OR 5.01; 95% CI: 4.01-6.27), immunisation brochures (OR 2.52; 95% CI: 2.12-
3.0), media (OR 1.93; 95% CI: 1.63-2.3), anti-vaccination sources (OR 1.76; 95% CI: 1.2-
2.56) and internet (OR 1.56; 95% CI: 1.27-1.92). Whilst many different whooping cough 
information sources were reported, certain types were more influential than others. Women 
who reported that the most influential source was vaccine information communicated by a 
‘health professionals’ (OR: 2.38 p<0.001; 95% CI: 1.73-3.27) or in the form of an 
‘immunisation brochure’ (OR: 1.5 p<0.001), were more likely to be vaccinated than women 
who did not report these sources.  
 
We were interested in sources of information among women who had not received a vaccine 
to see if they were lacking in receiving the appropriate influential sources of information. 
Figure 3 shows the various reported sources of ‘whooping cough’ information that women 
received and how frequently they were reported as influential to vaccine decisions among A) 
vaccinated participants and B) unvaccinated participants. Graph B of figure 3 shows a 
discrepancy in which sources were identified as influential among unvaccinated participants 
and the actual source that they received ‘whooping cough’ information from. Most notably, 
88% of unvaccinated participants reported that their health professionals were the most 
influential source in deciding about vaccination, yet only 55% had received any information 
about ‘whooping cough’ from their health professional. In Graph A of figure 3, only 7% of 
vaccinated participants who reported a health professional as an influential source had not 
received any information about ‘whooping cough’ from their health professional. 
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Figure 3: The association between sources and their influence on vaccine decision making 
among vaccinated (Graph A) and unvaccinated (Graph B) mothers. 
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Graph A: The association between 'whooping cough' information sources 
reported by vaccinated mothers (n=837) and their  influence on maternal 
decision-making*.
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Graph B: The association between 'whooping cough' information sources 
reported by unvaccinated mothers (n=1646) and their  influence on maternal 
decision-making*.
Communication
gap
* values exceed 100% (multiple-responses).’Other’: free-text option 
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Vaccine recommendations 
Vaccinated women had twice the odds of having been recommended the pertussis vaccine 
than unvaccinated women (OR: 2; p<0.001; 95% CI: 1.66-2.30). The most common reported 
provider of pertussis vaccination recommendations was ‘doctor’. Just less than one half of 
vaccinated women reported doctor as provider of the pertussis vaccine recommendation 
compared to a quarter of unvaccinated women. We also asked about other recommended 
vaccines during pregnancy. We identified that women who had been vaccinated against 
pertussis were also more likely to have been recommended the influenza vaccine during their 
pregnancy (p<0.001; 38.9% vs. 26.2%). Vaccinated women were also more likely to have 
received the influenza vaccine during pregnancy compared to unvaccinated women (p<0.001, 
24.5% vs. 13.9%).  
 
 
Thematic analysis 
The baby (i.e. protection or harm minimisation) was cited as the most influential reason for 
prior pertussis vaccine receipt. Other reasons included a ‘health professional’s 
recommendation’ (25.8%), ‘family/friends (10.9%), awareness of the pertussis epidemic 
(9.2%), work (8.2%), pre-conceptual care (8%), and travel (5.4%). These were further 
categorised under six main headings: ‘pregnancy’, ‘health system’, ‘general’, ‘social 
influence’, ‘pertussis’ and ‘vocation or leisure’ (Figure 4).  
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Figure 4: Thematic analysis of reasons for having the pertussis 
booster vaccine prior to pregnancy (n=805)*. 
*32=non-response; values exceed 100% (open-ended responses categorised into > 1 theme). 
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The key reason for prior vaccine receipt was ‘The baby’: 
“I have already had a booster, it’s easy and I want to protect my child..” (primip, 25-
29 y.o.)  
 
This also related to the effect that pertussis has on a baby: 
 
“Whooping cough is a dangerous condition which if infects your child could kill them. 
It is a preventable disease.” (multip, 35-39 y.o.)  
 
"(I) believe the advice of my GP and support any of her recommendations."( primip, 
25-29 y.o.) 
 
 
The next most common reason for prior vaccine receipt was due to a health provider’s 
recommendation. Women reported: 
  
“Didn't think much about it but offered by GP” (primip, 30-34 y.o.)  
 
Another key influence on their decision to have had the pertussis vaccine previous was their 
family and friends: 
 
"It's for the safety of kids & the community."(primip 35-39y.o.)  
 
This include vaccination as a social norm: 
 
“We have to protect our children & I feel it is a social responsibility.” (multip, 30-34 y.o.) 
 
Partner vaccination status 
 
Vaccinated women were over three times more likely of reporting that their partner had 
received the pertussis booster than unvaccinated women (75.5% vs. 49.0%; p<0.001; OR 3.2; 
CI: 2.66-3.85). The reasons listed for their partners being vaccinated (n=1144) were ‘the 
newborn’ (46.9%), recommendation from a health professional (22.1%), prevent transmission 
to the family (6.2%), wife’s influence (5.6%), family planning/pregnancy (5.6%), general 
prevention (4.2%), pertussis awareness (4.1%), travel (3.8%) and work (3.7%). 
 
Pertussis booster vaccine: Self-report & provider confirmation 
From November 2010 to July 2012 in the public hospital sample, 96.4% (1433/1486) of 
postpartum women screened were enrolled in the study (Figure 1: flow chart). There were 29 
subjects lost to follow up (missing or non-returned questionnaires). Of the 1404 remaining 
subjects enrolled, 324 (23%) had received a pertussis booster vaccine within the past 10 years 
and were classified as ‘up to date’. Table 3.1 below shows the range of year for those who 
received the dTpa booster prior to enrolment. This is divided into 5 year and 10 year 
increments, due to the revision of the pertussis booster recommendation from every 10 years 
to every 5 years. 
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Table 3.1: Year of vaccination for 48.5% (157/324) of ‘up to date’ mothers in 
the Maternal Pertussis Trial (RNSH), November 2010-July 2012. 
Year^ Total* 2004-2006 2007-2011 
dTpa (%) 157 35 (22.3%) 122 (77%) 
*157/324 up to date subjects recalling date of dTpa vaccination  ^median 2013 
 
From March 2012 to March 2013 in the private hospital sample, 1080 of 1121 mothers were 
enrolled (see flow chart). 17 were excluded (missing data). Of these 1063 remaining, the 
background pertussis booster rate (dTpa <10years) was 48.1% (n=514; 7 whilst pregnant). 
There were 10 mothers (private sample) and 3 mothers (public sample) who reported a 
history of pertussis. Table 3.2 (below) shows in which year the dTpa booster was received by 
‘up to date’ participants. Again, the years highlighted in red indicate a dTpa booster within 
the last five years, as per updated recommendations that occurred during the study period. 
 
 
Table 3.2: Year of vaccination for 51% (267/514) of ‘up to date’ mothers in the 
Maternal Pertussis study- NSP surveyed between march 2012-2013 
Year* Total 2005 2006 2007 2008 2009 2010 2011 2012 2013 
dTpa 
(%) 267 3 (1.2%) 3 
(1.2%) 
2 
(0.8%) 
19 
(7.1%) 
70 
(26.2%) 
102 
(38.2%) 
56 
(21%) 
6 
(2.2%) 
6 
(2.2%) 
*240 (89.9%) dTpa <5years [2013-2009] 
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Baseline Results among participants eligible for vaccination during pregnancy 
We screened 99.3% (723/728) of postpartum women approached for vaccine status (5 
declined: busy/tired). We excluded 342 (342/723; 47.3%) women vaccinated prior to 
pregnancy (dTpa<5years). The remaining 381 women completed a baseline questionnaire, of 
which 33 were excluded (2 misclassification; 31 missing data). Pertussis vaccine uptake 
during pregnancy was 8.7% (33/381) and occurred at an average of 34 weeks gestation 
(+5.15 weeks). We confirmed vaccine date with the family doctor for 75.8% of women 
reporting vaccination during pregnancy (1 false recall). Demographics did not differ 
significantly according to vaccine status, with participants on average aged 30-34 years, 
Australian-born (57.9%), English speaking (307; 88.5%) and multiparous (66%). 
Disease awareness and information sources 
Overall awareness of pertussis was high, with nearly all participants having heard of it as 
‘whooping cough’ (336; 97.1%). Women reported that they heard of ‘whooping cough’ from 
an average of three information sources. However, we noticed that whilst women reported a 
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Figure 5: Catergorised qualitative response for Pertussis Booster 
vaccine decision-making among women vaccinated prior to 
childbirth, stratified by hospital.
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range of information sources, certain sources influenced their choices about vaccination. 
Nearly all women reported that health professionals were most influential to their vaccine 
decision-making (315; 91%), followed by immunization brochures (109; 31.5%) and family 
or friends (86; 24.9%).  
Disease perception and knowledge 
Whilst nearly all participants perceived that pertussis was ‘very infectious’ (308; 89%), 
unvaccinated participants were more likely to perceive pertussis as ‘rare’ in their community 
(44.3% vs. 20%; p=0.018) (Table 1). Most women perceived the consequences of a pertussis 
infection for a newborn as severe; with 85% indicating ‘very severe’ (Appendix 2: Table 1.  
 
Pertussis booster vaccine attitudes and beliefs 
Participants generally agreed that pertussis booster vaccination would help prevent their baby 
getting whooping cough (321; 92.5%), and it was their parental responsibility to do so (321, 
92.5%). Barriers included transport to an immunization provider (10% vs. 0%; p=0.032) and 
vaccine safety concerns (15.8% vs. 0%; p=0.004) (Appendix 2: Table 1; Figure 1). One-third 
of unvaccinated women reported that they would only be vaccinated if the pertussis booster 
vaccine was funded: they would not pay to receive it.  
 
Vaccine recommendation 
Women vaccinated during pregnancy were significantly more likely to have received a 
pertussis booster recommendation (96.7% vs. 69.1%; p=0.001). In addition, vaccination 
during pregnancy was associated with the receipt of a pregnancy-specific pertussis booster 
recommendation by a health professional (91.3% vs. 37%). Among unvaccinated participants 
who were not recommended prenatal pertussis vaccination, 40.2% (53/132) would have 
agreed to vaccination during pregnancy had their doctor recommended it. Overall, 80.2% 
(247) unvaccinated women reported that they intended to have the pertussis booster vaccine 
(Graph 2).  
 
Reported partner vaccine status 
We found that women who had been vaccinated during pregnancy more frequently reported 
that their partner had also received the pertussis booster vaccine compared to unvaccinated 
women (70% vs. 11%; p<0.001) (Graph 2).  
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Pertussis vaccination versus routine pregnancy vaccination (Influenza)  
We also asked about another vaccine that is routinely given during pregnancy. Among all 
women, 60.2% reported having been recommended the influenza vaccine during pregnancy, 
yet only 39.1% were vaccinated against influenza during pregnancy. We looked at whether 
this differed by pertussis vaccine uptake during pregnancy, as it is plausible that these women 
were more accepting of vaccination in pregnancy in general (rather than which disease they 
were being immunized against). We found that woman vaccinated against pertussis during 
pregnancy not only had twice the odds of having been recommended the influenza vaccine 
(OR: 2.7; p=0.003; 95% CI: 1.1-6), but were also three times as likely to have been 
vaccinated against influenza during pregnancy (OR: 3.1; p=0.003; 1.4-6.7) (Appendix 2: 
Graph 2).    
 
 Controlled Intervention Trial: Public hospital (RNSH) 
Participants 
From November 2010 to July 2012, we enrolled 96.4% (1433/1486) of postpartum women 
screened (Figure 1). There were 53 (3.5%) women who declined participation due to: 
tiredness/busyness (23), said ‘no’ (8) ‘anti-immunisation’ (1), and not returning the study 
forms (21). We excluded 29 due to missing baseline questionnaire. Of the 1404 remaining 
subjects, 324 (23%) had received a pertussis booster vaccine within the past 10 years and 
were ineligible for the intervention study. The remaining 1080 participants requiring a 
pertussis booster vaccine were included in the interventional phase, which met the required 
sample size. This sample differed to the general Australian population: fewer indigenous 
women (0.7% vs. 3.3% state-wide(136)), lower employment rate during pregnancy (58% vs. 
68% Australia-wide((137)), higher socio-economic status (57% in top decile) and higher 
other region of birth (primarily South, South-East and North-East Asia). Differences were 
reflective of the population in this catchment area, which accommodates 11.2% of births 
state-wide (136). However, our sample also included 79 (7.3%) women outside the catchment 
area (but within metropolitan Sydney), 39 (3.6%) from regional/rural NSW and 3 (0.3%) 
from another state (1 Perth, 2 Canberra). Postcode data was missing for 3 (0.3%) participants. 
Demographics are outlined in Table 1.  
 
 
 
 
 
Figure 1: Maternal Pertussis Trial Flow Chart 
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*P value=0.62 in univariate analysis of the impact of the framing 
intervention on postpartum pertussis booster vaccine uptake. 
GAIN (n=346) LOSS (n=348) CONTROL (n=386) 
Education Intervention (sequential block allocation by week) (n=1080) 
 The research nurse collected baseline questionnaire, distributed education and informed participants 
that a free vaccine was available and to speak to hospital staff.  
 
Mothers enrolled and completed the 
baseline questionnaire (N=1433) 
Mothers approached on the 
postnatal ward within 8 hours-
3days postpartum (n=1486) 
Declined participation (n=53) 
 Tired/busy (n=23); 
 ‘No’ (n=8) 
 Didn’t return forms (n=21) 
 ‘Anti-immunisation (n=1) 
 
Missing questionnaires (n=29) 
 missing questionnaires (n=18) 
 questionnaire not returned (n=11) 
Mothers screened (1404) for pertussis 
booster status (dTpa<10years) 
Vaccine uptake on the 
postnatal ward* 
69.1% (n=239) 
Vaccine uptake on the 
postnatal ward* 
71.8% (n=250) 
Vaccine uptake on the 
postnatal ward* 
 68.8% (n=265) 
 Excluded from intervention phase: 
Mothers ‘up to date’ with pertussis 
booster at baseline (n=324; 23%) 
Follow up questionnaire: 
Completed by all participants on the ward following vaccination or vaccine decline (<72 
hours postpartum). 
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 Table 1: Demographic characteristics of women by allocation of message-framing 
intervention or control. 
Variable^ Total  
N=1080 
Gain 
n=346 
(32.0%)  
Loss 
n=348 
(32.2%) 
Control 
n=386 
 (35.7%) 
Maternal age (years)     
   <25  72 (6.7) 22 (6.4) 24 (6.9) 26 (6.7) 
   25-34  683 (63.2) 207 (59.8) 222 (63.8) 254 (65.8) 
   35-44 319 (29.5) 114 (32.9) 99 (28.4) 106 (27.5) 
   45 or over 6 (0.6) 3 (0.9) 3 (0.9) - 
Parity     
   Primiparous 707 (65.5%) 218 (63.0) 236 (67.8) 253 (65.5) 
   Multiparous 373 (34.6%) 128 (37.0) 112 (32.2) 133 (34.5) 
Living with a partner*     
   Yes 1024 (94.8%) 328 (97.0) 333 (96.5) 363 (95.0) 
   No 41 (3.8%) 10 (3.0) 12 (3.5) 19 (5.0) 
Region of birth     
   Australia 408 (37.8%) 121 (35.0) 140 (40.2) 147 (38.1) 
   Other 671 (62.2%) 225 (65.0) 208 (59.8) 239 (61.9) 
Indigenous status     
   Yes 9 (0.8) 3 (0.9) 2 (0.6) 4 (1.0) 
   No 1071 (99.2) 343 (99.1) 346 (99.4) 382 (99.0) 
Language*      
   English 737 (68.2) 230 (66.5) 247 (71.0) 260 (67.4) 
   Other 341 (31.6) 116 (33.5) 101 (29.0) 126 (32.6) 
Socioeconomic status  
(decile 1-10)* 
    
   1-5 33 (3.1) 9 (2.6) 13 (3.8) 11 (2.8) 
   6-8 149 (13.8) 46 (13.3) 45 (13.0) 58 (15.0) 
   9 287 (26.6) 101 (29.3) 93 (27.0) 93 (24.1) 
  10 607 (56.2) 189 (54.8) 194 (56.2) 224 (58.0) 
Employment status*     
Working (FT or PT) 619 (57.3) 193 (56.6) 217 (63.5) 209 (55.0) 
unemployed/homemaker/st
udying 
444 (41.1) 148 (43.4) 125 (36.5) 171 (45.0) 
Education level*     
 High school or less 134 (12.4) 45 (13.0) 40 (11.5) 49 (12.7) 
 Certificate/Diploma 
/partial degree  
208 (19.3) 58 (16.7) 73 (21.0) 77 (19.9) 
 Degree or higher 725 (67.2) 238 (68.9) 232 (66.7) 255 (66.1) 
*Values may not equal 100 due to missing data ^There were no significant differences between groups (univariate) 
(%)=  
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Vaccine uptake 
Overall vaccine uptake (dTpa) prior to hospital discharge was 70% (754/1080) (Figure 1). 
We observed no significant difference between the ‘loss’ framing intervention, the ‘gain’ 
framing intervention or the control (71.8% vs. 69.1% vs. 68.8%, p=0.62). At discharge, 
overall pertussis vaccine coverage had increased from an existing baseline of 23% to 77% 
among all mothers screened (1080/1404). 
Predictors of pertussis booster vaccine uptake 
Information sources, language, pertussis susceptibility and severity, and vaccine barriers, 
benefits, recommendation and intention were significant univariate variables used in the 
multivariate analysis. Significant predictors of pertussis vaccine uptake included baseline 
intention to have the vaccine (OR 2.46, 95% CI: 1.69-3.58, p<0.001), perceived benefits of 
vaccination (OR 1.61, 95% CI: 1.25-2.15, p<0.001) and having been recommended the 
pertussis booster vaccination (OR 1.68; 95% CI: 1.07-2.65; p=0.03) [Table 2]. The odds of 
vaccine uptake increased among participants who reported ‘English’ as their primary 
language (OR 1.46; 95% CI: 1.06-2.02, p=0.02). While there was a pertussis epidemic during 
the time period of the study, with heightened media attention on the topic, we did not observe 
an obvious relationship between postpartum vaccine uptake in our study and state-wide 
(NSW) mandatory reported pertussis cases (Figure 2).   
Table 2: Multivariate analysis of pertussis booster vaccine uptake on the postnatal ward^ 
Predictors* OR (95% CI)~ P value 
English spoken at home 1.46 (1.06-2.02) 0.022 
Intention to receive pertussis vaccine  2.46 (1.69-3.58) <0.001 
Recommended pertussis vaccine  1.68 (1.07-2.6) 0.025 
Vaccine benefits (score) 1.61 (1.25-2.15) <0.001 
*Significant univariate predictors included in multivariate analysis: language; Number of 
‘pertussis’ and ‘whooping cough’ information sources; Information sources: Health 
professional, media, family or friends; Influential information sources: Health professional, 
internet. alt. health practitioner; Scores: Susceptibility & Severity, benefits, barriers; 
Recommended pertussis vaccine ( & by a doctor, midwife); Intention to receive pertussis 
vaccine 
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Mediation Analysis 
A mediating relationship occurs when a third variable plays a key role in governing the 
relationship between the independent and dependent variables. As vaccine intentions did not 
always result in vaccine uptake, we used a mediation model to explore the extent to which 
independent predictors (vaccine recommendation and vaccine benefits) influenced the 
mediator variable (vaccine intentions) that, in turn, influenced the dependent variable 
(vaccine uptake). The odds of being vaccinated were 2.5 times higher for those who 
perceived the benefits of vaccination versus not; this was reduced to around 1.5 times higher 
when adjusted for intent. Furthermore, the odds of being vaccinated were 3.7 times higher 
among those who had been recommended the vaccine than those without a recommendation. 
These odds were reduced to 2.5 times higher when adjusting for intent. While ‘intention’ 
mediated the effect of vaccine benefits (-53.9%) and pertussis vaccine recommendation (-
46.6%) on vaccine uptake on the postnatal ward, both predictors remained significant when 
controlling for intent. 
Table 3.3: Meditation analysis for significant factors predictive of vaccine uptake in the 
logistic regression analysis 
 
 
 
Predictors 
Outcomes 
 
Percentage 
change in Odds 
ratio 
Intent to be 
vaccinated Vaccinated 
Vaccinated adjusted 
for intent (mediation) 
Vaccine 
benefits 
5.501**  
(4.206-7.194) 
2.457** 
 (1.994-3.027) 
1.672**  
(1.330-2.102) 
-53.9% 
Pertussis 
booster 
recommen
dation 
7.060** 
 (5.208-9.572) 
3.757** 
 (2.840-4.968) 
2.473** 
 (1.821-3.359) 
-46.6% 
**p<0.001 
 
 
Pertussis awareness and influential information sources  
There was a high awareness of pertussis in general among postpartum women; although they 
were more familiar with hearing the term ‘whooping cough’ (91.2%) than ‘pertussis’ (56.6%) 
(Table 3). Participants who accepted pertussis vaccine on the postnatal ward had more 
frequently heard of whooping cough from multiple sources (from >3 sources: 18.3% vs. 
11.7%) than those who declined vaccination. These sources were primarily a health 
professional (52.1%), the media (47.6%) and friends or family (45.5%). Participants who 
reported a ‘health professional’ as most influential to their vaccine decision-making were 
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more likely to accept the pertussis vaccine (85.5%, p=0.001), whereas the reverse was 
observed for ‘internet’ (6.4% vs. 12.6%; p=0.001) and ‘complementary medicine 
practitioner’ (e.g. naturopath, homeopath) (1.7% vs. 4.6%; p=0.011). Those who had received 
a pertussis booster vaccine recommendation were more likely to accepted pertussis 
vaccination (62.3% vs. 30.8%; 1.68, 1.07-2.65; p<0.001). Vaccinated participants also more 
frequently listed a health professional as the source of this recommendation than those who 
declined (doctor: 25.5% vs. 10.8%, p<0.001; midwife 21% vs. 8.9%, p<0.001). Participants 
immunised on the postnatal ward more frequently reported that their family members had 
received a pertussis booster vaccine recommendation compared to declining participants 
(52.1% vs. 22.5%; p<0.001). 
Pertussis Booster Vaccine Intentions 
Intention to receive the pertussis vaccine prior to receipt of the educational brochure was 
significantly higher amongst those who were vaccinated on the postnatal ward than those 
who were not (78.9% vs. 44.9%; p<0.001) (Table 4). Vaccine uptake was just under 20% 
(12/62) amongst participants with no intention to be vaccinated at baseline and 48% 
(109/228) among those ‘unsure’ of their vaccine intention. Interestingly, among the gain 
framed intervention had a significantly higher impact on women with no firm vaccine 
intentions. 
Vaccination intention score and qualitative analysis of vaccine intent 
Among participants who indicated at baseline that they intended to receive the vaccine, one 
in five declined vaccination on the postnatal ward (n=146; 19.7%). To further explore 
vaccine intentions we used multiple close-end questions, and attributed a score accordingly to 
quantify the strength of their intent. We did this as studies often report vaccine intent as an 
outcome rather than vaccine acceptance, and we wanted to evaluate whether intentions 
always translated into vaccine behaviour. For the question ‘Overall, how do you feel about 
getting a booster vaccine for whooping cough for yourself once your child is born?’ we 
assigned a score of 1-5 according to their response. We used a Likert Scale to quantify their 
support for maternal pertussis vaccination (1-strongly oppose to 5-strongly support) and 
asked them why they responded this way (qualitative thematic analysis). In addition, we 
asked ‘do you intend to receive the booster vaccine for whooping cough?’ (yes=2, unsure=1, 
no=0). There is a linear relationship showing that as vaccine intention score increases, 
vaccine acceptance increases. Vaccine decline on the other hand plateaued out from score 3, 
before dipping down for an intention score of 7. This is depicted in the graph and table 
below. 
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Table 3.5: Intention to receive the pertussis booster vaccine during the postnatal period 
reported by participants at baseline, stratified by vaccine uptake on the postnatal ward.  
Variable Total Declined (%) Accepted (%) p value 
N=1080 N=325 N=754  
Do you intend to receive the booster vaccine for whooping cough? <0.001 
   Yes    741 (68.7) 146 (44.9) 595 (78.9)  
   No 62 (5.7) 50 (15.4) 12 (1.6)  
   Unsure 228 (21.1) 119 (36.6) 109 (14.5)  
Vaccination Intention (score)    <0.000 
   1 6 (0.6) 5 (1.6) 1 (0.1)  
   2 19 (1.8) 18 (5.7) 1 (0.1)  
   3 106 (10.1) 65 (20.4) 41 (5.6)  
   4 115 (11.0) 61 (19.2) 54 (7.4)  
   5 143 (13.6) 53 (16.7) 90 (12.3)  
   6 267 (25.5) 67 (21.1) 200 (27.4)  
  7 393 (37.5) 49 (15.4) 344 (47.1)  
*Values may not equal 100 due to missing data 
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Graph 3.4: Intention to be vaccinated against pertussis (dTpa) score and vaccine 
uptake among the 1080 participants in the Maternal Pertussis Controlled Trial
Total N=1080
dTpa accepted
n=754
dTpa declined
n=324
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Here, we see the 44.9% of those who intended to act and receive the pertussis vaccine did not 
(declined vaccination). Thus, an intervention designed to help women act on their intentions 
rather than change their intentions would have a better chance of increasing vaccine uptake 
among this population. This decision is based on the frequencies in each cell, which can be 
used to guide decision-making around the interventional aim. On the contrary, we note that 
78.9% of women who intended to receive the vaccine were vaccinated on the postnatal ward. 
Following the intention-behaviour matrix(122), the reduction in environmental barriers may 
have had a greater impact on vaccine completion than the educational intervention aimed at 
attitudinal change. 
Impact of cost on vaccine intentions 
The impact of cost on intention to be vaccinated at baseline showed that 72% of participants 
preferred a free vaccine. Only half of these participants would pay $50 for the pertussis 
booster vaccine if necessary (Table 4) and a further 7.4% (n=80) indicated they would pay for 
it. The remaining participants were either unsure (n=125, 11.6%) or not willing (n=33, 3%) to 
be vaccinated. Cost also impacted the participants’ willingness to recommend their partner 
receive the pertussis booster vaccine with 77.1% preferring a free vaccine for their partner. 
Of these 731 participants, 325 would pay $50 for the vaccine if necessary. A small proportion 
of participants indicated they would pay $50 for the vaccine for their partner (7.5%; n=81). 
Of those remaining, 13% (n=141) were unsure whether to recommend their partner receive it, 
2.6% (n=28) were unwilling to recommend this vaccine to their partner and 7.5% (n=81) 
reported their partner had already received it. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Pertussis/ whooping cough information sources reported by women at baseline and 
vaccination uptake prior to discharge from the postnatal ward. 
 
Variable 
Total* 
N=1080 (%) 
Declined 
n=325 (%) 
Accepted  
n=754 (%) 
p value 
Number of pertussis 
information sources 
   0.03 
   0 (Have not heard of the 
term ‘pertussis’)  
611 (56.6) 200 (61.5) 411 (54.5)  
   1  
259 (24.0) 73 (22.5) 185 (24.5)  
   2 
93 (8.6) 30 (9.2) 63 (8.4)  
   3  
49 (4.5) 7 (2.2) 42 (5.6)  
   4 or more 
68 (6.3) 15 (4.6) 53 (7.0)  
Number of whooping cough    
information sources 
   <0.001 
   0 (Have not heard of  the 
term ‘whooping cough’)  
95 (8.8) 41 (12.6) 54 (7.2)  
   1  
417 (38.6) 146 (44.9) 271 (35.9)  
   2 
216 (20.0) 62 (19.1) 153 (20.3)  
   3  
169 (15.6) 34 (10.5) 135 (17.9)  
   4 or more 
183 (16.9) 42 (12.9) 141 (18.7)  
Whooping Cough information 
Source: 
    
Health professional (doctor or 
nurse) 
528 (48.9) 135 (41.5) 393 (52.1) 0.001 
Immunisation brochures or 
pamphlets 
382 (35.4) 109 (33.5) 273 (36.2) 0.41 
Media 
480 (44.4) 121 (37.2) 359 (47.6) 0.001 
Information from vaccine-
opposed groups 
30 (2.8) 10 (3.1) 20 (2.7) 0.69 
Friend or Family 
460 (42.6) 116 (35.7) 343 (45.5) 0.002 
Alternative health practitioner 
16 (1.5) 3 (0.9) 13 (1.7) 0.42 
Internet 
147 (13.6) 35 (10.8) 111 (14.7) 0.10 
Other  
150 (13.9) 42 (12.9) 108 (14.3) 0.57 
Most influential vaccine 
decision making source(s) 
(multi-response)~ 
    
Health professional 897 (83.1) 251 (77.2) 645 (85.5) 0.001 
Immunisation brochures or 
pamphlets 
262 (24.3) 76 (23.4) 186 (24.7) 0.70 
Family or friends 227 (21.0) 69 (21.1) 158 (21.0) 0.94 
Media 138 (12.8) 33 (10.2) 105 (13.9) 0.09 
Internet 89 (8.2) 41 (12.6) 48 (6.4) 0.001 
Alternative health practitioner 28 (2.6) 15 (4.6) 13 (1.7) 0.011 
*Values may not equal 100 due to missing data ~3 selected ‘none’, 105 (97%) selected other (not 
significant) 
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Reasons for vaccine decision-making at follow up 
Coded follow up responses to the question ‘what factors (were) most influential to your 
vaccine decision-making’ are outlined in Table 5. Some of the quotations informing the 
themes have been included for vaccine decline. This is because this is an area that needs to be 
improved upon if we are to see vaccine uptake increase. 
Vaccine acceptance 
A thematic analysis indicated that over half of the participants accepted the pertussis vaccine 
for baby’s protection. Other influential factors included a health professional 
recommendation, family/friends, pertussis awareness and convenience. The primary reason 
reported for declining this vaccine was a preference for vaccination by their General 
Practitioner (Table 5). We also looked at the influential factor among participants who, at 
baseline, were either not willing or unsure of whether to be vaccinated. ‘Baby’s protection’ 
influenced vaccine acceptance of almost half (54/109) of the participants who were ‘unsure’ 
of their vaccine intention at baseline. ‘Protecting the baby’ (n=4), the brochure (n=3) and the 
health professional’s recommendation (n=2) were key factors which influenced vaccine 
acceptance among participants who had no baseline intention to receive the vaccine. 
 
Vaccine decline 
The key reason for vaccine decline was ‘Trusts in their primary healthcare provider’. These 
participants preferred to see their GP at a later time for the vaccine: 
“I know my GP well and have everything organised for the next couple of months 
with her.” (primip, 20-24 y.o.)  
 
In addition, they also preferred to be vaccinated with their partner or baby at the GP: 
 
"I want to go to the GP with my husband - if available for both of us in hospital I 
would have had it." (primip, 30-34 y.o.) 
 
The next most common reason for decline was due to childbirth factors. Women reported 
feeling too tired, in too much pain, lost too much blood, had enough needles: 
  
“At the moment I just have plenty discomfort post-delivery” (primip, 25-29 y.o.)  
 
They also reported vaccine concerns in relation to having gone through childbirth and not 
wanting side effects this soon after delivery. They also expressed concerned about the 
vaccines’ effect on breast milk: 
 
“(I) don't want vaccine to affect my health when I'm trying to care for a newborn and 
breastfeeding.”(35-45y.o. mother of three)  
 
Some when reported the decision to delay vaccination until recovered following childbirth: 
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“I'll definitely do it, but I just think giving my body something extra will be too much. 
I've been through a lot” (primip, 35-44 y.o.). 
 
Another theme that emerged was ‘requiring additional time or information’. Here participants 
indicated that the timing was not ideal immediately postpartum.  
“Need more information and more time. Very tired. Will go to GP.” (primip, 25-34y.o.) 
“Lack of information (prior to delivery)…If I had the info well beforehand I would have 
chosen to get the vaccine.” (24-34y.o. mother of 2) 
“I have not had time to think about it so at this stage it's just unsure." (25-34y.o. mother of 
2) 
 
Again, additional information related more to the type and source needed, primarily a 
discussion with a healthcare providers, to enable participants to make an informed decision. 
“Would like to discuss further with the GP”. (primip, 25-34y.o.) 
"I have not had enough time to read this (brochure) because the baby has been 
unsettled... I need more time to make a decision." (primip, 25-34y.o.) 
“I need more information & time to discuss with my partner.” (25-34y.o. mother of 2) 
“I need to check with the GP regarding vaccine status & read up some more about it ”. 
(primip, 25-34y.o.)  
Another theme was that vaccination was perceived as unnecessary. Qualitative results 
indicated the following reasons for this belief and included: childhood vaccination, being 
healthy, not believing in immunisation, not requiring it with a previous pregnancy, no 
pertussis experience, and favouring treatment over prevention. There was also a related theme 
of ‘first-hand disease knowledge’, comprised of participants who reported they contracted 
pertussis (either as a child or adult). 
"Only because I never take anything if really I don't have to." (35-44 y.o. mother of two) 
 
Some women didn’t perceive it necessary for them, and the child was going to be vaccinated 
soon anyway.  
 
“My baby will have the vaccine so I don't see the need.” (20-24 y.o, mother of two). 
 
For some participants who declined vaccination, it was on account of their family and friends. 
Qualitative responses listed both the advice given by their family and/or friends as well as 
stories of their vaccine experience. For other participants, they wanted to consult family prior 
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to making a decision about vaccination. One participant gave an insightful comment into the 
social impact of vaccine decision-making:  
“My parents are bit hippy, I suppose. There is an element of doubt due to those who 
say it made my child sick. I'd never not vaccinate my children but for me personally, 
it's changing a generation of thinking.” (35-44 y.o. mother of two) 
 
Additional themes for vaccine decline included ‘vaccine concerns’. Here, participants 
reported concerns about the vaccine safety and side effects especially when administered 
immediately postpartum, vaccine efficacy, how long the pertussis booster vaccine had been 
around, vaccine components (e.g. triple antigen), and concerns around its administration (e.g. 
fear of needles).   
Postpartum routine vaccine eligibility and receipt 
During the study, Priorix (Measles-Mumps-Rubella) was the only routine postpartum 
vaccination provided within this setting. This is due to the need to immunise against rubella, 
as a strategy to prevent congenital rubella should a non-immune mother be exposed during 
her next pregnancy. Data was obtained for both rubella vaccine status (serology based 
indicator of immunity: ‘non-immune’, borderline, immune) and uptake for the women in the 
public hospital site. There were 22% of participants who were eligible for rubella 
vaccination, as determined by the rubella serology taken in the first trimester of the current 
pregnancy (eligibility was ‘non-immune’ or borderline result indicated by Rubella IgG <30). 
Status was unknown or not recorded for 2.6% of participants (0.6% up to date with pertussis 
booster vaccine versus 3.2% of those unvaccinated against pertussis). Among the 311 (22.35) 
participants eligible for postpartum rubella vaccination, 65.3% were vaccinated on the 
postnatal ward and a further 4.8% were counselled but declined vaccination. The remaining 
30% of eligible women did not receive the vaccine on the postnatal ward, with the database 
indicating it ‘to be given’ (‘vaccine delay’). Interestingly, there was no significant difference 
between rubella vaccine decline, vaccine acceptance or vaccine delay according to the 
baseline pertussis booster status of participants. This is detailed in Table 3.6 below: 
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Table 3.6: Results of immunity to and immunisation against rubella, according to baseline 
pertussis booster vaccine status of women in the public hospital site. 
Eligible for rubella 
vaccination 
Total 
N=1394 
Up to date (dTpa) 
n=316 
Not up to date (dTpa) 
n=1078 
Yes* 311 (22.2) 48 (14.8) 263 (24.4) 
No 1046 (74.5) 266 (82.1) 780 (72.2) 
Status unknown/not 
recorded 
37 (2.6) 2 (0.6) 35 (3.2) 
Received Rubella 
vaccine 
Total (eligible)* 
N=311 
Up to date (dTpa) 
n=48 
Not up to date (dTpa) 
n=263 
Yes 203 (65.3) 32 (66.7) 171 (65.0) 
No- counselled but 
declined 
15 (4.8) 2 (4.2) 13 (4.9) 
No- to be given 93 (29.9) 14 (29.2) 79 (30.0) 
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Table 5: Knowledge of and attitudes towards pertussis reported by women at baseline and 
vaccine uptake prior to discharge from the postnatal ward. 
 
Variable Total 
N=1080 
Declined 
n=325 (%) 
Accepted 
n=754 (%) 
p value 
Health Belief Model pertussis beliefs 
Susceptibility & Severity score^    0.005 
    5-9 9 (0.9) 4 (1.3) 5 (0.7)  
   10-14 59 (5.6) 28 (8.9) 31 (4.2)  
   15-19 370 (35.4) 121 (38.7) 249 (34.0)  
   20-24 483 (46.2) 130 (41.5) 353 (48.2)  
   25 or more 124 (11.9) 30 (9.6) 94 (12.8)  
Health Belief Model vaccination beliefs 
Benefits score#    <0.001 
    5-9 4 (0.4) 4 (1.3) -  
   10-14 8 (0.8) 8 (2.5) -  
   15-19 135 (12.7) 74 (23.3) 61 (8.2)  
   20-24 579 (54.6) 170 (53.6) 409 (55.0)  
   25 or more 335 (31.6) 61 (19.2) 274 (36.8)  
Barriers score~    0.002 
    5-9 524 (55.7) 140 (47.9) 384 (73.3)  
   10-14 385 (40.9) 144 (49.3) 241 (37.1)  
   15-19 32 (3.4) 8 (2.7) 24 (3.7)  
Cue to action     
Recommended pertussis vaccine* <0.001 
   Yes 570 (52.8) 100 (30.8) 470 (62.3)  
   No 452 (41.9) 206 (63.4) 246 (32.6)  
   Unsure 41 (3.8) 13 (4.0) 28 (3.7)  
Provided by: (open-response)     
   doctor 227 (21.0) 35 (10.8) 192 (25.5) <0.001 
   midwife 187 (17.3) 29 (8.9) 158 (21.0) <0.001 
   health system  41 (3.8) 5 (1.5) 36 (4.8)  
Intention to receive pertussis vaccine <0.001 
Yes 741 (68.7) 146 (44.9) 595 (78.9)  
No 62 (5.7) 50 (15.4) 12 (1.6)  
Unsure 228 (21.1) 119 (36.6) 109 (14.5)  
Willingness to be vaccinated if: <0.001 
Free; I would not pay for the 
pertussis booster vaccine 
402 (37.3) 128 (39.4) 274 (36.3)  
Free or $50 380 (35.2) 73 (22.5) 307 (40.7)  
$50 82 (7.6) 8 (2.5) 74 (9.8)  
Unsure 154 (14.3) 77 (23.7) 77 (10.2)  
Unwilling to be vaccinated 33 (3.1) 28 (8.6) 5 (0.7)  
*Values may not equal 100 due to missing data  ^Susceptibility & Severity: likelihood of transmission to mother and baby; 
severity of pertussis for mother and newborn; ease of transmission; commonality of pertussis in their community.  
 #Benefits: pertussis booster vaccination will a) help prevent their baby from contracting pertussis; b) would strengthen their 
immunity to pertussis c) a parental responsibility to protect the baby’s health d) effective in preventing pertussis e)vaccine 
benefits outweigh risks. ~Barriers: a) It is not easy to find time to be vaccinated b) A lack of access to information required 
for informed vaccine decision-making c) Concern of vaccine safety for adults d) Transport issues (to access vaccination). 
   
 
 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Qualitative responses for vaccine decision-making, stratified by pertussis 
booster vaccine (dTpa) uptake on the postnatal ward. 
Thematic analysis of reasons for vaccine acceptance on the postnatal ward*~ Vaccinated# 
n= 754(%) 
The Newborn - protection; decrease transmission risk 387 (51.0) 
Health professional recommended 91 (12.1) 
Family/friends- Advice or vaccine experience of family/friends. Or vaccinated for 
their protection (especially children).  
67 (8.9) 
Pertussis Awareness- Common (epidemic); a highly contagious disease with serious 
consequences. 
56 (7.4) 
Ease/Convenience- availability, cost-free, accessible. 46 (6.1) 
Information given- Brochures, government website, signs etc. delivered in the 
healthcare setting.   
36 (4.8) 
Disease experience- pertussis history; witnessed pertussis first-hand.  22 (2.9) 
Media- Frequency of reports (e.g. heard it on the news a lot), genres (e.g. the news), 
mediums (e.g. TV/radio) and headline details. 
11 (1.4) 
Vaccine concerns- vaccine safety and minimal side-effects.  6 (0.8) 
Childbirth factors- including breastfeeding. 2 (0.26) 
Thematic analysis of reasons for vaccine decline on the postnatal ward*~ Not Vaccinated 
n=325 (%) 
Trusts in their primary healthcare provider- Preference to see general practitioner 
at a later time; or for concurrent vaccination with their partner or baby. 
52 (16.0) 
Childbirth factors- Decision to delay vaccination until recovered. 40 (12.3) 
Requires additional time or information- than immediately postpartum  36 (11.1) 
Vaccination perceived as unnecessary- childhood vaccination is enough, being 
healthy, not believing in immunisation, not requiring it with a prior pregnancy, never 
seen pertussis, and prefer treatment.  
23 (7.1) 
Vaccine concerns- safety, side effects (esp. immediately postpartum), efficacy, 
history, composition, and administration route.   
20 (6.2) 
Family/friends- Advice or vaccine experience of family/friends; or a need to consult 
family prior to making a decision about vaccination. 
13 (4.0) 
History of pertussis 1 (0.3) 
*65 non-responses (8.6%).  ~4(0.5%) lost to follow up. #Does not add up to 100% due to multiple responses. ^ System error 
(vaccine not administrated) *61 non-response (19.9%) ^11(3.4%) lost to follow up. 
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Figure 2: In the state of NSW, any laboratory-confirmed diagnosis of pertussis is reported to 
the state bureau of health. We used this data to correlate the prevalence of pertussis with 
vaccine uptake in the study, as outbreaks are commonly noted in both media and state health 
communications. 
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Randomised Controlled Trial: Private Hospital (NSPH) 
Demographics 
From March 2012 to December 2013, we screened 97.97% (1979/2020) of the postpartum 
women approached on the postnatal ward (Figure 1). There were (41) who were not screened 
for vaccine status: 6 were ineligible (language barrier or health status) and the remainder 
declined participation due to: tiredness/busyness (23) or ‘no/other’ (12). There were 889 
(44.9%) up to date with their pertussis booster vaccine and therefore ineligible for the trial. 
Of the remaining 1090 women enrolled in the RCT, 52 were excluded due to 
misclassification (recent pertussis vaccination confirmed with their GP). A further 15 were 
excluded due to lost data (technical error). Of the remaining 1023 participants, 24 were lost to 
follow up and excluded from the intervention analysis. This sample differed to the general 
Australian population: fewer indigenous status (0.2% vs. 3.3% state-wide(136)), slightly 
lower proportion of mothers born in Australia ( 60.2% vs. 67.3% Australia-wide) slightly 
higher employment rate during pregnancy (72% vs. 68% Australia-wide(137)) and 
anecdotally have a higher socio-economic status as able to afford private health care. 
Differences are reflective of the population in this catchment area, which accommodates 
11.2% of births state-wide (136). Demographics did not differ according to intervention or 
control (Table 1).  
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Figure 1: The Maternal Pertussis Randomised Controlled Trial flowchart  
*P value=0.89 in univariate analysis of the impact of the framing intervention on postpartum pertussis 
booster vaccine uptake 
 
Enrolled in The Maternal Pertussis 
Intervention Study (N=1090) 
Baseline questionnaire (n=1038) 
Mothers randomised to intervention 
by week (n=1023) 
Vaccine uptake on 
postnatal ward* 
 85.6% (n=261) 
Vaccine uptake on 
postnatal ward* 
85.3% (n=295) 
Vaccine uptake on 
postnatal ward* 
86.5% (n=301) 
GAIN 34.8% 
(n=360) 
LOSS 34.6% 
(n=354) 
CONTROL 
30.5% (n=309) 
Declined participation (n=41) 
 Tired/busy (n=23); 
 ‘No’/other (n=12) 
 Did not meet inclusion criteria (n=6) 
 
Mothers approached on the 
postnatal ward (n=2020) 
Screened: dTpa <5years 
N=1979 (98%) 
Not eligible as ‘up to date’ 
(dTpa <5years) (n=889, 44.9%) 
 33 during pregnancy 
 
Misclassification (n=52) 
 Up to date (excluded) (n=52) 
 
Excluded: missing data (n=15) 
 missing questionnaires due to 
technical error (n=39) 
GAIN 34.8% 
(n=348) 
LOSS 34.6% 
(n=346) 
CONTROL 
30.5% (n=305) 
Lost to follow 
up n=24 
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Table 1: Demographic characteristics of women by allocation of message-framing 
intervention or control. 
Variable^ Gain 
N=360~ 
Loss 
N=354~ 
Control 
N=309~ 
Maternal age (years)    
   <25  1 (0.3) 7 (2.0) 3 (1.0) 
   25-34  208 (57.8) 207 (58.5) 151 (48.9) 
   35-44 150 (41.7) 139 (39.3) 154 (49.8) 
   45 or over 1 (0.3) 1 (0.3) 1 (0.3) 
Parity    
   Primiparous 240 (66.7) 101 (28.5) 193 (62.5) 
   Multiparous 120 (33.3) 253 (71.5) 116 (37.5) 
Living with a partner*    
   Yes 359 (99.7) 353 (99.7) 306 (99.0) 
   No 1 (0.3) 1 (0.3) 3 (1.0) 
Country of birth    
   Australia 220 (61.1) 194 (54.8) 187 (60.5) 
   Other 140 (38.9) 160 (45.2) 122 (39.5) 
Indigenous status    
   Yes - 1 (0.3) 1 (0.3) 
   No 360 (100) 353 (99.7) 308 (99.7) 
Language*     
   English 316 (87.8) 307 (86.7) 279 (90.3) 
   Other 44 (12.2) 47 (13.3) 30 (9.7) 
Employment status*    
Working (FT or PT) 255 (70.8) 251 (70.9) 214 (69.3) 
Unemployed /homemaker/ 
studying 
105 (29.2) 103 (29.1) 95 (30.7) 
Education level*    
 High school or less 19 (5.3) 31 (8.8) 18 (5.8) 
 Certificate/Diploma/partial degree  66 (18.3) 78 (22.0) 52 (16.8) 
 Degree or higher 275 (76.4) 245 (69.2) 239 (77.3) 
*Values may not equal 100 due to missing data ^There were no significant differences between groups (univariate) 
~ Analysis by allocation to frame 
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Primary Outcome 
Vaccine uptake (dTpa) was 85.8% (857/999) among eligible participants, with ‘gain’ framing 
promoting a non-significant increase in vaccination prior to discharge than loss-framing or 
the control (86.5% vs. 85.3% vs. 85.6%, p=0.89). Significant predictors of pertussis vaccine 
uptake were a baseline belief that the benefits of having this vaccine outweigh the risks (OR 
1.58, 95% CI: 1.16-2.16, p=0.003) and that it is a mother’s (my) responsibility to get 
vaccinated to protect the (my) baby’s health (OR 1.59, 95% CI: 1.19-2.13, p=0.002). Access 
to information on pertussis vaccination was important, however did not significantly predict 
uptake on the postnatal ward. Rather indicating a ‘health professional’ as an influential 
information source to vaccine decision making predicted uptake (OR 2.16, 95% CI: 1.03-
4.57, p=0.043). In addition, having a family member who had been recommended the 
pertussis booster vaccine also predicted uptake among women on the postnatal ward (OR 
2.41; 95% CI: 1.47-3.97; p=0.001). Indicating the intention not to be vaccinated regardless of 
whether the vaccine was funded significantly reduced the likelihood of pertussis booster 
vaccine uptake on the postnatal ward (OR 0.412; 95% CI: 0.30-0.57; p<0.001(Table 5). 
Pertussis information sources and vaccine recommendation 
Awareness of pertussis was reported by 98% of women. However, those who accepted 
vaccination were less likely to report a lack of awareness of ‘whooping cough’ than those 
who declined the vaccine (OR 0.3; 95% CI: 0.12-0.76; p=0.016) (Table 2). The number of 
vaccine information sources participants reported to have received did not impact upon 
vaccine uptake on the postnatal ward. Rather, the type of information source was significant 
to vaccine decision-making. Women accepting postpartum vaccination frequently reported 
hearing of whooping cough from a health professional (75.9%; OR 2.11 <0.001), friends or 
family (52.3%, OR 1.78, p=0.002), the Internet (22.7%; OR 1.79, p=0.02), and ‘other’ 
sources (6.3%, OR 4.72; p=0.016).  However, they less frequently reported hearing of 
whooping cough from an ‘alternative’ health practitioner compared to women who declined 
postpartum vaccination (2.1% vs. 5.6%; OR 0.36, p=0.023). In terms of sources most 
influential to vaccine decision-making, a ‘health professional’ (OR 3.66, p<0.001) followed 
by ‘immunisation brochure’ (34.4% vs. 23.9%, OR 1.66, p=0.016) increased the likelihood of 
vaccine acceptance on the postnatal ward.  Vaccinated women less frequently reported 
‘alternative health practitioner’ (3.0% vs. 10.6%; p<0.001) and ‘groups opposed to 
immunisation’ (7% vs. 2%; p=0.002) as influential compare to those who declined 
vaccination. Not only were those who accepted the vaccine more likely to have been 
recommended the pertussis booster vaccination (73.9% vs. 39.4%; OR 4.36, 95% CI: 3.01-
6.31; p<0.001), they more frequently listed ‘doctor’ as the source of this recommendation. 
Additionally, over half of those who accepted postnatal vaccination reported that a family 
member had received a pertussis booster vaccine recommendation compared to one-fifth of 
declining participants (52.1% vs. 22.5%; p<0.001). 
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Table 2: Pertussis and whooping cough information sources reported by women in Maternal 
Pertussis Study, stratified by decision to accept or decline pertussis vaccination on the 
postnatal ward. 
Variable Total* 
N=999^ 
Vaccinated 
N=857 
Not 
vaccinated 
N=142 
P value OR (95% CI) 
Unaware of ‘whooping 
cough’ 
20 (2.0) 13 (1.5) 7 (4.9) 0.016 0.3 (0.12-0.76) 
Number of information sources 
0 (Have not heard of it)  
20 (2.0) 13 (1.5) 7 (4.9) - - 
1  
230 (23.1) 180 (21.1) 50 (35.2)   
2 
189 (19.0) 162 (18.9) 27 (19.0)   
3  
248 (24.9) 225 (26.3) 23 (16.20   
 4 or more 
314 (31.5) 279 (32.6) 35 (24.14)   
Whooping cough information sources: 
Health professional 
(doctor or nurse) 
734 (73.6) 649 (75.9) 85 (59.9) 0.001 2.11 (1.46-3.06) 
Immunisation brochures 
or pamphlets 
531 (53.3) 466 (54.5) 65 (45.8) 0.057 - 
Media 
644 (64.6) 558 (65.3) 86 (60.6) 0.3  
Information from 
vaccine-opposed groups 
65 (6.5) 52 (6.1) 13 (9.2) 0.196  
Friend or Family 
501 (50.3) 447 (52.3) 54 (38.0) 0.002 1.78 (1.24-2.57) 
Alternative health 
practitioner 
26 (2.6) 18 (2.1) 8 (5.6) 0.023 0.36 (0.15-0.84) 
Internet 
214 (21.5) 194 (22.7) 20 (14.1) 0.02 1.79 (1.09-2.95) 
Other  
56 (5.6) 54 (6.3) 2 (1.4) 0.016 4.72 (1.14-19.6) 
Most influential source(s) (multi-response)~ 
Health professional 928 (93.1) 810 (94.7) 118 (83.1) <0.001 3.66 (2.15-6.23) 
Immunisation brochures 
or pamphlets 
327 (32.8) 293 (34.3) 34 (23.9) 0.016 1.66 (1.1-2.5) 
Family or friends 239 (24.0) 212 (24.8) 27 (19.0) 0.17 - 
Media 164 (16.4) 133 (15.6) 31 (21.8) 0.067 - 
Internet 116 (11.6) 93 (10.9) 23 (16.2) 0.09 - 
Alternative health 
practitioner 
41 (4.1) 26 (3.0) 15 (10.6) <0.001 0.27 (0.14-0.52) 
Other 38 (3.8) 29 (3.4) 9 (6.3) 0.98 - 
Groups opposed to 
immunisation 
27 (2.7) 17 (2.0) 10 (7.0) 0.002 0.27 (0.1-0.6) 
I would be willing to get the vaccine if it were (multiple responses): 
Free; I would not pay for 
it. 
312 (31.3) 283 (33.1) 29 (20.4)   
$50 474 (47.5) 447 (52.3) 27 (19.0) <0.001  
Unsure/ Not willing to 
get this vaccine 
148 (15.8) 67 (8.4) 81 (59.1)   
Frame (vaccinated)     0.89 
Gain 348   301(86.5) 47 (13.5)   
Loss 346 295 (85.3) 51 (14.7)   
Control 305 261 (85.6) 44 (14.4)   
*Values may not equal 100 due to missing data ~3 selected ‘none’, 105 (97%) selected other (not 
significant) 
^24 lost to follow up excluded from analysis (n=1023). 
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Table 3: Attitudes towards Pertussis(severity and susceptibility) by HBM construct reported 
by women in Maternal Pertussis RCT, stratified by decision to accept or decline pertussis 
vaccination on the postnatal ward 
Health Belief Model construct 
Baseline questionnaire item 
Total 
N=999^ 
Vaccinated 
N=857 
Not 
vaccinated 
N=142 
p value 
How likely are you to catch whooping 
cough? 
   0.087 
Very likely 22 (2.2) 19 (2.2) 3 (2.1)  
Moderately likely 199 (20.0) 181 (21.2) 18 (12.7)  
Neither likely nor unlikely 313 (31.4) 264 (30.9) 49 (34.5)  
Moderately unlikely 276 (27.7) 239 (28.0) 37 (26.1)  
Very unlikely 187 (18.8) 152 (17.8) 35 (24.6)  
How likely will your baby be to catch 
whooping cough? 
   0.031 
Very likely 63 (6.3) 57 (6.7) 6 (4.2)  
Moderately likely 277 (27.8) 247 (28.9) 30 (21.1)  
Neither likely nor unlikely 311 (31.2) 260 (30.4) 51 (35.9)  
Moderately unlikely 237 (23.8) 206 (24.1) 31 (21.8)  
Very unlikely 109 (10.9) 85 (9.9) 24 (16.9)  
How severe or mild are the consequences of 
whooping cough for an adult? 
   0.228 
Very severe 74 (7.4) 69 (8.1) 5 (3.5)  
Moderately severe 411 (41.2) 351 (41.1) 60 (42.3)  
Neither severe nor mild 193 (19.4) 159 (18.6) 34 (23.9)  
Moderately mild 282 (28.3) 243 (28.4) 39 (27.5)  
Very mild 37 (3.7) 33 (3.9) 4 (2.8)  
How severe or mild are the consequences of 
whooping cough for a newborn baby? 
   <0.001 
Very severe 821 (82.3) 718 (84.0) 103 (72.5)  
Moderately severe 143 (14.3) 114 (13.3) 29 (20.4)  
Neither severe nor mild 20 (2.0) 17 (2.0) 3 (2.1)  
Moderately mild 10 (1.0) 5 (0.6) 5 (3.5)  
Very mild 3 (0.3) 1 (0.1) 2 (1.4)  
How common or rare is whooping cough in 
your community? 
   0.046 
Very common 42 (4.2) 38 (4.4) 4 (2.8)  
Moderately common 310 (31.1) 278 (32.5) 32 (22.5)  
Neither common nor rare 257 (25.8) 214 (25.0) 43 (30.3)  
Moderately rare 265 (26.6) 227 (26.5) 38 (26.8)  
Very rare 123 (12.3) 98 (11.5) 25 (17.6)  
How easy or difficult is it to catch whooping 
cough? 
   0.015 
Very easy 436 (43.7) 388 (45.4) 48 (33.8)  
Moderately easy 452 (45.3) 384 (44.9) 68 (47.9)  
Neither easy nor difficult 69 (6.9) 52 (6.1) 17 (12.0)  
Moderately difficult 35 (3.5) 27 (3.2) 8 (5.6)  
Very difficult 5 (0.5) 4 (0.5) 1 (0.7)  
^24 lost to follow up excluded from analysis (n=1023). 
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Table 3 cont.: Pertussis booster vaccine barriers by HBM construct reported by women in 
Maternal Pertussis RCT, stratified by decision to accept or decline pertussis vaccination on 
the postnatal ward 
 
Questionnaire Item Total 
N=999^ 
Vaccinated 
N=857 
Not 
vaccinated 
N=142 
p value 
The booster vaccine for whooping cough 
would be effective in preventing whooping 
cough.  
   <0.001 
Strongly agree 579 (58.0) 539 (63.0) 40 (28.2)  
Moderately agree 333 (33.4) 269 (31.4) 64 (45.1)  
Neither agree nor disagree 64 (6.4) 39 (4.6) 25 (17.6)  
Moderately disagree 14 (1.4) 7 (0.8) 7 (4.9)  
Strongly disagree 8 (0.8) 2 (0.2) 6 (4.2)  
Transport to the clinic or GP to get a 
vaccination is a problem for me. 
   0.001 
Strongly agree 16 (1.6) 15 (1.8) 1 (0.7)  
Moderately agree 54 (5.4) 50 (5.8) 4 (2.8)  
Neither agree nor disagree 119 (11.9) 54 (5.4) 16 (1.6)  
Moderately disagree 169 (16.9) 141 (16.5) 28 (19.7)  
Strongly disagree 640 (64.1) 562 (65.7) 78 (54.9)  
I am concerned about the safety of the 
whooping cough vaccine for adults.  
   <0.001 
Strongly agree 47 (4.7) 35 (4.1) 12 (8.5)  
Moderately agree 110 (11.0) 78 (9.1) 32 (22.5)  
Neither agree nor disagree 252 (25.3) 195 (22.8) 57 (40.1)  
Moderately disagree 199 (19.9) 178 (20.8) 21 (14.8)  
Strongly disagree 390 (39.1) 370 (43.2) 20 (14.1)  
^24 lost to follow up excluded from analysis (n=1023). 
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Table 3 cont.: Pertussis booster vaccine benefits by HBM construct reported by women in 
Maternal Pertussis RCT, stratified by decision to accept or decline pertussis vaccination on 
the postnatal ward 
Questionnaire Item Total 
N=999^ 
Vaccinated 
N=857 
Not 
vaccinated 
N=142 
p value 
By getting a whooping cough booster vaccine, I 
will help prevent my child from getting 
whooping cough. 
   <0.001 
Strongly agree 687 (68.8) 638 (74.5) 49 (34.5)  
Moderately agree 238 (23.8) 181 (21.1) 57 (40.1)  
Neither agree nor disagree 48 (4.8) 20 (2.3) 28 (19.7)  
Moderately disagree 14 (1.4) 11 (1.3) 3 (2.1)  
Strongly disagree 11 (1.1) 6 (0.7) 5 (3.5)  
The benefits of getting a booster vaccine for 
whooping cough outweigh the risks. 
   <0.001 
Strongly agree 740 (74.1) 695 (81.2) 45 (31.7)  
Moderately agree 165 (16.5) 121 (14.1) 44 (31.0)  
Neither agree nor disagree 77 (7.7) 36 (4.2) 41 (28.9)  
Moderately disagree 8 (0.8) 1 (0.1) 7 (4.9)  
Strongly disagree 8 (0.8) 3 (0.4) 5 (3.5)  
Getting a booster vaccine for whooping cough 
would strengthen my immunity to it. 
   <0.001 
Strongly agree 443 (44.4) 411 (48.0) 32 (22.5)  
Moderately agree 270 (27.1) 228 (26.6) 42 (29.6)  
Neither agree nor disagree 226 (22.6) 182 (21.3) 44 (31.0)  
Moderately disagree 35 (3.5) 24 (2.8) 11 (7.7)  
Strongly disagree 24 (2.4) 11 (1.3) 13 (9.2)  
It’s not easy for me to find time to get a vaccine.     0.224 
Strongly agree 51 (5.1) 45 (5.3) 6 (4.2)  
Moderately agree 164 (16.4) 136 (15.9) 28 (19.7)  
Neither agree nor disagree 179 (17.9) 148 (17.3) 31 (21.8)  
Moderately disagree 230 (23.0) 195 (22.8) 35 (24.6)  
Strongly disagree 374 (37.5) 332 (38.8) 42 (29.6)  
It’s my responsibility to get vaccinated to 
protect my future child’s health. 
   <0.001 
Strongly agree 747 (74.8) 695 (81.2) 52 (36.6)  
Moderately agree 176 (17.6) 132 (15.4) 44 (31.0)  
Neither agree nor disagree 54 (5.4) 20 (2.3) 34 (23.9)  
Moderately disagree 11 (1.1) 5 (0.6) 6 (4.2)  
Strongly disagree 10 (1.0) 4 (0.5) 6 (4.2)  
I have access to the information I need to make 
a good decision about receiving whooping 
cough vaccine. 
   <0.001 
Strongly agree 524 (52.5) 485 (56.7) 39 (27.5)  
Moderately agree 324 (32.5) 275 (32.1) 49 (34.5)  
Neither agree nor disagree 88 (8.8) 62 (7.2) 26 (18.3)  
Moderately disagree 48 (4.8) 26 (3.0) 22 (15.5)  
Strongly disagree 14 (1.4) 8(0.9) 6 (4.2)  
^24 lost to follow up excluded from analysis (n=1023). 
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Table 4: Pertussis booster vaccine ‘Cues to action’ reported by women in Maternal Pertussis 
RCT, stratified by decision to accept or decline pertussis vaccination on the postnatal ward 
Variable Total 
N=999^ 
Vaccinated 
N=857 
Not vaccinated 
N=142 
p value OR  
(95% CI) 
Recommended 
pertussis vaccine* 
   <0.001 4.36  
(3.01-6.31) 
   Yes 689 (69.0) 633 (73.9) 56 (39.4)   
   No/Unsure 309 (31.0) 223 (26.1) 86 (60.6)   
By a doctor 
(“Obstetrician” n=103) 
(“GP” n=106) 
345 
 
322 
(99) 
(97) 
23 
4 
9 
N/A N/A 
By a nurse-midwife 173 158 15 N/A N/A 
By the health system 83 77 6 N/A N/A 
‘Non-medical’: family, 
friends, workplace,  
94 88 7 N/A N/A 
Not specified 35 27 7 N/A N/A 
Intention to receive 
pertussis vaccine 
   <0.001  
Yes 772 (79.8) 738 (89.0) 34 (24.6)   
No  44 (4.6) 9 (1.1) 35 (25.4)   
Unsure 151 (15.6) 82 (9.9) 69 (50.0)   
Family recommended 
pertussis vaccine* 
   <0.001 5.43 
 (3.63-8.13) 
Yes 591 (59.2) 555 (64.8) 36 (25.4)   
No / Unsure# 407 (40.8) 301 (35.2) 106 (74.6)   
Recommended 
antenatal influenza 
vaccine 
481 (48.1) 420 (49.0) 61 (43.0) 0.36 - 
Influenza vaccine 
during pregnancy 
226 (22.9) 212 (25.0) 14 (10.1) <0.001 2.98 
 (1.68-5.28) 
National Immunisation 
Handbook-‘ 
Postpartum vaccination 
as an alternative to 
vaccination during 
third trimester of 
pregnancy’ 
 
 
N=387~  
 
 
331 (85.5) 
 
 
56 (14.5) 
 
 
- 
 
 
- 
*Values may not equal 100 due to missing data #No/unsure combined for analysis (unsure n=30). ~subjects recruited since April 2013 
following guidelines introduction in March 2013. ^24 lost to follow up excluded from analysis (n=1023). 
 
Baseline Intention  
Intention to receive the pertussis vaccine prior to receipt of the interventional brochure was 
significantly higher amongst those who were vaccinated on the postnatal ward than those 
who were not (89.0% vs. 24.6%; p<0.001) (Table 5). Vaccine uptake was 20.5% (9/44) 
amongst participants with no intention to be vaccinated at baseline and 54.3% (82/151) 
among those ‘unsure’ of their vaccination intentions.   
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Table 5: Multivariate analysis of pertussis booster vaccine uptake on the postnatal ward^ 
Predictors* OR (95% CI)~ P value 
Family member was recommended the pertussis booster vaccine 2.41 (1.47-3.97) 0.001 
It’s my responsibility to get vaccinated to protect my baby’s health. 1.59 (1.19-2.13) 0.002 
The benefits of having the pertussis booster vaccine outweigh the risks. 1.58 (1.16-2.16) 0.003 
I would not be willing to get the WC vaccine, regardless of cost. 
0.412 (0.30-0.57) <0.001 
‘Health professional’ reported as influential source of vaccine 
information. 
2.16 (1.03-4.57) 0.043 
I have access to the information I need to make a good decision about 
receiving a pertussis booster vaccine. 
1.26 (1.00-1.58) 0.47 
Significant univariate predictors included in multivariate analysis (entered on step 1): Intervention frame, born 
in Australia, parity, English (primary language), have not heard of ‘whooping cough’, whooping cough 
awareness (from Health professional, Friend/family, Alt. Health practitioner, Internet, other ), number of 
pertussis information sources, Influential information sources (Health professional, Immunisation brochures, 
Alt. Health practitioner, Groups opposing immunisation)Likelihood of transmission to baby, Disease severity 
for adult/newborn, Pertussis common/rare, transmission ease/difficulty, vaccination will help protect the baby, 
Protective immunity from vaccination, Parental responsibility, Information access, vaccine efficacy, transport 
barrier, safety concerns, pertussis booster vaccine recommendation, vaccination intention, family pertussis 
booster vaccine recommendation, antenatal influenza vaccine uptake,: cost-based vaccine intentions (free, 
$50, unsure/not willing)  
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Table 6: Thematic results: Reasons for vaccine decision-making at follow up (NSPH) 
A. Thematic analysis of reasons for vaccine acceptance on the NSP postnatal ward* Vaccinated 
n=857 (%) 
The Newborn  167 (19.3) 
Having a newborn 
Protecting the newborn: protect/health/safety/ prevent/wellbeing/ best for baby/ 
precaution 
Risk to the newborn: risk/concern/sick/ fear of transmission/ baby's very susceptible/ 
exposure/ disease effect is severe, fatal ‘not killing my child’  
7 (4.2) 
105 (62.9) 
 
55 (32.9) 
Health professional recommended 
Specified (multiple response): 
GP 
Obstetrician 
‘doctor’ 
Midwife/nurse 
(Health department) 
Health professional 
58 (6.7) 
 
25 
18 
7 
7 
(2) 
5 
Pertussis Awareness- Common (epidemic); a highly contagious disease with serious 
consequences. 
35 (4.1) 
My protection 
(mentioned maternal protection to minimise transmission to baby) 
25 (2.9) 
(12) 
Information provided within the health system 
      -Antenatal class 
19 
(8) 
Family/friends- source of information and advice.  18 
Severity of pertussis for a newborn 16 
Provaccination  15 
Vocation- aware of importance of immunisation due to profession / workplace 
recommendation 
12 
Accessibility- availability, ease of receipt, convenience. 
(cost-free) 
10 
(4) 
Media Coverage 9 
Disease experience- witnessed pertussis first-hand.  8 
Vaccine benefits outweigh risks- i.e. minimal side-effects.  8 
Common sense- the sensible thing to do 8 
Herd immunity- vaccination in order to protect others 7 
Keeping ‘up to date’ with vaccination 6 
*multiple categories allowed- categories formed via thematic analysis of data  
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B. Thematic analysis of reasons for vaccine decline on the postnatal ward* Not 
Vaccinated 
n= 134^ (%) 
Requires additional information 34 (25.4) 
Inadequate time for decision-making- ‘I need to think about it’ 9 (6.7) 
Delay vaccination- Decision to delay vaccination until recovered. ‘I’ve had enough’, 
‘don’t want to add anything extra’, too much going on, unsure at this time. 
22 (16.4) 
Trusts in their primary healthcare provider- Would like to consult their doctor or 
preference to see general practitioner at a later time; or for concurrent vaccination with 
their partner. 
21 (15.7) 
Vaccine safety concerns-  
side effects (perceived) 
adverse reactions (familial or personal experience) 
allergic (medically advised not to) 
additives 
17 (12.7) 
(15) 
(8) 
(4) 
(2) 
Perceive vaccination as unnecessary 16 (11.9) 
Unaware- wasn’t discussed, never thought of it 5 
Misclassification- found out at follow up they had been recently vaccinated 4 
Not advised 
(due to medical condition) 
4 
(1) 
System error- not administered by midwife, not offered the option of vaccination 3 
Partner’s involvement in decision making- prefers to speak to their partner first 3 
Perceived lack of vaccine efficacy- does not offer full protection 2 
Philosophical questions -why we need to vaccinate against every possible thing. 1 
*multiple categories allowed- categories formed via thematic analysis of data ^94.4% response rate 
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Chapter 4 Discussion 
 
This evaluation of the cocooning strategy will focus on two key time points across the two 
studies:  
1) The uptake of the pertussis booster vaccine prior to the implementation of hospital-
based vaccination, which will be referred to as the baseline rate (retrospective cross-
sectional surveys).  
2) The uptake of the pertussis booster vaccine within the postpartum ward setting 
(prospective controlled trials).  
Both of these will be discussed in the context of the setting, the patient and the provider.  
 
Baseline vaccine status 
There were 2607 participants in the Maternal Pertussis baseline study, which is currently the 
largest known cross-sectional survey of the attitudes of newly delivered mothers on pertussis 
vaccination. Participation rate was 96% (2467/2607). We found that among postpartum 
women on postnatal wards, 33.7% (417) of participants reported receiving a pertussis booster 
vaccine within the last ten years (dTpa<10 years). The majority of participants had been 
vaccinated between 2009 and 2011, when NSW Health funded the pertussis booster vaccine 
was funded for new mothers as part of the cocooning strategy. With the recent shift towards 
vaccination during pregnancy, we also focus on the attitudes, knowledge and timing of 
vaccination of a sub-set of participants who were eligible for antenatal vaccination.   
 
Pertussis vaccine coverage 
Pertussis vaccine coverage of 34% among our participants was double the rate previously 
reported in NSW in 2011(101). However our sample was larger, verified vaccine receipt and 
also measured coverage in both private and public hospitals from 2010-2012. The odds of 
being vaccinated were higher for women who were multiparous, spoke English at home and 
were a private patient. We observed a significant difference between baseline status among 
women in the public and private hospitals (23.1% vs. 47.5%, respective). However, we also 
noted that parity may also influence prior vaccine receipt and thus conducted additional 
analysis to account for this. Figure 4.1 (below) is a schematic representation of reported 
reason for vaccination prior to pregnancy.  
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Figure 4.1:Schematic representation of themes that emerged from previously vaccinated 
participants. 
Statewide ‘cocooning campaign’ 
There were a higher proportion of multiparous women in the private hospital sample, who 
may have had the opportunity to receive the government funded pertussis booster vaccine 
during their previous pregnancy. This formed a central component of the state-wide pertussis 
‘cocooning’ program introduced in March 2009 in NSW (which had been available to new 
mothers for 2 years and 9 months prior to the commencement of this study among the private 
hospital sample). To support this assumption, we noted that 90% of these women had 
received a pertussis booster during the epidemic (2009-2012), when the NSW Ministry of 
Health funded-cocooning strategy was available. However, as caregiver pertussis vaccination 
via general practice had been funded since 2009, we adjusted for parity and found only 
hospital type remained significant. In other words, first-time mothers receiving obstetric care 
at a private hospital were more likely to have received a pertussis booster vaccination prior to 
childbirth. As only 24% of the state population receive private obstetric care(136), 
continuation of funding for pertussis booster vaccination in the public hospital context is 
critical for new mothers who may otherwise have limited physician contact during their 
pregnancies.  
 
Media attention  
The influence of the media may have varied according to site of recruitment due to staggered 
commencement. To control for fluctuating media coverage of the pertussis epidemic and the 
NSW Health funded vaccination for new parents, we compared baseline data during the time 
period when recruitment was concurrent across sites (1st March 2012-31st July 2012). We 
observed that the overall pertussis vaccine coverage was 33.6%, which is similar to the 34% 
reported for the entire baseline sample (2010-2012). Therefore, the potential study weakness 
due to an extraneous delay in study commencement at the private hospital did not alter the 
overall rate of baseline coverage. This is unsurprising; as recruitment at both sites occurred 
when national pertussis immunisation recommendations and state-wide policy were uniform.  
Among participants recruited concurrently, we found a significant difference by hospital site. 
Baseline pertussis booster uptake was 16.6% in the public hospital vs. 45.3% in the private 
hospital. It is likely that the higher vaccine baseline status among private patients was due to 
work
pertussis epidemic
family & friends
health professional
baby
pre-conceptual care
travel
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a higher socioeconomic status. The impact of low socioeconomic status has been previously 
identified to account for a low baseline of vaccine coverage(15). This translates into 
increased access to a doctor, which could mean they have higher awareness of the need for 
vaccination. In addition to access being important for awareness, they are more likely to have 
the means to pay for both the vaccine and its administration compared to the general 
population. Within NSW, the majority of general practitioners charge a fee per visit that is 
over the scheduled publicly funded rate (i.e. Medicare scheduled fee). For women requiring 
vaccination, the fee to have it administered within the general practice may have been an 
additional barrier over and above the cost of the vaccine. Our baseline data highlights a 
disparity in vaccine coverage between those with private obstetric care and those with public 
midwifery-based care. This suggests the need for additional vaccine delivery strategies aside 
from a funded vaccine provided in the general practitioner setting.  
Pertussis vaccine uptake as part of a controlled intervention trial 
This is the first controlled trial of an educational intervention to promote postpartum pertussis 
vaccine uptake. We achieved high vaccine uptake of 70% in our study sample of 
unvaccinated new mothers in the public hospital setting, when vaccine education was 
accompanied by the offer of a free vaccine. Message framing did not significantly increase 
vaccine uptake. Vaccine uptake was significantly increased in women who reported the 
following: perceived vaccine benefits, vaccine recommendation and baseline intentions to be 
vaccinated. Nevertheless, education delivered to a receptive population in a ‘trusted’ 
environment with minimal access barriers increased pertussis vaccine coverage to 76% 
among postpartum women from a baseline of 23%. 
We also conducted a randomised controlled trial with allocation concealment to test the gain-
loss framing intervention among private hospital participants. We achieved an 86% uptake on 
the postnatal ward, with gain-framing promoting a non-significant increase in vaccination 
prior to discharge. In this study we also noted that perceived vaccine benefits predicted 
vaccine uptake in this setting, in particular the belief that it is ‘a parent’s responsibility to be 
vaccinated to protect (their) baby’s health’. Whilst a vaccine recommendation did not 
significantly predict uptake among private patients, indicating that a health professional was 
most influential to making a decision about vaccination was. In addition, women who 
reported that their partner had been recommended the vaccine were also more likely to have 
been vaccinated. This is reflective of the ‘cocooning strategy’ and its promotion for both 
primary caregivers of an infant to be vaccinated against pertussis. Interestingly, participants 
who intended not to be vaccinated were not swayed by whether the vaccine was funded or 
$50, as indicated by being significantly less likely to be vaccinated on the postnatal ward. It 
could be plausible that this represents the minority of women who are conscientious 
objectors, but may also include a few participants unable to be vaccinated due to a medical 
contraindication. 
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Comparison to maternal vaccine delivery in the literature 
The coverage achieved in our study was similar to the 53-86% pertussis vaccine uptake 
among other studies in the hospital setting(15, 17), with variation accounted for largely by 
higher baseline coverage (23% vs. 6%)(15). Use of a vaccine standing order and bilingual 
education also achieved high uptake(15, 17). We observed the importance of multilingual 
information indirectly, as uptake was higher among participants reporting ‘English’ as their 
primary language. One small cross-sectional study in Victoria, Australia reported a 37% 
postpartum pertussis vaccine uptake across both hospital and community settings (from a 
baseline of 7%) (82). In our study, provision of education by a nurse-midwife accompanied 
by administration of a free vaccine on the postnatal ward resulted in uptake of 70% among 
susceptible women. Even higher uptake is anticipated within populations where baseline 
coverage is very low. 
Message Framing 
Message framing, which highlights what one may either gain from vaccination or lose from 
not being vaccinated, has produced mixed results (119, 120, 128). Our trial aimed to evaluate 
the impact of message framing among postpartum women on vaccine uptake, rather than 
vaccine intention (which is the outcome factor for the majority of studies testing message-
framing). Message framing did not impact on overall vaccine uptake in our study. Our 
finding is contrary to theory, which postulates that loss-framed messaging promotes 
vaccination. This is on the premise that participants are more likely to engage in a 
preventative behaviour that may have some risk (e.g. side effects) when presented with the 
disease consequences of not engaging in it(2). A recent meta-analytic review of 38 studies 
found no significant difference between gain or loss-framed messages in promoting 
vaccination(3). The authors also reported that results may have potentially been modified by 
vaccine recipient (i.e. message recipient vs. vaccination of another, e.g. child). However, 
none of the included studies examined vaccination of the message recipient on behalf of 
another (e.g. cocooning). Our study provides high-level evidence that receipt of vaccination 
on behalf of a baby does not modify the framing effect (138). It should also be noted that 
there was a non-significant finding favouring ‘loss message framing’, which may reflect the 
maternal biological response to prevent any adverse events to her newborn. More recently, a 
2014 systematic review focusing on message-framing for HPV vaccination was conducted. It 
reported that among the few well-designed, sufficiently powered studies, gain or loss 
message-framing was not found to be effective in increasing uptake.   
Rationale for conducting Maternal Pertussis RCT in the private hospital 
Previous studies have looked at parental decision-making regarding the vaccination for their 
child. Underpinning all vaccine decision-making is maternal trust in the medical profession, 
primarily the clinician providing the immunisation. Maternal vaccination differs slightly, in 
that the mother is receiving the vaccine on behalf of their baby. It also differs by model of 
obstetric care. Whilst women in the private system have one primary care provider (their 
obstetrician), the remaining 75% receiving public care generally have multiple care 
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providers(136). We conducted the Maternal Pertussis Study among participants receiving 
care from a primary obstetrician, enabling us to explore the construct of ‘trust in the medical 
profession’. Our main objective was to understand how postpartum women in the private 
hospital setting make decisions about vaccination and whether the way the information is 
‘framed’ persuades them. 
The framing intervention did not lead to a significant impact on vaccine uptake in the private 
hospital setting; rather it was the provision of a funded vaccine accompanied by an 
educational brochure provided in the postnatal ward. Overall, uptake was a very high 86% 
despite a high baseline vaccination rate of 45%. Overall, the RCT increased vaccine coverage 
among postpartum women to 88%. This differed from the uptake of 70% achieved in the 
public hospital, which increased overall coverage to 77% among postpartum women on 
discharge from hospital. Even though a higher point percentage increase in coverage was 
observed in the public hospital (54% increase vs. 43%), the private hospital setting achieved 
the highest absolute coverage among postpartum women on discharge (88%). This 
demonstrates that the cocooning strategy can be highly effective on a population level when 
implemented within the hospital setting.  
In terms of message framing, there was a non-significant 3% increase in uptake among 
participants in the public hospital allocated the ‘loss-framed’ brochure compared to the 
control (71.8% vs. 68.8%). Whilst the difference by intervention was much lower among 
participants in the private hospital sample, the gain brochure yielded a 1.2% non-significant 
increase in vaccine uptake when compared to the loss-framed brochure and the control 
(86.5% vs. 85.3% vs. 85.3%). Perhaps it was the mode of information delivery, rather than 
the frame of the message, which also influenced the participant’s response to the information.    
A postulation as to why the framing of the brochure had a non-significant effect could relate 
to maternal preference over vaccine sources. This links into the varying influence each source 
has on vaccine decision-making. At baseline, around half of participants reported hearing of 
pertussis from an immunisation brochure. However, a third of women rated the brochure as 
most influential to vaccine decision-making. In addition, those who declined vaccination on 
the postnatal ward were less likely to rate a brochure as influential (24%) compared to 
vaccine acceptors (34%). This suggests there are other more influential sources of vaccine 
information within the postpartum setting that impacted upon the high uptake achieved. It 
should also be noted that whilst vaccine information is a key component of vaccine decision 
making, transition from intention to behaviour is limited or enabled by the setting in which 
vaccination is provided. This is depicted below in Figure 4.2:  
 
Figure 4.2: Vaccine decision making diagram 
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Vaccine uptake by intentions 
Overall, the framing intervention did not impact pertussis booster vaccine uptake among 
participants on the postnatal ward. However, the ‘gain’ frame (i.e. ‘Whooping cough booster 
vaccination keeps you and your baby protected’) was associated with an increase vaccine 
uptake among women with no firm vaccine intentions. This may be attributed to its direct 
appeal to the maternal instinct to ‘protect’ their offspring and mitigate all risk, whether actual 
or perceived(125). In the general context of vaccination, it has been postulated that the 
framing effect is dependent on the perceived risk and uncertainty associated with 
vaccination(120). Based on this premise, they concluded that public health campaigns should 
target messages at risk perceptions associated with vaccination rather than focusing on the 
function of this health behaviour (i.e. protection against disease). This conflicts with the 
‘fuzzy trace’ theory, which suggests ‘bridging the gaps’ in vaccine knowledge (e.g. how 
vaccination works) is more effective than the function of the health behaviour (e.g. to prevent 
disease)(123). Other research suggests that vaccine concerns need to be addressed, and this is 
most effectively done by a provider-led discussion initiated with a presumptive approach to 
vaccination (139). Overall we found that a high perception of vaccine benefits coupled with a 
vaccine recommendation predicted postpartum vaccine uptake. Provider discussions rather 
than message-framing may have been effective due to the positive relationship between 
vaccine confidence and reliance on medical advice provided by a doctor (140).  
Whilst the aforementioned studies examined parental decision-making around childhood 
vaccination (primary series), our study focused on the influence the healthcare professional 
and a vaccine recommendation has among postpartum women. Whilst a vaccine 
recommendation was a predictor of vaccine uptake among public hospital participants, it was 
the primary influence of the health practitioner in vaccine decision-making that predicted 
uptake among private hospital participants. This difference could be attributed to the fact that 
participants in both settings listed ‘non-medical’ sources as the provider of a vaccine 
recommendation. In addition, private patients are paying for primary care by a medical 
specialist and therefore are more likely to be influenced by them in comparison to public 
hospital patients consulting a range of obstetric providers (i.e. midwife, general practitioner, 
obstetric trainee doctors). Whilst it is difficult to disentangle the recommendation from 
provider discussions, health professionals are influential in vaccine decision-making and 
should put forth a strong recommendation for their patients to be vaccinated against pertussis. 
This may be of particular importance with the shift towards antenatal administration, due to 
the ‘default’ of pregnant women and, to an extent, healthcare providers, in avoiding any 
unnecessary ‘medications’.  
Qualitative analysis to support predictors of uptake  
A key component of this study was the qualitative analysis, which helped us understand what 
factor was most influential to the decision to decline or accept the pertussis vaccine on the 
postnatal ward. Below is a summary of previously identified enablers of vaccination 
acceptance by mothers on behalf of their child. We compare these with findings from our 
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study, by clustering themes that emerged among mothers accepting vaccination on the 
postnatal ward (Table 4.3). 
Table 4.3: Thematic comparison of vaccine enablers and our qualitative results  
Enablers (Benin et al., 2006(112)). Our qualitative analysis 
Trusting the doctor Health professional recommended - Women recommended 
vaccine by their GP, midwife or obstetrician as part of 
preconception care, antenatal education or postnatal care. 
Feeling satisfied by the 
paediatrician’s discussion 
Discussion with the health professional. 
Feeling that vaccinating is the 
cultural norm 
Family/friends- Women listed the advice given by or vaccine 
experience of family and/or friends. Some also wanted to protect 
family and friends (especially children) by getting vaccinated.  
Believing in the social contract Prevent transmission 
Having positive past experiences 
with vaccines 
Vaccine concerns- Women reported vaccine safety, its minimal 
side effects and it being the only choice. 
General health and prevention. Pro vaccination   
Wanting to prevent disease The newborn - To protect the baby and decrease the risk of them 
catching pertussis. 
Pertussis awareness- Pertussis is common, there is an epidemic 
and it is highly contagious with serious consequences. 
 
We also schematised the main themes that emerged among women who declined vaccination 
on the postnatal ward. We know from the literature that vaccine decision-making is not 
purely a linear process (see figure below), and we will explore in this discussion factors 
related to the setting, the patient and provider that impact upon vaccine completion. 
       
Figure 4.4: The four stages of vaccine decline 
1. Probably will be 
vaccinated 
 
2. Likely to be 
vaccinated 
 
3. Unlikely to be 
vaccinated 
4. Probably will not 
be  vaccinated 
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SETTING 
General 
Vaccination is a social practice which is normatively driven among mothers(141), and 
therefore it is important to consider the general setting in which it is provided. Within 
Australia, pertussis remains the most common vaccine preventable disease. In the years just 
prior to this study (2008-2009), pertussis notifications in NSW were 2.7 times higher than the 
preceding five years, peaking at 178 per 100 000 in 2009(48). This was in part attributed to 
an epidemiological shift towards adolescents and adults, who were now susceptible due to 
waning immunity from their childhood series of pertussis immunisation(25). The challenge 
was that symptomology tended to be atypical in presentation, making timely recognition and 
diagnosis difficult. This proved problematic, as infected adults could unknowingly transmit 
pertussis to a vulnerable infant. Awareness of the need for adults and adolescents to have a 
pertussis booster vaccine was likely low, as reflected by a national survey reporting 6.7% 
pertussis vaccine coverage among adults prior to 2008(65). In 2009, the NSW Department of 
Health initiated a pertussis control program that included a large-scale social marketing 
campaign to promote vaccination and health behaviours in order to minimise transmission as 
well as funded vaccination for new parents and grandparents/carers of an infant (<12months). 
In addition, the primary immunisation series for pertussis was brought forward from 8 to 6 
weeks, and the booster dose brought forward from 4 years to 3½ years of age(142).  
 
Influences which shape maternal perception on vaccination 
Whilst the media has been identified as a provider of ‘vicarious experiences’ among 
mothers(141), in our study it had minimal reported influence on vaccine-decision making. 
This was evidenced by only 12.8% of women indicating that the media was an influential 
information source. It is worth noting that media attention is heightened against the backdrop 
of an epidemic, creating greater awareness that may indirectly influence uptake. This has 
been reported for antenatal influenza vaccine uptake(105). Whilst we did not directly 
measure media reports on the pertussis epidemic, we saw no relationship between pertussis 
vaccine uptake and the number of pertussis case notifications in NSW by month. These 
mandatory notifications served as a proxy of the pertussis epidemic. This is not to say the 
media had no influence per se, rather there was no observed influence of media reports on the 
uptake of the pertussis booster vaccine in the hospital setting. This suggests there are other 
factors that directly impact vaccine uptake within the postnatal ward context. 
 
 
 
Best practice for the communication of perinatal pertussis booster recommendations    
122 
 
Health Care system 
The Hospital Setting 
The hospital platform provides a springboard for both pertussis vaccine awareness and 
uptake(15). Our study showed that immunisation information provided by the health system 
was an influential source in vaccine decision-making for one-third of women in both public 
and private hospital settings. A trusted source of vaccine information has previously been 
suggested as being influential to uptake(17) and, when provided in the hospital context, is a 
key factor in pertussis vaccine completion(68). Our thematic analysis supports this, with 
‘health professional recommendation’ influencing uptake among half of vaccinated 
participants in the public hospital. We also noted that whilst 87% of unvaccinated women 
reported that a health professional was most influential to vaccine decision-making, yet only 
57% of them had heard of whooping cough from a health professional. We noticed this trend 
among private hospital participants, where 83% of unvaccinated participants reported a health 
professional as influential to vaccine decision-making, yet only 60% had been informed of 
whooping cough by a health professional. In addition to the task of providing vaccination in 
the postnatal ward setting, clinical guidelines need to mandate vaccine education and 
recommendation of the pertussis booster vaccine by obstetric providers.  
We identified ‘time constraints’ as an additional barrier, with unvaccinated mothers more 
likely to agree that ‘it is not easy for me to find time to get a vaccination’ than vaccinated 
mothers. Additionally, perceived and actual costs as well as the logistics of accessing a 
General Practitioner have been previously reported as the reason for 76% of mothers not 
being vaccinated (82). These barriers can be minimised by offering free vaccination at the 
bedside during the postpartum hospital stay. Furthermore, postpartum immunisation 
occurring shortly after delivery is important to minimise the window of pertussis 
susceptibility for neonates(67, 143). With the recent introduction of antenatal pertussis 
vaccination guidelines (2013)(4), provision of vaccination in the antenatal clinic may reduce 
barriers to access for women in the public setting.  Incorporation of immunisation 
infrastructure into consulting rooms will enable obstetricians to provide vaccination to their 
patients. This is vital, as women may not access their General Practitioner routinely during 
pregnancy. 
We observed that 80% of women in the private hospital intended to receive the pertussis 
booster vaccine compared with only 68.7% in the public hospital. Out of all women with a 
baseline intention to be vaccinated, uptake in the private hospital was 95% versus 78.9% in 
the public hospital. One hypothesis is that women in the private hospital received care from a 
private obstetrician, and thus ‘trusted’ the hospital setting in which their provider oversaw 
their care. This differed to the predominately midwifery-led care in the public setting; where 
women who declined vaccination in the hospital cited the main reason was ‘trust in their 
primary health care provider’ (e.g. the general practitioner). This may be an important 
difference when considering which setting antenatal pertussis booster implementation will 
yield the highest uptake. It should also be noted that within the private hospital, the average 
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length of stay for participants was twice that of the public hospital, which may have provided 
additional time for vaccination.      
Barriers to vaccine delivery in the hospital setting  
 System errors, primarily vaccination not performed by a midwife, accounted for 11% of 
women remaining unvaccinated on discharge from the public hospital. In the private hospital, 
system errors accounted for 3%, which may be due to an increased length of stay providing 
more opportunity to vaccination. The perception a midwife has of her/his ability to provide 
vaccination is central to postpartum administration, which highlights the importance of staff 
training (78). This is key, as nurse-midwives are ‘pivotal’ to high postpartum uptake(15). A 
standing order and ward stock can further allay hospital vaccination barriers, with subsequent 
high uptake demonstrated(15). Standing orders coupled with education can also enhance this 
process, as occurred with postpartum rubella vaccine uptake in one study(80, 81). This shows 
how elements of successful adult vaccination programs can be effective in the postpartum 
hospital setting.  These elements include funded vaccines(15), staff training(15), extended 
vaccination hours(15)  (15, 16), standing orders or prescription(15, 69, 82) and accessible 
stock(15).  
 
The context of vaccine provision  
Whilst vaccine intentions reflect the process of vaccine decision-making, it can either be 
enabled or hindered by the context in which vaccination is provided. Barriers that can hinder 
the transition from vaccine intention to completion include access, timing and type of 
immunisation provider (e.g. doctor vs. nurse/midwife). Our data showed that despite 68.7-
80% of women intending to be vaccinated (68.7% vs. 80%), a larger percentage of public 
patients declined vaccination within the hospital platform (19.7% vs. 4.4%). The key reason 
for decline among public patients was preference of vaccine delivery within the general 
practice setting. This difference could be attributed to trust in their primary healthcare 
provider, with public patients having multiple care providers in the hospital setting versus a 
private obstetrician. However, when comparing participants from the public and private 
hospitals, 16% of participants in both settings delayed vaccination due to the preference to 
see their general practitioner. A qualitative response was ‘We would like to have it (the 
pertussis booster vaccine) at the GP-more reliability as we are attached to the GP more than 
to the hospital staff’ (25-29 y.o. primiparous woman). This is an example of trust in an 
individual practitioner taking preference over trust in the hospital-based obstetric providers 
(e.g. midwife, obstetric residents). 
In the private setting, 15.5% of participants declined the pertussis booster vaccine on the 
postnatal ward. The main reason for declining the vaccine was requiring additional 
information. An immunisation brochure had been given to all participants on the postnatal 
ward once the baseline survey was completed. However, with the demands of a new baby, the 
timing as well as the type of information may have had an effect. Provision of the 
information during the antenatal period may have raised awareness, and prompted discussion 
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with their obstetrician. In addition, it would have given ample time for mothers to have their 
questions answered.  
As outlined, the context of vaccine provision can also be a vaccine promoter for some 
women. Funded vaccination that covers the cost of the vaccine and the administration was 
influential to vaccine-completion. A subject who accepted vaccination on the postnatal ward 
listed the following factors: “getting it over and done with, better than not putting it off. Plus 
free. I would expect to pay $50” (35-39 y.o. mother of two). Within the hospital setting, 
mothers receive care 24 hours a day and thus are not restricted by access issues (i.e. 
scheduling an appointment, cost) within the general practice setting. In addition, transport 
barriers are removed as vaccine delivery is provided at the hospital bedside. Accessibility (i.e. 
ease/convenience) was reported as most influential to vaccine uptake among 10% of women 
vaccinated in the private hospital setting and 6% of women in the public hospital setting.  
There are still barriers within the postnatal ward context that need to be overcome. System 
errors, primarily where a midwife did not perform vaccination, were more commonly 
detected in the public hospital setting (n=38, 11.7% of unvaccinated participants at discharge) 
than the private hospital setting (n=3, 2.2%). Our previous research showed that whilst 
midwives perceived pertussis booster vaccination as important, those in the private hospital 
also perceived the timing of providing vaccination prior to discharge as important compared 
to midwives in the public hospital(78). 
We aimed to determine whether these vaccine administration omissions were related to the 
perception around pertussis booster vaccine timing or whether there were other barriers 
within the system to administering a vaccine. Firstly, we noted that 12.3% of women in the 
public hospital and 16.4% of women in the private hospital delayed vaccination due to 
childbirth factors. However, timing was not the only factor that accounted for vaccine decline 
on the postnatal ward. From review of postpartum rubella immunisation data, we could see 
30% of vaccines ‘to be given’ could be attributed to factors in the postnatal ward setting. This 
suggests that there could be some underlying system factors that act as a barrier to routine 
provision of postpartum vaccines within the postnatal ward setting. 
A key system barrier in the postnatal ward setting is the requirement for a medical officer to 
prescribe routine vaccines for each patient. This has previously been addressed by the 
inclusion of a standing order which reportedly increased postpartum pertussis vaccine uptake 
to over 80%(15). Within our study, there are currently no postpartum maternal vaccine 
standing orders in either hospital, even for routinely administered rubella booster vaccination. 
Interestingly, there is a standing order for routine neonatal hepatitis B immunisation in the 
public hospital. When we looked at vaccination rates for the offspring of participants in our 
study, neonatal hepatitis B vaccine uptake was 88.5% (with 6.4% ‘counselled but declined’; 
5.1% missing data). The routine delivery platform for administration of this vaccine is the 
delivery suite, not the postnatal ward. Therefore, system differences in vaccine uptake could 
be due to a higher staff- patient ratio (1:1-2 patients versus 1:5-7 patients), antenatal 
completion of education/parental consent for neonatal vaccination (occurs during a third 
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trimester appointment) and timing of vaccination (immediately following birth vs. on 
discharge). There may also be a difference in perception of maternal versus neonatal 
vaccination. To minimise system errors, which accounted for 6-11% of participants not being 
administered a pertussis booster vaccine, postpartum vaccination could be trialled in the 
delivery suite. 
Predictors of vaccine status 
In our study, perceived benefits of vaccination across all participants and pertussis vaccine 
recommendation (among public patients) independently predicted vaccine uptake. Other 
studies have identified that these predictors are correlated with intentions to be vaccinated, 
not actual vaccination behaviour (17, 96). Whilst baseline vaccine intention significantly 
predicted uptake on the postnatal ward, it did not always lead to vaccine completion within 
this setting (4.4% private vs. 19.7% public). Among participants in the public hospital who 
reported vaccine intentions at baseline, 13.5% declined vaccination on the postnatal ward due 
to ‘childbirth factors’ and ‘trust in their primary healthcare provider’. A theoretical 
explanation is that beliefs about performing a certain behaviour (i.e. vaccination) may differ 
with changes in both context (e.g. general practice) and time (preference for after the 
immediate postpartum period) (122). As the cocooning strategy is optimised by immediate 
postpartum vaccination, the importance of early vaccination needs to be communicated 
alongside a provider’s recommendation and vaccine benefits. 
The formation of attitudes is influenced by a complex interaction between education, societal, 
personal and other factors, which can make the categorisation of parental vaccine attitudes 
difficult (144). To address this, we used the Health Belief Model framework to evaluate 
maternal attitudes at baseline, towards both pertussis and the pertussis booster vaccine. 
Measures of vaccination benefits included efficacy, the advantages outweighing risks, 
protection for both the mother and baby, and vaccination as a parental responsibility. Our 
findings concur with a recent meta-analysis, which concluded that the strongest predictors of 
health behaviour are perceived benefits and barriers(115). Previously, vaccination benefits 
and a recommendation had only been linked to a pregnant women’s intention to be vaccinated 
with the pertussis booster following childbirth (17, 101). Whilst the majority of women acted 
on their intentions when provided vaccination in a setting of minimal barriers, we also noted 
that vaccine intentions do not always translate to vaccine completion. 
In our study, 44.9% of postpartum mothers who reported that they intended to act and receive 
the pertussis vaccine did not within the context of the public postnatal ward. Interestingly, 
within the context of the private hospital postnatal ward less than 5% of women intending to 
receive the pertussis booster vaccine were not vaccinated. According to the intention-
behaviour matrix, an intervention designed to help women act on their intentions rather than 
change their intentions would have a better chance of increasing vaccine uptake among this 
sub-group. However, within a context where the majority of access barriers had been 
removed, it is likely that a lack of vaccine completion could be due to system errors or a 
preference for another postpartum setting.  
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We observed that 79% of public hospital participants and 95% of private hospital participants 
intending to receive the pertussis booster vaccine were vaccinated on the postnatal ward. 
Following the intention-behaviour matrix(122), the reduction in environmental barriers may 
have had a greater impact on vaccine completion than the educational intervention aimed at 
attitudinal change. It is likely that contextual factors may have had a larger impact, which 
could account for message-framing intervention yielding a non-significant result.   
Our findings also demonstrate that even in the absence of an intention to be vaccinated, 
vaccine benefits independently predict vaccine uptake among new mothers. This was 
supported by our thematic analysis, where ‘baby’s protection’ afforded by the cocooning 
strategy was influential in postpartum uptake among almost half of public hospital 
participants who were ‘unsure’ at baseline whether they would receive the pertussis booster 
vaccine. Additionally, 19-20% of women not intending to be vaccinated at baseline accepted 
the vaccine on both the public and private postnatal wards. Again ‘baby’s protection’, 
brochures and health professional recommendations were influential in decision-making for a 
majority of this sub-group. This supports education on the benefits of vaccination, which 
could account for message framing and the generic NSW Health information brochure having 
an equal effect on uptake when provided within the postnatal ward context. 
PATIENT 
Attitude towards pertussis 
Pertussis awareness 
Communication is a key component of encouraging vaccine uptake among new mothers, and 
needs to be adjusted to a non-medical audience. We found that that on a whole, mothers were 
highly aware of the disease. However, there was a significant difference in awareness of its 
medical name ‘pertussis’ between those who had received the pertussis booster vaccine and 
those who had not. When discussing vaccination with patients, using the colloquial name 
‘whooping cough vaccine’ rather than ‘pertussis booster vaccine’ in health information may 
be important. Among mothers unaware of the disease, nearly all were unvaccinated 
(101/103). Providers play a key role in ensuring all women are aware of prevalent diseases 
that impact a pregnant woman and their offspring, and the benefits afforded by vaccination. 
Attitude towards vaccination 
The key attitude that predicted vaccine uptake by both public and private patients was the 
perception of vaccine benefits. These findings concur with a recent meta-analysis, which 
concluded that the strongest predictors of health behaviour are perceived benefits and 
barriers(115). It could be postulated that barriers to vaccination (i.e. cost, access, time, a lack 
of information) were not a significant predictor to uptake as many were mitigated in the 
postnatal ward setting.  Previously, vaccination benefits and a recommendation had only been 
linked to a pregnant women’s intention to be vaccinated with the pertussis booster following 
childbirth(17, 101).  However, our findings demonstrate that even in the absence of an 
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intention to be vaccinated, vaccine benefits independently predict vaccine uptake among new 
mothers.  
Our thematic analysis highlights the importance of educating women of the benefits of 
vaccination for both themselves and their baby. We found that ‘baby’s protection’ afforded 
by the cocooning strategy was influential in postpartum uptake among almost 51% of public 
hospital patients and 20% of private hospital patients. For an additional 16% of women 
vaccinated in the private hospital, the severity of pertussis for a newborn prompted their 
decision to be vaccinated. Vaccine benefits were specifically cited as the reason for vaccine 
uptake by 8% of private patients and 6% of public patients.  For 20% of private patients and 
5% of public patients, it was the information provided within the hospital setting that 
influenced their decision to be vaccinated. This is in addition to the 12% of public patients 
and 7% of private patients influenced by a health professional’s recommendation. Our 
qualitative analysis supports education on the benefits of vaccination, particularly its 
likelihood of preventing disease, delivered within the health system. 
Vaccination behaviour as predicted by the Health belief Model 
Overall perceived susceptibility and severity of pertussis by new mothers was not significant 
to uptake, as previously reported (17), rather ‘vaccine side-effect concerns’ emerged 
thematically as a major reason for vaccine decline. Vaccine safety concerns were the reason 
12.7% of women declined the pertussis booster vaccine on the ward of the private hospital. 
Whilst a potential side effect was the main reason, half of the women who declined reported 
that they had previously experienced an adverse vaccine reaction (resulting in 4 subjects 
indicating they were medically advised not to be vaccinated). Two women were concerned 
about the additives in this vaccine, two stated a lack of vaccine efficacy and another was 
‘philosophically’ against vaccination. Among public hospital participants, 6% declined 
vaccination due to vaccine concerns. This has been previously identified in quantitative 
research as a key barrier to vaccine uptake by postpartum women (17, 69, 82). Whist it is 
encouraging that the majority of participants had confidence in the safety of the pertussis 
booster vaccine; this may be impacted by perinatal factors. Our study found that 12.3-16.4% 
declined vaccination due to factors related to childbirth, which is likely to be higher during 
pregnancy. To alter perception of vaccine side effects, education should address this 
knowledge gap by focusing on how vaccines work and the benefits afforded by both mother 
and offspring.   
Risk perception  
Vaccination is a preventative health behaviour that may be perceived as ‘risky’, due to 
potential side effects and localised pain, compared to other health preventative behaviours 
(e.g. sunscreen use). The Health Belief Model (HBM) argues that people are less likely to 
adopt a preventative behaviour if they perceive there are strong barriers (i.e. side 
effects)(115). We found that unvaccinated women reported vaccine safety concerns more 
often. This has been previously identified as a factor that influences postpartum vaccine 
intentions(101) and uptake(17, 82). Vaccinated women, however, more often reported little 
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or no concern over vaccine safety, tending to focus on the severity of disease consequences. 
This is predicted by the HBM, which correlates the perceived severity of a negative disease 
outcome with an individual’s motivation to avoid that outcome(115).  This is further 
reinforced by the decreased susceptibility to pertussis reported by vaccinated women, as 
(theoretically) their beliefs have aligned with their behaviour following its adoption(115). 
With the shift towards antenatal pertussis vaccination, further research is needed to explore 
whether maternal attitudes differ according to the timing of vaccination. This may be 
particularly relevant to vaccine safety concerns, with the general propensity to avoid any 
‘medications’ during pregnancy.  
Vaccine intentions 
High vaccine intention yet low vaccine uptake among new parents due to barriers has been 
reported previously(79). Our study quantified these in terms of safety, access to provider, 
access to information and cost. We showed that an increase in reported vaccination barriers 
significantly decreased the odds of having been vaccinated, particularly for vaccine safety. 
Educating maternity staff to address vaccine concerns may help women overcome this 
barrier, which has been postulated to be pivotal to the success of postpartum vaccination(68). 
This is a key strategy, with the influence of a healthcare provider predicting uptake within the 
private postnatal ward setting. 
Mediation analysis 
Intention to be vaccinated at baseline was a significant factor to postpartum vaccine uptake in 
the public hospital. Intent has been suggested as the precursor to behaviour, which mediates 
the effect of antecedent factors on influencing certain behaviour (i.e. vaccine uptake) (133). 
We found that intent mediated the relationship of perceived vaccine benefits with vaccine 
acceptance. This suggests that perceived vaccine benefits increased a participant’s intention 
to be vaccinated, leading to a greater probability of vaccine completion. In addition, the 
relationship between pertussis vaccine recommendation and vaccine acceptance was also 
mediated by intent, which also increased the likelihood of vaccine completion. To a lesser 
degree, these predictors still significantly impacted vaccine uptake amongst participants who 
either had no intention to be vaccinated or were unsure.  
Our mediation analysis among public hospital participants showed that regardless of vaccine 
intentions, pertussis benefits independently predicted vaccine uptake. This is a key finding, 
and supports prior research that suggests that vaccine perception rather than disease 
perception may be more effective in encouraging vaccine uptake(123). That being said, one 
may perceive the risk of contracting a disease as high but it may not automatically translate 
into a preference for vaccination. To shift an individual’s preference towards vaccination, you 
first need to change their perception so that the ‘cost/risk’ of being vaccinated is nil. This is 
of particular importance among postpartum mother, whose prerogative is to protect her 
newborn. Thus, highlighting the benefits of vaccination for both herself but more importantly 
her baby is essential in achieving high uptake. This may be an important factor in promoting 
vaccination during pregnancy. 
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Language 
Among public participants, those who spoke English at home were more likely to accept 
vaccination on the postnatal ward compared to 31.2% of women who primarily spoke another 
language in the home. This could reflect the diversity of regions women were from, which 
was significant in the univariate analysis but not in the multivariate logistic regression. The 
majority of women were born overseas (62.2%): South-East/East Asia (29.1%), the UK and 
Europe (13.7%) and Central/South/West Asia (10.9%). This is reflected in the main 
languages other than English reported to be spoken in the household: Chinese (10.5%), 
Korean (3.6%) and Indian (3.2%). This propensity towards Asian languages could reflect 
Australia’s geographical location within the Asia-pacific region.  
Whilst study participants enrolled could speak English, the level of understanding of 
information may have contributed to language spoken at home predicting vaccine acceptance. 
Provision of pertussis booster vaccine education in a woman’s native language may improve 
understanding of vaccine information. This has been reported to be effective in increasing 
uptake on the postnatal ward of a study where Latin Americans were the predominant 
minority(68). In addition to multilingual vaccine brochures, health professionals can access 
interpreters (either phone or appointment) to aid understanding and facilitate discussions 
about vaccination. Hospital-based postnatal care is an opportunistic immunisation platform 
for migrant women who otherwise may have difficulty accessing or may not routinely access 
community health-based services 
Within the context of parturition 
The timing of being offered the vaccine within days following childbirth was another reason 
why 16.4% of women in the private hospital declined vaccination. Participants expressed a 
sense of having gone through an intense experience and that anything extra was too much. 
Others commented on how there was too much going on at this time and that they would 
delay vaccination until they had recovered. A portion of women delayed vaccination as they 
wanted to receive the vaccine with their partner or consult their general practitioner at a later 
time. For others, the immediate postpartum hospital period (4-6 day average LOS) was an 
inadequate length of time for them to make a decision. This theme was indicated by 
comments such as ‘I need time to think about it’. Additional themes included numerous 
demands for time on the postnatal ward, adjusting to parenthood and physically recovering 
from childbirth. These are barriers to vaccine decision making within the immediate 
postpartum period, which may have been mitigated by vaccine education, guidance and 
consent during antenatal appointments. 
The impact of maternal attachment on vaccine decision-making 
We undertook a qualitative analysis of the factors that were most influential in vaccine 
decision-making among new mothers. The main theme, which emerged among vaccine-
acceptors, was that new mothers accepted vaccination on the postnatal ward ‘for their 
newborn’. This is reflective of nurturing and protective behaviours, which are biologically 
driven within humans as a way to preserve the species(145). Such behaviours are clustered 
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under the construct known as ‘maternal attachment’. It may be plausible that this maternal 
instinct may have overridden the effect of message framing, yet was the driver of high 
vaccine uptake in this setting. A desire to protect the unborn baby and meet his/her needs, 
even at the expense of the mother’s own needs, is a key indicator of maternal-foetal 
attachment(126).  This has emerged in qualitative literature as ‘an innate desire to 
protect’(125). The maternal-foetal bond forms in early pregnancy, with the development of 
feelings such as love and protection providing a strong emotional tie.  
This maternal-foetal bond that has developed during pregnancy is so strong that this 
‘protection’ instinct is activated regardless of the degree of risk(125). Thus, risk is not a 
continuum but rather an absolute. It could be this delineation which needs to be made when 
promoting vaccines in pregnancy: this vaccine will help protect your unborn baby rather than 
have this vaccine to protect you during pregnancy. 
What is unique during the early postpartum period is that the mother undergoes as transition 
from maternal-foetal attachment to the parental caregiving system. This system functions to 
provide protection, comfort and care for the offspring, and prevent any threat (126). The 
parental caregiving system differs from maternal-foetal attachment, which only seeks 
protection when the individual is under attack. We see this transition among postpartum 
women. They have a strong innate desire to protect their baby by providing protection to 
prevent a threat rather than protect when the baby is under threat. This is reflected in 
women’s responses ‘I'd do anything to protect our baby’ (primiparous mother) and ‘to 
eliminate risk overall anyway for baby (primiparous mother). Pertussis is seen as a threat, as 
indicated by the consensus of postpartum participants who perceived pertussis as severe for a 
newborn baby. With the shift towards vaccination during pregnancy, where threat to the 
‘baby’ is not imminent, engaging in a health behaviour that carries an element of risk may not 
be as widely accepted as it is following delivery.  
The desire to prevent the disease in their newborn was the most influential reason for 
acceptance for the majority of women. This is an indicator of the maternal-foetal bond, 
whereby a mother instinctively protects their newborn from any potential risk of harm by 
mitigating risk(126).  This is reflected in responses such as ‘the main factor is knowing (that) 
I won’t infect my baby’ (18-24 y.o primiparous mother). For these women, vaccination 
affords a ‘peace of mind’ that they have actively mitigated a potential threat to their newborn. 
It is this perception of a threat, and viewing risk as an absolute (dichotomously as ‘at risk’ or 
‘not at risk’) that may override the effect of the message framing. 
 Vaccination in the perinatal context has implications when devising health communications 
for new mothers. It is likely that the reason why the health framing intervention did not make 
a significant difference is related to the perception of risk. Studies have shown that the loss 
frame is more effective as the risk of the disease overrides the potential ‘temporal’ risk of the 
health behaviour (vaccination). However, owing to the maternal instinct to mitigate potential 
risk to their baby even at the expense of their own health, the main promoter of vaccine 
uptake was the perception of the benefits of vaccination. This is reflected in comments such 
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as …I have never been vaccinated for anything due to my brother being in induced coma with 
encephalitis due to immunisation when little. After having a baby of my own though I want to 
protect her and would like to have it (the vaccine) (25-29 y.o. mother of two). Whilst 
extreme, this nevertheless demonstrates the strength of the maternal instinct to protect the 
offspring despite a long-standing perception of vaccine side effects, and subsequent rejection. 
What should be noted is that the vaccine was seen as a means of protection for the baby, and 
highlights the role of health professionals in reiterating the benefits of vaccination.    
The Health Belief model is a value-expectant theory which attempts to illustrate types of 
health expectations that influence preventative behaviours and evaluated the extent of the 
desire to avoid illness. Therefore, the likelihood of engaging in a preventative behaviour is a 
function of the degree to which disease susceptibility, the perceived negative personal impact 
of that disease and the degree to which engaging in health behaviours to avert the threat 
outweighs perceived barriers of that behaviour. 
We observed that four out of five mothers had a high perception of pertussis severity for their 
newborn, which is congruent with the general notion that newborns are susceptible to 
infection. However, the difference between mothers of accepted vaccination and those who 
declined it was their perception of vaccination being beneficial to avert this threat. Therefore, 
the benefits of the vaccine outweighed the barriers to engaging in the behaviour of getting 
vaccinated. As offering funded vaccination at the hospital bedside mitigated numerous access 
barriers, the primary barrier left remaining was ‘vaccine concern’.  
We explored ‘vaccine concern’ in more depth in the qualitative analysis of vaccine decision-
making. We found that vaccine decline was related to the timing of immunisation occurring 
in close proximity to childbirth. Others specified a concern that the (potential) transient side 
effects would hinder their ability to care for their newborn. Additional concerns included the 
potential harm caused by the vaccine via the breast milk. Most women expressed a need for 
additional time and information to make a decision, with the resolve that they would seek out 
their general practitioner. ‘Preference not to act when there is any risk’ is a vaccine inhibitor 
previously identified in the literature(112). It could be possible that this is heightened in new 
mothers due to an inherent instinct for risk aversion. This could be reflected in their 
dichotomous view of risk (an absolute). Interestingly, when we looked at maternal vaccine 
uptake during pregnancy versus immediately postpartum, mothers vaccinated during 
pregnancy reported ‘no concern’ over vaccine safety. There is a need for health professionals 
to address all vaccine safety concerns in a manner tailored to the patient so that ‘no gaps’ in 
knowledge are left. This is underpinned by the ‘fuzzy-gist’ theory, whereby ‘dual mental 
representations’ comprised of verbal information, images and events are combined with 
values and applied to vaccine decision-making(123). This is problematic where recollection 
of anti-immunisation is used to fill knowledge gaps, blocking the individual from getting the 
‘gist’ of vaccine messages.   
A health decision is made by a) internalisation of the advocated frame and b) risk perception 
of performing the health behaviour. This is moderated by cognitive and affective processes 
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which affect the judgment of these two factors(117).  We see these moderating processes at 
play when considering maternal vaccination. It appears that mothers tended to internalise 
both the gain and loss message-frame as ‘protecting the newborn by minimising any threat to 
his or her health’. This is reflected in the maternal-foetal bond, which makes mothers 
instinctively risk adverse when it comes to the health of their newborn. This instinct overrides 
the potential risk that performing certain preventative behaviours may have on their health, 
provided it is not perceived to adversely affect their ability to care for their newborn. This 
theme emerged in the qualitative analysis of decision-making among women who declined 
vaccination. Those who expressed vaccine concerns did so in relation to the effect it may 
have on their breast milk and any possible risk that this may pose to their baby. In addition to 
this, reported concern of vaccine side effects was in relation to the mother’s ability to care for 
her baby. Thus, temporal risk of vaccination was an important factor for vaccine decision-
making during the immediate postpartum period, and influenced the decision to delay 
vaccination by some participants.  
 
PROVIDER 
Doctors, social networks and ‘seeing the disease’ have been previously identified as core 
influences of mothers’ perception of vaccination(141). At baseline, 83% of women listed 
their health professional as influential in their vaccine decision-making. A lack of trust in the 
source of information has been identified as a predictor of vaccine decline(17). A qualitative 
study reported that mothers note if informants are medically trained before deciding to 
believe vaccine information(141). In our study, a health professional’s recommendation was 
reported to have influenced 12% of prior vaccine acceptance among women ‘up to date’ at 
baseline. Trust in their primary healthcare provider also influenced vaccine decline in the 
public postpartum ward setting. This supports the previous finding that the family doctor is 
an ‘integral point of reference’ in vaccine decision-making for some mothers(141). Family 
and friends were similarly important in both vaccine acceptance and decline, highlighting the 
sway of social networks. Disease experience was influential for only 3% of vaccinated 
participants; however it was only in qualitative response that participants reported ‘seeing the 
disease’. A lack of disease experience among the general population has previously been 
linked to heightened focus on vaccine side-effects(8). 
Health care providers: role or relationship? 
This brings up a key question of whether this lack of trust in the hospital providers was 
related to how their professional role was perceived, or whether it was purely related to a lack 
of relationship. There has been research around the importance of the continuity of obstetric 
care by one main provider throughout pregnancy and the immediate postpartum period. It 
suggests that trust is linked to the relationship with the provider, rather than the provider’s 
role. However, this has not been assessed for vaccination. Furthermore, there is a gap in 
proficiency between a midwife and a doctor’s role, which may only be bridged by a midwife 
completing additional immunisation provider qualifications. A strategy in France was to 
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integrate immunisation provider credentialing within the role of a midwife, which lead to 
increase vaccine provision among postpartum women(69). As previously discussed, trust in 
the healthcare providers competency is important, as perceived by both the patient and 
provider. Nurse immunisers, who form an integral part of local government vaccine service, 
have been widely accepted by the paediatric population in Australia. With the recent 
promotion of vaccination during pregnancy, provision by midwives who routinely care for 
woman may be enhanced by immunisation credentialing.  
Vaccine decision-making is rarely made in isolation, with ‘social networks’ comprised of 
people and sources of vaccine information influencing this process(146). There is a 
substantial body of evidence around parental vaccine decision-making for their child, but 
scarce data regarding vaccination on behalf of a child (e.g. cocooning). A key study showed 
the following were influential to child vaccine decisions: spouse (55%), healthcare 
professional (34%), and internet (27%), health system ‘handouts’ (26%), other family 
member (6%), books (6%) and media articles (6%) (percentages exceed 100% due to 
multiple source selection)(146). We observed similarities among postpartum mothers 
(unvaccinated at baseline) who indicated numerous ‘most’ influential information sources to 
their vaccine-decision making. These included health professional (88%), immunisation 
brochures (27%), family/friends (21%), media (14%), the Internet (9%) and alternative health 
practitioner (3%). Whilst sources were similar to paediatric studies, there was some variation 
in the order of influence. This could be due to maternal rather than offspring receipt of the 
vaccine. Figure 4.4 below is a schematic representation of networks influencing vaccine 
decision-making. 
Figure 4.4:Vaccine recommendations: degrees of influence on maternal vaccine behaviour 
 
 
When looking at access to vaccine information, it appears that it is not the amount of 
information given but rather the parental importance placed on the type of information 
source. Research has shown that this may also be influenced by the relationship the parents 
have with their healthcare provider. Parents who reported ease of communication and trust in 
the advice given by their healthcare provider more often believed that they had access to 
enough information to make an informed vaccine decision. However, this study primarily 
focuses on paediatric providers and therefore may differ for obstetric providers. The belief 
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that vaccines were unsafe also significantly decreased the likelihood that a practitioner 
influences a parent’s vaccine decision-making (146, 147).  
Vaccine recommendations 
When asked to list who provided the woman with the pertussis booster vaccine 
recommendation, a range of key stakeholders were mentioned in addition to health 
professionals. The extent of the influence of a recommendation according to who delivers it 
could be deduced from responses ranking influential sources of vaccine decision-making. 
Within the framework of not just vaccination, but having a baby in the social event, we 
looked at the key influences on the childbearing woman. In the medical arena, a vaccine 
recommendation is often perceived as being given by a health professional. However, our 
data shows that postpartum women also perceive ‘non-medical’ persons as providers of a 
vaccine recommendation. This indicates a level of influence held by people of certain roles 
within the circle of the postpartum woman. Identifying non-medical influential figures is 
important due to their potential impact upon the woman’s vaccine decision-making. 
Expanding vaccination information, health provider education and health promotion 
campaigns to reach these key social figures may help increase vaccine uptake among women 
during the perinatal period.  
Theoretical overview regarding maternal vaccine decision making 
Vaccine decision-making is a complex process, which extends beyond just being provided 
with information and then accepting or declining. In the literature, the concepts of vaccine 
‘promoters’ and ‘inhibitors’ have been identified in the context of maternal decision-making 
for childhood vaccination. Promoters include a desire to prevent disease, the belief in the 
social contract (whereby altruism motivates participation in vaccination to promote herd 
immunity), band wagoning (the desire to partake in a health behaviour seen as a cultural 
norm) and having a positive past experience with vaccination(112). These promoters were 
represented within our thematic analysis on vaccine decision-making among both public and 
private patients. 
Trust in the medical profession does not merely imply trust in the provider; rather it 
encompasses an overarching trust in the health system as a whole. This perception has been 
previously identified as influential vaccine to uptake during pregnancy(101) and is the 
undercurrent in all vaccine decision-making (147). We observed this in our data, whereby the 
health professional was ranked the most influential in vaccine decision-making by 
participants, regardless of vaccine acceptance or decline. However, despite the overwhelming 
influence of these practitioners, there were a significantly lower proportion of vaccine-
rejecters who identified with the health practitioner. A study looking at maternal trust in 
paediatricians identified the enablers and disablers to trust in the therapeutic relationship. 
Factors that promoted trust included trust in the individual practitioner, satisfaction with the 
vaccine discussion with the doctor, and a desire not to diverge from the cultural norm. 
Alternatively, factors which eroded trust in the medical profession included alienation or 
distrust of the doctor, concern over permanent vaccine side-effects, perception that the child 
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is ‘not at risk’ (either as the disease is not serious or the child is protected by herd-immunity), 
and trust in a naturopath or influential ‘other’ who was unsupportive of vaccination. The 
latter is reflected in our data, with significantly more vaccine rejecters identifying an 
alternative health practitioner (i.e. naturopath) and information from anti-vaccination groups 
as most influential to vaccine decision-making. Further research is needed to explore this 
relationship within pregnancy, which is generally perceived as a medication-avoidant state. 
One of the key barriers for obstetric providers is not feeling confident in leading a mother in a 
vaccine discussion. Interestingly, this was the gap noted among women at baseline whereby a 
significant proportion had not heard of pertussis from their healthcare provider. This is a 
potential area for vaccine promotion, as the majority of women identifying the healthcare 
provider as the most influential to their vaccine decision-making. One of the key predictors of 
vaccine acceptance is a vaccine recommendation. However, if providers are not engaging in 
vaccine discussions with women, strategies need to be targeted to promote provider-led 
discussions.   
Provider-based barrier 
We observed a gap between the frequencies of reports that ‘health professionals’ are an 
influential vaccine information source compared to reports of hearing of whooping cough 
from one. Although 88% of unvaccinated women at baseline reported health professionals as 
influential to their decision-making, only 57% reported hearing of whooping cough from 
their practitioner. This equates to almost one-third of mothers, either receiving care from a 
midwife, general practitioner or obstetrician, who had not been informed of the funded 
parental pertussis booster vaccine during a nation-wide epidemic. An inconsistency in 
vaccine education by obstetric providers has been identified previously(60, 148), and there is 
an opportunity for postpartum hospital-based immunisation to ‘bridge’ this gap.    
To promote postpartum vaccine provision, it is useful to canvas the attitudes of obstetric 
providers. A recent study found that whilst 63% of obstetricians thought it was beneficial to 
vaccinate their patients following childbirth, they perceived the following barriers: patient 
refusal, reimbursement difficulties, time constraints, staffing, unease in providing vaccine 
education, liability and frequent changes in guidelines(60). Another study reported 
anticipated barriers were uncertainty of the date of prior vaccination (74%) and other 
priorities during the obstetric visit (19%)(149). Improving healthcare infrastructure may 
assist in mitigating these perceived barriers and enable provision of vaccination by 
obstetricians. 
Not only is the patient-provider conversation important, but also the way it is initiated has 
been shown to impact on how a vaccine recommendation is viewed. Of the 84% of paediatric 
providers who initiated a vaccine recommendation, 74% adopted a presumptive approach 
resulting in high parental vaccine acceptance than those who used a participatory approach 
(74% vs. 4% acceptance)(139). Assuming that a patient is going to be vaccinated 
(presumptive) rather than asking the patient what they would like to do regarding vaccination 
(participatory) has not been evaluated in the perinatal context. Vaccine recommendations 
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have been shown to influence postpartum uptake, and may serve as a proxy to the 
‘presumptive approach’ where there is no doubt in the provider’s opinion of which action the 
woman should take. This may be of particular importance among pregnant women due to 
their perception of risk.   
 
Predictors of prior vaccination versus postpartum vaccination 
 
Key correlates of having been previously immunised against pertussis prior to pregnancy 
centred on awareness of the pertussis epidemic and vaccine perception coupled with parental 
responsibility that vaccination is protective for their baby. Over half of the vaccinated women 
perceived whooping cough as being common in their community, which may have impacted 
on their perceived susceptibility. However, when we looked at this questionnaire item we 
noted that they actually had a lower perception of disease susceptibility compared to 
unvaccinated women. It is probable that this is linked to perception of the effectiveness of the 
pertussis booster vaccination (which they have all received), rather than their perception of 
susceptibility of an unvaccinated person.  
Vaccine perception was a key difference observed not just among those vaccinated prior to 
pregnancy, but also among those who accepted the pertussis booster vaccine on the maternity 
ward and those who declined it. A key baseline difference was that 96% of vaccinated 
women agreed that by having the pertussis booster vaccine they would help prevent their 
child from contracting pertussis. Interestingly, when we adjusted for having a child prior to 
pregnancy, this was not significant between primiparous women who had the vaccine and 
those who did not. Similarly, the parental responsibility to get vaccinated to protect their 
child’s health was a belief held by 97% of vaccinated women. However, when the analysis 
compared vaccinated primiparous women to unvaccinated women, this belief did not differ 
significantly. The perception that differed significantly both among primiparous women and 
the baseline sample was concern over pertussis booster vaccine safety for an adult. Within the 
sample, only 8.7% of vaccinated women expressed any concern about this vaccine’s safety. 
This is a key barrier to vaccination, which needs to be addressed by health care professionals 
to enable women to make informed vaccine decisions.     
Vaccine information sources 
Whilst there is a body of evidence regarding maternal perceptions of childhood vaccination, 
there is limited research of the mother as recipient on her child’s behalf. A study examining 
maternal attitudes towards neonatal vaccine information for their newborn showed that 
brochures had a limited effect on their attitudes. Whilst it increased vaccine confidence and 
increased immunisation concerns, it did not influence beliefs around vaccine concerns. 
Timing of receipt of information was important, with most indicating a preference to receive 
vaccine brochures during pregnancy.  
Klein et al, 2009 depicted the attitude continuum consisting of four vaccine stances that fitted 
into the dichotomy of acceptance or decline(150). Vaccine information sources could be 
Best practice for the communication of perinatal pertussis booster recommendations    
137 
 
preferentially assigned to one of the four quadrants. They found that mothers classed as 
‘vaccine rejecters’ tended to be older, better educated and of high socio-economic status. This 
is similar to previous studies in the USA and England (147, 151). Consequently, they were 
less responsive to additional vaccine information (e.g. immunisation brochure) and thus 
tended to seek information elsewhere. Within our study, we found women in the private 
hospital tended to fit into the demographic criteria of ‘vaccine rejecters’. Interestingly, we 
observed that the primary reason for vaccine decline was ‘requiring additional information’. 
Whilst baseline data showed that women reported hearing of whooping cough from an 
average of two vaccine information sources, ‘needing more information’ could be related to 
insufficient information rather than lack of information. This is an observation that has been 
reported among women of higher socioeconomic status, who were less responsive to 
additional information provided in the consulting room setting and more likely to seek 
additional information elsewhere (e.g. internet) (150). This alludes to the impact of both the 
type of information and its content, source reliability and whether specific concerns are 
answered all come into play.        
Vaccine decision-making is not merely a process of having the information, rather it is about 
‘being informed’(123). The need for additional information could indicate that mothers 
require additional information to make a decision about vaccination. Research shows that 
parents often have concerns about vaccine safety or hold misconceptions about vaccines 
which are important in the decision making process. The rise in vaccine concerns is due to an 
amalgamation of factors. Firstly, the introduction of vaccination led to such a steep drop in 
disease prevalence that many people today have not experienced vaccine-preventable 
childhood diseases. With high coverage in the population, the frequency of adverse events 
has increased and led to heightened parental concern over vaccine safety. This is problematic, 
as most adverse events are temporally associated with the vaccine yet parental perceptions 
often attribute causation. These concerns are fuelled by the media, in which minority views 
are overrepresentation, leading to a distorted view of vaccine safety that affects public 
confidence(140).     
Public confidence in vaccination is paramount to herd immunity, which is pivotal to disease 
control. However, public health messages warn and persuade yet rarely provide key 
information about how vaccination works(123). This is problematic, as a lack of background 
explanations to ‘fill in the gaps’ makes it difficult to link concepts of a vaccine education 
message required for vaccine decision-making(123). These ‘gaps’ leave a desire for meaning, 
which is formed by knowledge, experience, plausibility beliefs and causal narrative exposure 
that generate inferences needed to process ‘lay’ vaccine information sources (e.g. media, 
internet). We observed that participants often delayed vaccination because they needed more 
information, time to process the information or wanted to consult their doctor. Patient-
provider discussions are therefore critical, as they can be tailored specifically to the 
individual’s concerns and therefore help them ‘fill the gaps’ in vaccine knowledge(123).  
We found that a significant predictor of vaccine uptake was vaccine benefits. These included 
the potential for the pertussis booster vaccine to help prevent transmission to the newborn and 
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the benefits of maternal vaccination outweighing any risks. However, among women who 
declined vaccination they did so due to concerns over vaccine safety, particularly relating to 
childbirth. This highlights a knowledge gap among new mothers about how vaccinations 
work in the context of pregnancy and childbirth. Addressing this gap is of particular 
importance due to the general consensus during pregnancy for medication avoidance and the 
innate instinct to avoid any ‘potential threat’ to the foetus. Therefore, mothers would prefer to 
not actively take a risk, even a temporal one (e.g. immunisation side effects).  
Predictors of vaccine uptake during pregnancy among eligible women 
Our study reported an 8.7% (95% CI: 6%-12%) pertussis booster vaccine uptake during 
pregnancy among eligible women, at an average of 34 weeks gestation as recommended (29-
36weeks)(4, 31). This increased pertussis vaccine coverage to 51% among all postpartum 
women screened for vaccine status. Women who were vaccinated against pertussis during 
pregnancy were more likely to have received a pertussis booster vaccine recommendation, as 
well as have had their health professional recommend this vaccine during pregnancy. These 
women who were vaccinated against pertussis during pregnancy also reported no vaccine 
safety concerns (p=0.006), held the perception that whooping cough was ‘common’ in their 
woman’s community (p=0.018), and less frequently reported transport barriers to accessing 
their family doctor to receive a vaccine (0.032). We also observed that women who had the 
pertussis vaccine during pregnancy were three times as likely to have also been vaccinated 
against influenza during pregnancy. Low uptake in pregnancy suggests that added measures 
may be required, in addition to a health wide media announcement highlighting vaccination 
shift to during pregnancy(5). 
Prior to the introduction of national guidelines, we previously reported an even lower 
pregnancy pertussis uptake of 0.5% among eligible women, without any specific education or 
strategy (152). Our current data shows that uptake in pregnancy has increased to 8.7% since 
the introduction of national guidelines recommending pertussis vaccination during 
pregnancy. However, uptake remains low compared to other countries that have 
systematically implemented this guideline or recommendation. In the UK, 49% population-
wide pertussis vaccine uptake during pregnancy was sustained by systematically offering a 
free (publically funded) pertussis vaccine to women during routine antenatal appointments 
with their midwife or GP(72, 73). In the Australian context, while guidelines exist, there is 
not a systematic approach to antenatal pertussis vaccination. We identified factors which 
suggest the role for a three-tiered approach to implementation: the setting, the patient and the 
provider.  
Setting 
Access to an immunization provider is an important consideration: women vaccinated against 
pertussis during pregnancy less frequent reported transport barriers to accessing their family 
doctor to receive a vaccine (0.032). This may be a conservative estimate, as our sample was 
biased to a more affluent demographic given these women could afford private obstetric care 
(25% of Australian women)(136). As the majority of Australian women receiving midwifery 
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care may not routinely see a doctor during pregnancy, accessing an immunization provider 
may be a greater barrier than identified by our data. This barrier to vaccination has previously 
been reported by 73% of pregnant women receiving public obstetric care who were eligible 
for influenza vaccine; with uptake 29% higher in the prenatal clinic with a nurse dedicated to 
providing funded vaccination (17% vs. 46%)(101). Integration of pertussis booster 
vaccination into routine antenatal settings may increase uptake.  
Patient 
In our study, over 90% of women agreed that the benefits of receiving the pertussis booster 
vaccine outweighed the risks. However, this general perception of the vaccine may differ 
among women in the context of pregnancy. We observed that women who received the 
pertussis vaccine during pregnancy reported no vaccine safety concerns (p=0.006). This 
suggests that pregnant women perceive vaccine ‘risk’ as absolute rather than a continuum. 
This is congruent with the maternal-foetal bond, characterized by an ‘innate desire to protect’ 
the foetus through prevention of any threat(126). Therefore, if pregnancy is a risk-adverse 
state, addressing vaccine safety concerns may be of greater importance than emphasizing 
disease risk.    
Women who accepted the pertussis vaccine whilst pregnant were also three times as likely to 
have been immunized against influenza during pregnancy. It may be plausible that these 
women were generally accepting of vaccination during pregnancy, rather than uptake being 
related to a specific vaccine. We also noted that overall influenza vaccine uptake was higher 
than pertussis vaccine uptake during pregnancy (38.3% vs. 8.7%). This may be due to 
variations in the timing of vaccine recommendations during pregnancy, with the pertussis 
vaccine only nationally recommended since 2013. However, cost needs to be considered as 
only the influenza vaccine is currently publically funded for pregnant women in Australia 
(and hence free of charge to women). Our data indicated that One third of unvaccinated 
women would have agreed to have pertussis vaccine in pregnancy if it were free. Extending 
funding to include the pertussis booster vaccine for pregnant women may help increase 
uptake during pregnancy.                                
Provider  
Among postpartum women, we found that health professionals were most influential to their 
vaccine decision-making (91%), followed by immunization brochures (31.5%) and 
family/friends (25%). The overarching influence of health professionals may be attributed to 
the model of obstetric care (private obstetrician) that is offered in the private sector. Prior 
research in the public setting showed that an obstetrician has a lesser role (49%)(153). In our 
study, nine out of ten vaccinated women were recommended the pertussis booster vaccine 
during their recent pregnancy. This differed significantly to unvaccinated women, who were 
less likely to have been recommended a pertussis booster vaccine during their pregnancy. 
There is scope for improvement in pregnancy pertussis vaccination uptake where there is an 
increase in provider recommendations as 40% of unvaccinated women in our sample reported 
that they would have received the pertussis vaccine during pregnancy if their doctor had 
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recommended it. We also observed that in this private sector setting, obstetricians gave a 
pertussis vaccine recommendation during pregnancy more than twice as frequently than 
general practitioners (GP) (47% vs. 20%), and almost three times more frequently than 
midwives (47% vs. 16%). Patient-provider vaccination communication during pregnancy is 
clearly important for vaccination uptake in general, as has been demonstrated with influenza 
vaccine uptake (153). Provision of a pregnancy-specific recommendation by any health 
professional is likely to increase pertussis vaccine uptake during pregnancy. 
Limitations 
Limitations of baseline cross-sectional study 
Our large, multi-site, mixed-methods study was not without limitations. A cross-sectional 
design limits the extent to which causation between HBM factors and coverage can be 
observed. The large sample-size, powered for the intervention study, may lead to type II error. 
Since the conclusion of the study, national pertussis booster vaccine recommendation has 
changed from every 10 years to 5 years. This has a minor impact on our results as vaccination 
primarily occurred within this adjusted timeframe (figure 2). Although study commencement 
was staggered by site (due to extraneous factors), participants were recruited during the 
recent pertussis epidemic when ‘cocooning’ was the statewide vaccination strategy. 
Questionnaire mode variation (electronic vs. paper) did not to appear to impact upon our 
recruitment rate or data completeness, although systematic differences by mode are possible. 
The questionnaire was in English, so generalisability of findings may be limited to hospital 
settings in English-speaking countries.  
Study limitations 
Our study was conducted in English, which limits generalisability to English-speakers only. It 
could also be argued that using sequential block allocation rather than randomisation with 
allocation concealment may have introduced some bias into the study. However, no 
relationship between vaccinated participants and pertussis notifications was observed and 
lack of allocation concealment may cause bias towards the intervention rather than against, 
which was not evident in our results. Study strengths included direct outcome measurement 
and a sole recruiter (EH) to ensure consistency in recruitment.  
Specifically related to the pregnancy subset, it is difficult to make definitive conclusions from 
the findings of this study or to generalise to other populations. This was a post-hoc analysis 
of baseline data from the Maternal Pertussis Randomized Control Trial(134). Participants 
were only women receiving private obstetric care. It is likely that pertussis vaccine uptake 
would be lower among pregnant women across Australia, and in non-English-speaking 
populations.  
 
Another limitation was that the study was commenced at different time points between the 
two hospital sites. Due to the media coverage of the pertussis epidemic during this time, and 
the impact this may have had on maternal awareness and decision-making during this time, 
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the time delay may have prevented comparison of the results. In addition, the allocation of 
the intervention and control was difference. Sequential allocation was selected for the public 
hospital as random allocation may lead to weeks of a consecutive intervention being 
allocated. This was thought to be problematic due to the high media coverage of the pertussis 
epidemic, which may have influenced the results and been falsely attributed to one 
intervention. However, this was reconsidered when commencing the study at the private 
hospital. It was decided that the likelihood of this was low, compared to the benefits to the 
methodology of the study being random, rather than sequentially allocated. 
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Chapter 5 Conclusion 
 
Synopsis 
Pertussis remains a public health concern, despite high global coverage of the primary 
immunisation series. A recent epidemiological shift has been observed in developed 
countries, with higher notifications among adolescents and adults. This has been attributed in 
part to waning vaccine-induced immunity and improved disease diagnosis and reporting (9). 
A key issue is that adult cases of pertussis are frequently atypical, leading to late clinical 
presentation and low recognition rates(20). This makes them a prime reservoir for pertussis 
transmission to young infants. 
Selective vaccination of groups that are significant in disease transmission is a strategy 
targeted at reducing the incidence among ‘at risk’ populations.  For pertussis, an 
epidemiological link between the increased incidence among adults and the serious threat this 
poses to young infants has been established(33). Among susceptible household contacts, 
primarily unvaccinated infants, a 90% transmission rate of pertussis has been reported(12). 
Infants <3months, who suffer the highest morbidity and mortality, are the most vulnerable as 
they are too young to be fully vaccinated against pertussis. Therefore, pertussis control 
strategies have focused on selective vaccination of adult household members and caregivers. 
This is an attempt to make a ‘cocoon of protection’ around the infant by breaking the 
transmission link. 
‘Cocooning’, as a pertussis control strategy, was first introduced in 2006 following the first 
Roundtable Pertussis Initiative Meeting(9). In order to be effective on a population level, this 
strategy was estimated to have required a high coverage rate of 85%(14). Research has 
highlighted the importance of pertussis education, yet the content and delivery of educational 
material has yielded varying outcomes. Our study addresses the need for randomised control 
trials to evaluate pertussis education within this context. 
The overall thesis aim was to determine whether the cocooning strategy could be successfully 
implemented within the postnatal ward context of the Australian health system. This involved 
evaluation of both maternal attitudes, vaccine decision-making and system factors in 
promoting or hindering vaccine completion within both public and private hospital settings. 
We also determined the best practice for communication of pertussis booster vaccine 
recommendation, by evaluating the impact of gain-loss message framing on vaccine uptake. 
Empirical Findings 
Our study found that only one in every three postpartum women had received a pertussis 
booster vaccine prior to pregnancy, against the backdrop of a pertussis epidemic. Vaccination 
primarily occurred during 2009-2013, which spans the time period when the pertussis booster 
vaccine was funded for parents and caregivers of an infant in NSW. This was delivered 
within the general practice setting, where the majority of previously vaccinated participants 
were confirmed to have received their pertussis booster vaccine. Our study observed that 
baseline coverage among new mothers varied by 25% between the public midwifery-led and 
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private obstetric-led hospitals (23% vs. 48% respective). This gap can be reduced with the 
introduction of vaccination within the postnatal ward. In this setting we showed that the 
provision of a funded pertussis booster vaccine accompanied by an educational brochure 
increased vaccine coverage by a point increase of 45-54%. Pertussis booster vaccine 
coverage among new mothers was increased to 77% and 93% upon discharged from public 
and private maternity hospitals, respectively. Whilst the gain-loss message framing 
intervention did not yield a significant difference, overall pertussis booster vaccine uptake of 
70-85% was achieved across maternity settings. This highlights the effectiveness of 
information provision accompanied by funded vaccination to a receptive population within a 
setting with minimal vaccine barriers.  
Baseline findings 
Vaccine uptake during an epidemic has been suggested to increase due to widespread media 
coverage, as demonstrated by a study evaluating influenza vaccine uptake during 
pregnancy(105). In the preceding eighteen months of this study, the NSW ministry of health 
had embarked on a widespread media campaign that included funded pertussis vaccination 
targeted at parents and caregivers of an infant under one. In our study, the majority of 
participants who were ‘up-to-date’ with the pertussis booster vaccine had received it whilst 
this strategy was in progress. It is likely that they were vaccinated as part of this strategy, as 
evidenced by a large proportion of pertussis vaccination reported following a previous 
pregnancy or as part of preconception care.  
Despite this widespread public health media campaign accompanying funded parental 
vaccination, baseline coverage among new mothers was low (33.7%). The 25% difference in 
baseline coverage between the public and private hospital sites is likely due to differences in 
socioeconomic status, multiparty and staggered study commencement. Our sub-group 
analysis of the time period of concurrent recruitment supports the difference by hospital site. 
Whilst over 90% of women were aware of ‘whooping cough’, those vaccinated prior to 
pregnancy had more frequently heard of pertussis from a health professional. Disease 
perception differed according to vaccine status, with vaccinated women perceiving pertussis 
as a common disease that had severe consequences for an adult. Interestingly, this did not 
have an impact upon their perception of how vulnerable they were to contracting pertussis. 
This is most likely a reflection of their perception of the efficacy of the pertussis booster 
vaccine.   
Interestingly, there was no difference according to vaccine status in the perception of 
pertussis as severe for a newborn. However, when looking at the attitudes towards the 
pertussis booster vaccine, women who had been vaccinated prior to pregnancy more often 
held the following beliefs. Firstly, that it was their parental responsibility to get vaccinated. 
This is likely attributed to a larger proportion of multiparous women having previously 
received the vaccine, most likely as part of the funded government ‘cocooning strategy’ 
which had been available since 2009 through general practice. Another belief held by 
vaccinated women was that by being immunised would help prevent their baby from 
contracting pertussis. This indicates an understanding of ‘cocooning’, which is most likely a 
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result of the initial NSW health ‘Cocooning’ Campaign. This is reflected in prior uptake 
clustered around 2009-2011, when the program was introduced in the state. As these two 
beliefs pertaining to the baby were not significant among primiparous women only, they are 
likely representative of multiparous mothers vaccinated as part of the cocooning campaign. 
Whilst this state-wise campaign appears to have had some impact among this population, low 
coverage is insufficient to provide adequate protection to vulnerable newborns. 
Sub-optimal coverage of the cocooning is not the only factor that supports delivery of the 
cocooning strategy via the hospital platform. A key gap in the cocooning strategy is the time-
lag it takes for maximal efficacy to be achieved following vaccination(67). This is significant, 
as a lag as long as a fortnight provides a potential window of pertussis susceptibility for a 
newborn. This can be minimised with vaccination during the immediate postpartum period, 
utilising the hospital-immunisation platform. When introducing a new vaccination program, it 
is important to include interventions that will improve vaccine coverage. These can be 
clustered under the following headings: community demand, enhanced access to vaccination 
services, and provider-based interventions(57). Using findings related to the patient, the 
setting and the provider, we demonstrate how the above interventions can be tailored to 
promoting pertussis booster uptake among new mothers.  
Increasing community demand for vaccination (patient) 
Understanding the role of socio-demographics and attitudes is crucial to informing 
educational interventions aimed at increasing uptake. This is an important component of 
promoting community demand for vaccination. A key finding of our research was that 
vaccine intentions do not always predict vaccine uptake within a particular setting. We found 
that 25-45% of women who declined vaccination in both postnatal wards had reported that 
they intended to be vaccinated against whooping cough. Interestingly, perceived 
susceptibility and the severity of pertussis did not significantly influence vaccine completion. 
Highlighting the protective benefit to baby (and mother) of timely vaccine completion may 
be a strategy to encourage uptake within the immediate postpartum period.  
Raising awareness is another strategy that promotes vaccine uptake. An existing NSW health 
strategy is the ‘yellow sticker’ on the front of the baby’s health record, stating ‘watch out, 
whooping cough’s about’. Commonly referred to as the baby’s blue book, this health record 
is given out in delivery suite following childbirth. The actual study itself, whereby a mother 
was informed of a vaccine trial, completed a questionnaire on pertussis and vaccination and 
then was given some educational intervention may have raised awareness among both 
hospital staff and participants. The offer of a free pertussis booster vaccine delivered on the 
postnatal ward would have increased knowledge of this vaccine service, which may have 
encouraged participants to ‘take advantage’ of this service. Uptake on the public and private 
postnatal wards was 48-55% among mothers who were initially unsure whether to be 
vaccinated, and 19-20% among those who initial did not intend to be vaccinated. 
Furthermore, removing out-of-pocket costs improved vaccine availability, and may have 
impacted on high demand. In this way, the hospital platform can be opportunistic for those 
who are either unsure or are not intending to be vaccinated.  
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Other studies have utilised the hospital platform to provide vaccine education, thus increasing 
community demand for vaccinations. In France, a crossover design tested the provision of 
oral and written information concomitantly, then in isolation (69).  Midwives, followed by 
paediatricians then obstetricians, most frequently provided vaccine education. The provision 
of a script for the pertussis booster vaccine served as a prompt for vaccine completion in the 
community setting. We found that those who had previously received the pertussis booster 
vaccine prior to pregnancy were twice as likely to have heard of whooping cough from a 
health professional. This disproportionate finding highlights the responsibility of health 
professionals in instigating discussions about pertussis and vaccination with their patients 
during antenatal consultations. 
Enhanced Access to vaccination services (setting) 
The cocooning strategy was initially offered to new mothers via their general practitioner. 
However, whilst providing education in the hospital setting encourages uptake within the 
community setting, vaccination often occurs outside of the immediate postpartum period. 
Previous research has highlighted the demands a new baby has on parents’ time, and how 
barriers to accessing a vaccine provider impact on both vaccine completion and timeliness. In 
our study, we achieved a high vaccine uptake within the postnatal ward setting where 
professional advice and vaccination was available twenty-four hours a day, on any day. 
Vaccination occurred within the first week postpartum, which is an advantage this setting 
offers in minimising the gap of maternal and indirect neonatal protection. Optimisation of the 
cocooning strategy is vital to maximise its effectiveness, which is achieved in this setting 
yielding high coverage of 85% within days of childbirth.  
Like with any immunisation platform, there are system errors that need to be addressed to 
optimise vaccine delivery. Within the private hospital, system errors prevented 3% of 
participants who requested the pertussis booster vaccine from being vaccinated. It is likely 
that system errors were minimised due to the presence of ward vaccine stock and a longer 
length of stay to arrange vaccination. Vaccine ward stock is an intervention that has 
successfully increased uptake among study populations within the postnatal ward setting(15, 
154). Ward stock may have allayed pharmacy barriers in the public hospital, where system 
errors account for 11% of participants remaining unvaccinated on discharge. 
Provider-based interventions (provider) 
Strategies to increase vaccine uptake within the postnatal setting have included a vaccine 
standing order and automated computerised prompt for providers to prescribe (80, 155). 
Standing orders for pertussis booster vaccination, which increased uptake to 69%, were said 
to empower obstetric nurses to provide immunisation as they could initiate it without 
obtaining an order from a doctor. Our study attempted to mitigate this barrier by ensuring the 
pertussis booster vaccine was both prescribed on the medication chart and placed in the 
postnatal ward vaccine fridge for ease of administration. Whilst this removed the 
administrative burden for the midwife, it did not provide the empowerment given by a 
standing order. Thus, the onus of decision-making and vaccine advice remains on the doctor, 
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with the midwife functioning as the administrator. On a departmental level, a standing order 
communicates to maternity staff that the vaccine is for all patients and, vaccination becomes 
the routine default rather than an extra task. This assists in integrating new immunisation 
strategies into routine postnatal care, as demonstrated with over 88% coverage of neonatal 
Hepatitis B vaccination when routinely administered within the labour ward setting. 
Within the postnatal ward setting, a key barrier faced by up to 11% of unvaccinated 
participants was that vaccination not performed by hospital staff (primarily a midwife). 
Introduction of a prompt incorporated into the existing maternity care plan may be beneficial 
for the discharging midwife to ensure vaccination is performed. Following that of routinely 
administered Rubella, this could include computerised and care plan reminders to check 
serology for susceptibility and vaccine administration. This could use an existing platform, 
such as the ‘ObstetriX’ Database that supplies 45% of mandatory perinatal data across the 
state of NSW. Additionally, this data routinely forms a printed discharge summary of 
postnatal care. This is given to the general practitioner and early childhood centre, as well as 
an additional copy operating as a hand-held record for the new mother. On a population level, 
the ObstetriX Database is the largest source (44.4%) of mandatory data for the NSW 
Perinatal Data Collection(136). Recording pertussis vaccination information on hospital 
discharge would not only serve as a prompt for the midwife, or record for the patient or 
general practitioner on the discharge summary, but could be used of more accurately estimate 
coverage among new mothers.  
Theoretical and policy implications 
Elements of successful adult vaccination programs include funded vaccines(15), staff 
training(15), extended vaccination hours(15, 16), standing orders or prescription(15, 69, 82)  
and accessible stock(15). These are strategies that enhance access to vaccination services for 
the patient and make service delivery easier for the provider. The latter is of particular 
importance, as ‘health professionals’ are a key stakeholder in vaccine delivery within the 
hospital setting. With the additional demand of vaccine provision now being placed on 
obstetric staff, there are specific hurdles that need to be addressed.  
The first is that immunisation is a paradigm that has not traditionally been delegated to 
obstetric providers. Therefore, it raises concerns about it being both time-consuming and 
cumbersome(149). In addition, it puts the onus on the obstetric provider to be familiar with 
national recommendations for immunisation amongst this target group, provide education to 
educate mothers, as well as stock and administer vaccination. In an Australian survey, the 
reason why 62% of women had not received the pertussis booster vaccine was because they 
were not aware of the free vaccine(82). Almost one-third (561/2079) of unvaccinated 
postpartum participants identified health practitioners as influential to their vaccine decision-
making, yet had not been informed of pertussis by one. Furthermore, a significant predictor 
of vaccination on the private postnatal ward was the influenced a health professional had on 
their vaccine decision-making. Among unvaccinated public hospital participants, a vaccine 
recommendation significantly predicted uptake yet only half reported receiving one. Raising 
awareness and ownership among key stakeholders is needed for successful implementation 
Best practice for the communication of perinatal pertussis booster recommendations    
147 
 
on a statewide level. Additional strategies, such as a place to document that a vaccine 
recommendation has been given, will increase the professional responsibility obstetric 
providers to protect their patients.   
Understanding why a strategy is in place and how that fits with current epidemiology is vital 
to engender provider support(149). It has previously been noted that among health 
professionals there is a relative lack of awareness of the need for a booster vaccine due to 
pertussis immunity waning following childhood vaccination(156). This is problematic as 
adults are susceptible to atypical pertussis and provide a reservoir of serious infection for 
infants. This is the crux of the cocoon strategy and the implementation of a vaccine strategy 
is dependent on the level of awareness of health professionals.  Our previous research showed 
that a midwife’s own perceived self-efficacy in providing vaccination is central to postpartum 
vaccine administration(78). This is an important area to address, with maternity staff being 
identified as pivotal to the success of the cocooning study in international hospital 
settings(15), To encourage provider education and implementation of this strategy, up-
skilling of midwives to credentialed immunisation providers needs to be integrated into 
midwifery training rather than as an additional postgraduate certificate. 
A significant predictor of pertussis booster vaccine uptake on the postnatal ward was prior 
recommendation of the vaccine. We have already highlighted the influence a provider has in 
vaccine decision-making. It is vital that this process occurs prior to childbirth, to enable an 
informed decision to be made without time pressure or the demands of caring for a newborn. 
Provider discussions shape vaccine intentions, which is a precursor to behaviour that will 
increase the likelihood of vaccine completion. Whilst the maternity ward is instrumental in 
vaccine education and access, the moderating effect vaccine intentions had on uptake are 
evidence for decision-making to occur prior to childbirth. Thus, health professionals need to 
be aware of current pertussis prevention strategies in order to raise awareness with the 
patients through discussion and providing vaccine recommendations. This is important in 
vaccine completion. We found that those who had previously received the pertussis booster 
vaccine prior to pregnancy were twice as likely to have heard of whooping cough from a 
health professional. Due to the clear impact on vaccine uptake, interventions to encourage 
whooping cough discussions and monitor vaccine recommendations given by obstetric 
providers need to be devised and tested.  
Our trial was conducted during a time where the cocooning strategy to control pertussis 
among infants was being expanded in response to data supporting antenatal vaccination. In 
March 2013, Australian Immunisation guidelines were updated to include vaccination during 
the third trimester of pregnancy as a suitable alternative to postpartum vaccination. During 
this transition period, we found that pertussis booster vaccine uptake during pregnancy 
among eligible women was low at just under 9%, despite high awareness of ‘whooping 
cough’. Those who accepted vaccination during pregnancy expressed no safety concerns to 
pertussis. To improve uptake, health professionals should systematically recommend the 
vaccine to eligible women as a routine part of their antenatal care. In addition; providers 
should explore and address any vaccine safety concerns in particular those related to 
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pregnancy. Funding the pertussis vaccine for pregnant women and utilising the prenatal clinic 
or obstetricians’ rooms as an immunisation platform may minimise barriers to vaccination 
within the Australian health system. In our larger study, we demonstrated that a funded 
postpartum vaccination program with education and nurse recommendation yielded a 70% 
uptake in the postnatal ward setting, hence this alternative needs continued support until high 
coverage during pregnancy can be achieved. 
This is the first control trial of an educational intervention to promote postpartum pertussis 
booster vaccine uptake. Message framing was as effective as the provision of a factsheet on 
pertussis, in achieving a high vaccine uptake of 70-86% among eligible participants across 
public and private hospital settings. This increased overall coverage to 83.5% among 3, 383 
participants across two major maternity services in this area, which almost meets the 85%  
estimated coverage required for cocooning efficacy(14). Cocooning vaccination has the 
potential to be highly successful when implemented on the postnatal ward, with benefits 
likely exceeding the minimal cost of a vaccine and a brochure. Our study also suggests that 
provider recommendation and promoting pertussis vaccine benefits is likely to increase 
postpartum uptake. Our study is the first in Australia to report on actual uptake during 
pregnancy among eligible women, and the attitudinal differences among those who deferred 
in until the postpartum period. We found that obstetric providers need to give a strong 
recommendation whilst counselling pregnant women on the vaccine safety, in order to 
mitigate any vaccine concerns. Further research is needed to explore antenatal provider 
acceptability and acceptability of pertussis vaccination during antenatal visits outside of the 
general practice setting. 
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Appendix 2: Publication 2 
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Appendix 3: Publication 3 
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Appendix 4: FAOPS & PSANZ Congress, 2012 
17th Congress of the Federation of Asian and Oceania Perinatal Societies (FAOPS) and the 
16th Annual Congress of the Perinatal Society of Australia and New Zealand 
(PSANZ)(Sydney, Australia, 18th-21st March 2012)  
Implementation of paternal dTpa booster vaccination on the postnatal ward in NSW. 
E.H. Hayles, S.C. Cooper, N.J. Wood, S.R. Skinner, J.H.K. Sinn. 
Background: Cocooning is a strategy to protect vulnerable infants from pertussis, where 10–
26% are infected from their fathers. NSW Health has implemented a limited funded 
vaccination program for mothers in hospital prior to discharge. However, fathers are required 
to go to the GP in order to be vaccinated. Offering vaccination to fathers on the postnatal 
ward has been successfully implemented in America. Feasibility in the Australian health 
system is unknown.  
Method: Fathers who have not received a dTpa booster in the last 10 years were recruited on 
the postnatal ward of a NSW public hospital in 2011. They completed a pre-questionnaire in 
English, received a brochure and were offered the dTpa vaccination by the research midwife.  
Results: 60 fathers were enrolled and 57 (95%) opted to be vaccinated with dTpa prior to 
discharge of the mother. 44 (73%) fathers were vaccinated simultaneously with the mother. 
10 were vaccinated by themselves as their partner had already received the booster within the 
last 10 years. 3 fathers declined vaccination as they wanted to consult their own practitioner. 
68% were first-time fathers. 3 fathers had not heard of whooping cough.  
Conclusions: Vaccinating fathers on the postnatal ward is feasible, with 97% vaccine uptake. 
In order to promote the cocooning strategy, extra hours need to be allocated to the ‘discharge 
planner’ midwife. This will enable dTpa vaccination to parents in the postnatal ward prior to 
maternal discharge, reducing the risk of pertussis transmission to infants by 70%.  
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Appendix 5: Poster Presentation, 31st Annual Meeting of the European Society for  
Paediatric Infectious Diseases, Milan, Italy, May 28th-31st, 2013. 
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Appendix 6: The XI World Congress of Perinatal Medicine (Moscow, Russia, 20th-22nd  
June 2013)  
CORRELATES OF MATERNAL ATTITUDES AND MODIFIABLE FACTORS OF 
PERTUSSIS BOOSTER VACCINE UPTAKE AMONG POSTPARTUM WOMEN  
Hayles, E.H., Cooper, S.C., Skinner, S. R., Wood, N. , Sinn, J.H.K. 
 
Introduction/Background: The re-emergence of pertussis epidemic sparked the introduction of 
maternal vaccine strategies, which aim to protect vulnerable infants indirectly. The cocooning 
strategy, which was implemented in Australia in 2009, can have a strong protective effect against 
pertussis in infants. To achieve high maternal coverage, understanding maternal attitudes and other 
potentially influential factors is important. In this study, we examined baseline correlates of pertussis 
vaccination status in postpartum mothers recruited to a randomised controlled trial of health 
information framing    
Patients: Postpartum women were sequentially recruited on weekdays from an urban, private hospital 
postnatal ward in Sydney, Australia (March 2012- 2013).  
Methods: Subjects completed a web-based knowledge and attitudes questionnaire on an Apple Ipad®. 
The questions were based on the Health Belief Model constructs (perceived susceptibility to 
contracting pertussis, severity of pertussis, barriers to vaccination, cues to action and vaccine 
effectiveness). Multivariate analysis by baseline vaccination status was performed. Subjects were 
classified not ‘up to date’ with pertussis booster recommendations if they reported no receipt of 
diphtheria, tetanus, acellular pertussis vaccine (‘dTpa’) within 10years. Vaccine status was confirmed 
for ‘up to date’ subjects. 
Results: 1080 of 1121 mothers approached were enrolled. Baseline analysis was performed on a 
sample of 1063 subjects (17 excluded: missing data). 549 (51.6%) were not up to date with the 
pertussis booster recommendation. Compared to mothers not up to date , ‘up to date’ subjects (n=514, 
48.4%) were more likely to be multiparous (OR = 6.07 p<0.001 4.65-7.93), had more frequently 
heard of ‘whooping cough’ from multiple sources (p<0.001), namely health professionals (OR: 3.69 
p<0.001 95% CI: 2.6-5.3), immunisation brochures (OR: 1.8 p<0.001 95% CI 1.41-2.31) and media 
(OR: 1.55 p=0.001 95% CI: 1.19-2.01). These mothers also: 1) had perceptions of pertussis as a more 
severe illness, and perceived higher susceptibility to it (p=0.024); 2) ranked vaccine benefits as high 
(p=0.001) 3) perceived low barriers to vaccination (p<0.001). Sources that were reported most often 
to assist in vaccine decision-making were health professional (95.2%), immunisation brochures 
(34.8%) and family or friends (22%). Recommendations from doctors were reported most frequently 
by ‘up to date’ subjects (49.2%) vs. not (34.8%). Among primiparous women, those with lower 
perceived barriers to vaccination (p=0.032) had higher odds of being ‘up to date’ with their pertussis 
booster at baseline vs. not. When individual barriers were analysed (transport, information access, 
safety and time), primiparous subjects who reported no concerns over vaccine safety had 2.6 times 
higher odds (p=0.004; 1.27-5.3) of having been vaccinated at baseline than those who had safety 
concerns. Those who primarily spoke English at home, had increased odds of being ‘up to date’ with 
their pertussis vaccination (OR: 3.43, p=0.011).    
Conclusions: In this large postpartum study, pertussis vaccine coverage was 48%. Information and 
vaccine recommendations from health professionals are key factors in decision-making. Low 
concerns over vaccine safety and the perception of pertussis having severe consequences on the 
newborn were significant factors to vaccine uptake among postpartum women. These attitudinal 
factors may also be relevant to recommendations for vaccination during pregnancy.   
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Appendix 7:Poster Presentation, Marie Bashire Institute Colloquim, 5th December 2013 
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Appendix 8: Pamphlet Development (Ass. Prof. Spring C. Cooper) 
The current study involved testing two pamphlets that were specifically developed for the 
project: one in a gain-frame format and one in a loss-frame format.  The two pamphlets that 
were created for the study were based on the Health Belief Model and followed health 
communication recommendations for clear and concise messages. 
 
Development of the pamphlets began with a review of currently available information about 
pertussis booster vaccination.  Information that is publicly available online, drug company 
information provided in the form of pamphlets to women in Australia, and information 
provided by the Australian government were all reviewed.  After determining what type of 
information was appropriate to be included in the pamphlets, two pamphlets were created. 
 
Reading levels were checked using the Flesch-Kincaid and Flesch measurements.  In 
addition, the SMOG index and Gunning-Fog score were used to determine polysyllable 
words that may cause some women difficulties.  Words that were highlighted as potentially 
confusing were changed to simpler language.  After the pamphlets were drafted, experts in 
immunization were consulted to determine accurate word choice.  Edits were made after 
these consultations, and readability was re-assessed. 
 
The pamphlets were then pilot tested with women in a prenatal waiting room.  Seven women 
were approached to read the gain-frame pamphlet and seven women were approached to read 
the loss-frame pamphlet.  Each woman was approached individually and was given a 
pamphlet to read while she was waiting for her appointment.  The researcher told the woman 
that the pamphlets were being tested and that any feedback would be appreciated.  The 
woman was instructed to read the pamphlet and told that the researcher would then ask for 
her opinions.  While the woman read the pamphlet, the researcher read a magazine so that the 
woman would not feel rushed or uncomfortable.  Once a woman finished reading a pamphlet, 
the researcher first asked for any comments.  After a woman finished giving general 
comments, the researcher asked the following questions: What did you like about the 
pamphlet?  What didn’t you like about the pamphlet?  Did you experience any strong 
emotions while reviewing the pamphlet?  Were there any words or sections of the pamphlet 
that you didn’t understand?  After reading the pamphlet, do you feel prepared to make a 
decision about booster vaccination?  Is there more information you would want from a doctor 
before making a decision?  Are there any illustrations that you specifically liked or didn’t 
like?  What other changes would you make to this pamphlet? 
 
The mothers and mothers-to-be had many helpful comments about the pamphlets.  Women 
repeatedly discussed the clarity of the pamphlets.  Women also commented on the ease of 
reading the pamphlet, that they liked the sub-headings and highlighted words, and their desire 
to get the vaccine.  A few women (in both pamphlet groups) commented that the descriptions 
of a baby’s potential pertussis infection outcomes seemed serious, and that the seriousness 
convinced them that the issue of booster vaccination should be sincerely considered.   
 
As part of the pilot testing, women were asked whether they felt that they had enough 
information to make a decision about booster vaccination for themselves.  Three out of 
fourteen women asked for more information: two in one pamphlet group and one in the other.  
The women wanted to know if there were any side effects of vaccination and whether it 
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would affect breastfeeding.  As a result of this requested information, facts about side effects 
and breastfeeding were added to both pamphlets. 
 
Women were also asked about the pamphlet pictures and the relevance to the text.  One 
woman mentioned that a photo of a happy baby should be included; one woman mentioned 
that a photo of a blue, sick baby struggling with pertussis infection should be included in the 
pamphlet.  However, twelve of the fourteen women thought the illustrations were clear and 
appropriate.  Therefore, no changes were made to the pamphlet pictures. 
 
When asked whether there were any words or phrases that were difficult to understand, two 
women pointed to the name of the study on the back of the pamphlet: “The Maternal 
Pertussis Study.”  These women commented that they didn’t know what the word “pertussis” 
meant.  The word was defined inside the pamphlet, but the pamphlet then explained that 
pertussis was commonly called whooping cough and the pamphlet subsequently called the 
infection “whooping cough.”  As a result of the word choice throughout the pamphlet and 
these women’s comments, the name of the study was changed to “The Mums and Whooping 
Cough Study.” 
 
Other miscellaneous changes, based on women’s recommendations, were that the title size 
was increased; the word “free” (in reference to cost of the vaccine) was highlighted; and two 
additional words (“after birth”) were added to a bullet point to clarify when the booster 
vaccination should be received.   
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Appendix 9: Gain-framed brochure 
 
 
What’s whooping cough? 
Whooping cough is caused by bacteria in the 
lungs.  It is also called pertussis, which means 
“forceful cough.”  It is highly contagious and is 
spread through close contact with an infected 
person.   
Is whooping cough serious? 
Yes.  In babies, whooping cough can be very 
serious.  It begins with flu-like symptoms.  It 
can then progress to a thick mucous in the 
throat that makes eating, drinking, and  
breathing harder.  The baby may not be able 
to get enough oxygen and will cough with a  
gasping or whooping sound.  They may turn 
blue and/or vomit from the coughing.  A baby’s 
infection can lead to pneumonia, brain  
damage, and even death.  
In adults, whooping cough may seem like a 
bad chest cold.   Even if the disease does not 
seem serious in an adult, parents and carers 
can easily give whooping cough to a baby.   
Is whooping cough common? 
NSW is in the midst of a whooping cough  
outbreak.  Most cases are in adults, but adults 
can easily transmit whooping cough to babies.  
 
Newborn babies are vulnerable because they 
are not fully protected before they have their 
three whooping cough vaccinations (the first 
is at two months of age).  Most babies with 
whooping cough are infected by a caregiver.   
Whooping Cough: Booster vaccination keeps you and your baby protected 
How can I prevent whooping 
cough? 
Vaccinating yourself can protect your baby’s 
health.  The best way to reduce risk of  
infection in your new baby is by making sure  
you and other adults caring for the baby have 
received a booster vaccination.   
Mothers can’t receive the vaccination until 
after their baby is born, but should then have 
it as soon as possible.   
 
To help protect 
your baby from 
whooping cough, 
the Maternal  
Pertussis Study is 
offering the  
vaccine to you for 
free as soon as 
you give birth, while you are still in the  
maternity ward.   Whooping cough booster is 
safe for you to have while breastfeeding.   
 
Do I need a whooping cough 
booster vaccination? 
Even if you have been vaccinated against 
whooping cough before, it is important to get 
a booster vaccination.  This is because  
immunity doesn’t last through adulthood.  
Boosters last for about ten years.  If you have 
had one recently, you do not need another. 
Who should get a booster? 
The best way to protect your baby from 
whooping cough is by vaccinating yourself.  
Other adults who caring for the baby should 
also be vaccinated.   
 
To increase immunity and prevent adults 
passing whooping cough to babies, the  
following groups should have a whooping 
cough booster vaccination: 
 
Women planning to become  
pregnant 
Partners of women who are  
pregnant 
New mothers (as soon as the baby is 
born) 
Other adults who care for young  
children 
 
 
Are there risks to booster 
vaccination? 
Serious side effects to the vaccination are 
rare.  Like with many vaccines, the adult who 
is vaccinated may experience a fever.  They 
may also have pain or swelling in the arm 
where the needle was given.   
 
Whooping cough booster is safe for you to 
have while breastfeeding.  
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Appendix 10 : Loss framed brochure  
 
 
What’s whooping cough? 
Whooping cough is caused by bacteria in the 
lungs.  It is also called pertussis, which means 
“forceful cough.”  It is highly contagious and is 
spread through close contact with an infected 
person.   
Is whooping cough serious? 
Yes.  In babies, whooping cough can be very 
serious.  It begins with flu-like symptoms.  It 
can then progress to a thick mucous in the 
throat that makes eating, drinking, and  
breathing harder.  The baby may not be able 
to get enough oxygen and will cough with a  
gasping or whooping sound.  They may turn 
blue and/or vomit from the coughing.  A baby’s 
infection can lead to pneumonia, brain  
damage, and even death.  
In adults, whooping cough may seem like a 
bad chest cold.   Even if the disease does not 
seem serious in an adult, parents and carers 
can easily give whooping cough to a baby.   
Is whooping cough common? 
NSW is in the midst of a whooping cough  
outbreak.  Most cases are in adults, but adults 
can easily transmit whooping cough to babies.  
 
Newborn babies are vulnerable because they 
are not fully protected before they have their 
three whooping cough vaccinations (the first 
is at two months of age).  Most babies with 
whooping cough are infected by a caregiver.   
Whooping Cough: Without a booster vaccination, you and your baby are at risk of  infection 
How can I prevent whooping 
cough? 
If a newborn baby’s parents and main carers 
have not received a booster vaccination, the 
baby will have a higher risk of catching the 
infection.    
Mothers can’t receive the vaccination until 
after their baby is born, but should then have 
it as soon as possible.   
 
Babies are much more vulnerable to catching 
whooping cough if the parents have not had a 
booster vaccine.  
The Maternal  
Pertussis Study is  
offering the  
vaccine to you for 
free as soon as 
you give birth, 
while you are still 
in the maternity 
ward.  
 
Do I need a whooping cough 
booster vaccination? 
Even if you have been vaccinated against 
whooping cough before, it is important to get 
a booster vaccination.  This is because  
immunity doesn’t last through adulthood.  
Boosters last for about ten years.  If you have 
had one recently, you do not need another. 
Who should get a booster 
vaccination? 
Without vaccinating adults who will be  
caring for the baby, the best way to  
prevent whooping cough in the baby has 
been missed.    
 
Unless the following groups receive a  
whooping cough booster vaccination, 
adults passing whooping cough to babies is 
more likely to occur: 
 
Women planning to become  
pregnant 
Partners of women who are  
pregnant 
New mothers (as soon as the baby 
is born) 
Other adults who care for young 
children  
Maternal Pertussis Study 
Contact: Dr. John Sinn 
Royal North Shore Hospital 
L5 Douglas Building 
St Leonards NSW 2065 
E-mail: jsinn@med.usyd.edu.au  
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Appendix 11: Control brochure ( NSW Health factsheet) 
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Appendix 12: The Maternal Pertussis Study ( baseline questionnaire) 
  
Version 1, 9 June 2009 Page 1 of 6
Maternal Pertussis Questionnaire
Your answers are strictly confidential.  Please indicate your responses by ticking the box or boxes that 
correspond with your answer and give details in the space provided, if relevant.
A1. Where have you heard of pertussis (tick all that apply)?
Have not heard of it Religious or spiritual advisor
Health professional (doctor or nurse) Alternative health practitioner
Media publicity such as TV, radio, newspapers or 
magazines
Immunisation brochures or pamphlets
Information from group opposed to immunisation The Internet
Friend or family member Other
A2. Where have you heard of whooping cough (tick all that apply)?
Have not heard of it Religious or spiritual advisor
Health professional (doctor or nurse) Alternative health practitioner
Media publicity such as TV, radio, newspapers or 
magazines
Immunisation brochures or pamphlets
Information from group opposed to immunisation The Internet
Friend or family member Other
Which of the following sources do you consider most influential to your decision making 
regarding information about vaccination?
A3.
Health professional (doctor or nurse) Alternative health practitioner
Media publicity such as TV, radio, newspapers or 
magazines
Immunisation brochures or pamphlets
Information from group opposed to immunisation The Internet
Friend or family member None
Religious or spiritual advisor Other
ID: _________
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Appendix 13: Follow up questionnaire 
 
Version 1, 9 June 2009 Page 1 of 1
Maternal Pertussis Follow-up
Your answers are strictly confidential.  Please indicate your responses by ticking the box or boxes that 
correspond with your answer and give details in the space provided, if relevant.
ID: _________
Q1. Did you receive the whooping cough booster vaccine?
Yes No
Q2. What factors were most influential in your decision-making process?
Q3. Did your husband or partner receive the whooping cough booster vaccine?
Yes  Why? ______________________________________ No Why not? ___________________________________
Q4. What factors were most influential in that decision-making process?
Q5. Whether or not you chose to receive the vaccine, did you find the appreciate the 
opportunity to have the vaccine while in the maternity ward?
Yes
No Unsure
Q6. Are there any other recommendations you have for improving whooping cough 
booster vaccine uptake among new parents?
Yes  What? 
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
No
Q7. May we send you an email in a few months to follow-up about vaccination status?
Yes, email address: ____________________________________________ No
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Appendix 14: Amended follow up questionnaire (pertussis vaccination in pregnancy)  
  
Version 2, 17 July 2013! 1!
 
Maternal Pertussis Follow-up 
                                              
Your answers are strictly confidential. Please indicate your responses by ticking the box or boxes that 
correspond with your answer and give details in the space provided, if relevant. 
 
Q1a. Did you receive the whooping cough booster vaccine? 
 Yes, during this pregnancy 
 Yes, on the maternity ward 
 No. 
 
Q1b. What factors were most influential in your decision-making process? 
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________ 
 
Q2a. Were you recommended the whooping cough booster vaccine during this pregnancy? 
 
 Yes, by:________________ 
 No 
 Unsure 
 
Q2b. If no, would you have received the whooping cough booster vaccine during this pregnancy 
if your doctor had recommended it? 
 
 Yes  
 No 
 Unsure  
 
Q3. Did your husband or partner receive the whooping cough booster vaccine? 
 Yes  Why?____________  No  Why not?_____________
 
Q4. What factors were most influential in that decision-making process? 
 
________________________________________________________________________________________ 
 
Q5. Whether or not you chose to receive the vaccine, did you appreciate the 
opportunity to have the vaccine while in the maternity ward? 
 Yes 
 No 
 
 
 Unsure 
 
Q6. Are there any other recommendations you have for improving whooping cough 
booster vaccine uptake among new parents? 
 No 
 Yes  What? 
________________________________________________________________ __________________________________
__________________________________________________________________________________________________
___________________________ _______________________________________________________________________  
 
 
Q7. May we send you an email in a few months to follow-up about vaccination status? 
 Yes, email address:________________________ 
 No
ID:______!
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Appendix 15: Literature review of paper versus electronic mode 
Author Population 
(N) 
Intervention Comparison Outcomes Study design 
Yu, de corten, 
Pan et al., 2009 
Fiji medical 
students 
(120) 
Electronic (PDA) Paper   Error rates (0% vs. 20.8%)= 
significant reduction 
 Perceived to take less time 
 Data entry, validation & 
cleaning ( 1.5hrs vs. 20.5hrs) 
 Reduced cost 
 Data collectors & participants 
prefer PDA 
RCT cross-over 
Juniper, 
Langlands, & 
Juniper., 2009 
Respiratory 
patients 
(116) 
Electronic paper  Significant bias between the two 
modes 
 Modest concordance 
=pts may respond differently to 
questionnaires in different 
formats & must not be used 
interchangeably. 
Randomised 
?cohort ( paired 
sample) 
Galliher, 
Stewart, 
Pathak et al., 
2008 
Immunisation 
survey-older 
adults (1003) 
Handheld 
computers 
paper  Better return rate for paper 
(94% vs. 82%)- technical 
difficulties; stolen or lost device 
 Errors of omission- paper (35% 
vs. 3%) 
cross-over 
random 
assignment  
Matthew, 
Currie, Irvine 
et al., 2007 
Prostate cancer 
clinic 
(152) 
PDA 
1.Paper-PDA 
2.PDA-paper 
3.PDA-PDA 
Paper  Similar internal consistency 
 Test-retest reliability confirmed 
for PDA repeated 
administration 
 Data strongly correlated 
between modes 
 Lower missed item rates- PDA 
 PDA preferred ( 82.8% 
participants) 
 
Randomly 
assigned 
? 
 
Bushnell, 
Reilly, Galani 
et al., 2006 
 
Subjects with 
IBS 
 
(72) 
1.Electronic* 
2.Paper (24hrs 
later) 
3.Paper (retest- 1 
week later) 
*hand held device 
1.Paper 
2.electronic* 
(24hrs later) 
3.electronic* 
(retest-1 week 
later) 
 No significant differences 
between baseline (paper & 
electronic) and crossover scores 
 Comparable internal 
consistency, ease of use 
 More patients preferred 
electronic 
 Generally comparable 
(electronic vs. paper) for retest. 
Paired sample 
Cross over 
design with 
retest 
 
VanDenKerkh
of, Goldstein, 
Blaine et al., 
2005 
 
 
Adults- 
preadmission 
clinic (360) 
1. Paper 
Electronic (touch 
screen): 
2.PDA 
3.touch screen 
desk top computer 
(kiosk) 
4.tablet 
Paper 
(PAAQ 
completed in 
surgeon’s 
office) 
 94% agreement with all study 
arms and prestudy PAAQ 
 Pts comfortable using 
technology ( 10% to 97% 
between pretest & electronic 
version) 
 Pt preferred electronic to paper 
modes 
Retrospective 
Unblinded RCT 
4 study arms 
Saleh, 
Radosevich, 
kassim et al., 
2002 
 
 
Clinic patients 
with knee/hip 
pain 
(96) 
Palm-top 
computer devices 
Or paper 
Paper (mailed, 
completed 3 
weeks prior) 
 Comparable scale distribution, 
floor & ceiling effects, and 
retest reliability  
 Dissimilar internal consistency 
 Lack of reliability across 
modes 
 Potential advantage of decrease 
cost and convenience of 
electronic mode 
?cohort 
Data stratified by 
age ( variance in 
baseline 
characteristics) 
Sellors, 
Hayward, 
Swanson et al., 
2002 
Blood donors 
(1239) 
Computerised 
handheld tool 
paper  Self-administered computerised 
method may increased risk 
reporting 
Randomised 
cross over trial 
Escandon, 
Searing, 
Goldberg et al., 
2008 
Bolivia- field 
work 
12 sites 
PDA paper  Incompatible data files, 
inadequate back-up protocol 
Qualitative 
(pilot project) 
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